CA3000396A1 - Antagonistic antibodies specifically binding human cd40 and methods of use - Google Patents
Antagonistic antibodies specifically binding human cd40 and methods of use Download PDFInfo
- Publication number
- CA3000396A1 CA3000396A1 CA3000396A CA3000396A CA3000396A1 CA 3000396 A1 CA3000396 A1 CA 3000396A1 CA 3000396 A CA3000396 A CA 3000396A CA 3000396 A CA3000396 A CA 3000396A CA 3000396 A1 CA3000396 A1 CA 3000396A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- nos
- human
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000027455 binding Effects 0.000 title claims abstract description 139
- 238000000034 method Methods 0.000 title claims abstract description 63
- 230000003042 antagnostic effect Effects 0.000 title claims abstract description 33
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 162
- 239000002157 polynucleotide Substances 0.000 claims abstract description 162
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 162
- 239000000427 antigen Substances 0.000 claims abstract description 85
- 108091007433 antigens Proteins 0.000 claims abstract description 85
- 102000036639 antigens Human genes 0.000 claims abstract description 85
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims abstract description 60
- 239000012634 fragment Substances 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims description 120
- 238000002560 therapeutic procedure Methods 0.000 claims description 120
- 230000035772 mutation Effects 0.000 claims description 95
- 210000004443 dendritic cell Anatomy 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 44
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 33
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 27
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 25
- 208000027866 inflammatory disease Diseases 0.000 claims description 18
- 238000002054 transplantation Methods 0.000 claims description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 230000004663 cell proliferation Effects 0.000 claims description 14
- 238000010494 dissociation reaction Methods 0.000 claims description 13
- 230000005593 dissociations Effects 0.000 claims description 13
- 206010003246 arthritis Diseases 0.000 claims description 11
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 10
- 208000024908 graft versus host disease Diseases 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 9
- 229940068977 polysorbate 20 Drugs 0.000 claims description 9
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 8
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 claims description 8
- 239000002254 cytotoxic agent Substances 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 208000033464 Reiter syndrome Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 208000002574 reactive arthritis Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 5
- 208000023328 Basedow disease Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 5
- 238000010322 bone marrow transplantation Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000012216 imaging agent Substances 0.000 claims description 5
- 229940127121 immunoconjugate Drugs 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 150000003873 salicylate salts Chemical class 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 93
- 101150013553 CD40 gene Proteins 0.000 description 90
- 108090000623 proteins and genes Proteins 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 50
- 238000003556 assay Methods 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 33
- 125000003275 alpha amino acid group Chemical group 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 108060003951 Immunoglobulin Proteins 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 102000018358 immunoglobulin Human genes 0.000 description 18
- 239000012636 effector Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 230000004913 activation Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000008484 agonism Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 102200007406 rs148775298 Human genes 0.000 description 11
- 102200021640 rs2722372 Human genes 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- -1 ICAM Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 230000001270 agonistic effect Effects 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 239000012979 RPMI medium Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000833 heterodimer Substances 0.000 description 5
- 230000002998 immunogenetic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 102220582002 Phospholipid-transporting ATPase ABCA3_N53Q_mutation Human genes 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000005734 heterodimerization reaction Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 238000006317 isomerization reaction Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 101001117471 Aspergillus phoenicis Aspergillopepsin-1 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102220498105 Electron transfer flavoprotein subunit beta_N53A_mutation Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000288950 Callithrix jacchus Species 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 102220620951 SHC-transforming protein 4_N52D_mutation Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001074571 Homo sapiens PIN2/TERF1-interacting telomerase inhibitor 1 Proteins 0.000 description 1
- 101001073025 Homo sapiens Peroxisomal targeting signal 1 receptor Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000850762 Homo sapiens TNF receptor-associated factor 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102100036257 PIN2/TERF1-interacting telomerase inhibitor 1 Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000001021 fluorone dye Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 229940115747 halobetasol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000046854 human TRAF3 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 239000001014 oxazin dye Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000004804 polysaccharides Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 102220002645 rs104894309 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- MKNJJMHQBYVHRS-UHFFFAOYSA-M sodium;1-[11-(2,5-dioxopyrrol-1-yl)undecanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O MKNJJMHQBYVHRS-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The present invention relates to antagonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing.
Description
Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use Field of the Invention The present invention relates to antagonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing.
Background of the Invention The cell surface CD40 molecule is a member of the tumor necrosis factor receptor superfamily (TNFR) and a key regulator in both innate and adaptive immune responses.
CD40 is constitutively expressed on antigen presenting cells, in particular B-cells, dendritic cells and macrophages, but can also be found on fibroblasts, synoviocytes, smooth muscle cells, endothelial cells and epithelial cells.
The natural ligand of CD40, designated CD154 or CD4OL, is mainly expressed on activated T lymphocytes and platelets. The interaction of CD40 with CD4OL on T
cells induces both humoral and cell- mediated immune responses. CD40 regulates this ligand-receptor pair to activate B cells and other antigen-presenting cells (APC) including dendritic cells (DCs), driving T cell activation. For example, activation of CD40 on B cells induces B cell proliferation, somatic hypermutation, differentiation into antibody secreting cells and isotype switching in germinal centers of secondary lymphoid organs.
In vitro studies have shown direct effects of CD40 activation on cytokine production (e.g. IL-6, IL-10, IL-12, TNF-a), expression of adhesion molecules and costimulatory receptors (e.g.
ICAM, CD23, CD80 and CD86), and increased expression of MHC class I, MHC class II, and TAP transporter by B lymphocytes.
Antibodies that modulate the CD40/CD4OL interaction are of interest in treating diseases such as inflammatory diseases, including autoimmune diseases.
Summary of the invention The invention provides for an isolated antagonistic antibody or an antigen binding portion thereof specifically binding human CD40 of SEQ ID NO: 1, comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 5, a HCDR2 of SEQ
ID NO: 61, a HCDR3 of SEQ ID NO: 62, a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 63, a LCDR2 of SEQ ID NO: 9 and a LCDR3 of SEQ
ID
NO: 10.
The invention also provides for an isolated antagonistic antibody or an antigen binding portion thereof specifically binding human CD40 of SEQ ID NO: 1, comprising certain HCDR1, HCDR2, HCDR3, LCDR1, LCDR3, LCDR3, VH, VL, HC and/or LC
sequences.
The invention also provides for a pharmaceutical composition comprising the antibody of the invention and a pharmaceutically acceptable carrier.
The invention also provides for an immunoconjugate comprising the antibody of the invention linked to a therapeutic agent or an imaging agent.
The invention also provides for an isolated polynucleotide encoding the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26;
the VL of SEQ ID NOs: 12 or 27; or the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL of SEQ ID NOs:
12 or 27.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 13, 14, 28, 29, 30, 31, 32, 33, or 34.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46.
The invention also provides for an isolated polynucleotide encoding the light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46 and a light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 77 or 78.
The invention also provides for a vector comprising the polynucleotide of the invention.
The invention also provides for a host cell comprising the vector of the invention.
The invention also provides for a method of producing an antagonistic antibody or an antigen binding portion thereof specifically binding human CD40 of SEQ ID NO:
1,
Background of the Invention The cell surface CD40 molecule is a member of the tumor necrosis factor receptor superfamily (TNFR) and a key regulator in both innate and adaptive immune responses.
CD40 is constitutively expressed on antigen presenting cells, in particular B-cells, dendritic cells and macrophages, but can also be found on fibroblasts, synoviocytes, smooth muscle cells, endothelial cells and epithelial cells.
The natural ligand of CD40, designated CD154 or CD4OL, is mainly expressed on activated T lymphocytes and platelets. The interaction of CD40 with CD4OL on T
cells induces both humoral and cell- mediated immune responses. CD40 regulates this ligand-receptor pair to activate B cells and other antigen-presenting cells (APC) including dendritic cells (DCs), driving T cell activation. For example, activation of CD40 on B cells induces B cell proliferation, somatic hypermutation, differentiation into antibody secreting cells and isotype switching in germinal centers of secondary lymphoid organs.
In vitro studies have shown direct effects of CD40 activation on cytokine production (e.g. IL-6, IL-10, IL-12, TNF-a), expression of adhesion molecules and costimulatory receptors (e.g.
ICAM, CD23, CD80 and CD86), and increased expression of MHC class I, MHC class II, and TAP transporter by B lymphocytes.
Antibodies that modulate the CD40/CD4OL interaction are of interest in treating diseases such as inflammatory diseases, including autoimmune diseases.
Summary of the invention The invention provides for an isolated antagonistic antibody or an antigen binding portion thereof specifically binding human CD40 of SEQ ID NO: 1, comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 5, a HCDR2 of SEQ
ID NO: 61, a HCDR3 of SEQ ID NO: 62, a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 63, a LCDR2 of SEQ ID NO: 9 and a LCDR3 of SEQ
ID
NO: 10.
The invention also provides for an isolated antagonistic antibody or an antigen binding portion thereof specifically binding human CD40 of SEQ ID NO: 1, comprising certain HCDR1, HCDR2, HCDR3, LCDR1, LCDR3, LCDR3, VH, VL, HC and/or LC
sequences.
The invention also provides for a pharmaceutical composition comprising the antibody of the invention and a pharmaceutically acceptable carrier.
The invention also provides for an immunoconjugate comprising the antibody of the invention linked to a therapeutic agent or an imaging agent.
The invention also provides for an isolated polynucleotide encoding the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26;
the VL of SEQ ID NOs: 12 or 27; or the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL of SEQ ID NOs:
12 or 27.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 13, 14, 28, 29, 30, 31, 32, 33, or 34.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46.
The invention also provides for an isolated polynucleotide encoding the light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46 and a light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 77 or 78.
The invention also provides for a vector comprising the polynucleotide of the invention.
The invention also provides for a host cell comprising the vector of the invention.
The invention also provides for a method of producing an antagonistic antibody or an antigen binding portion thereof specifically binding human CD40 of SEQ ID NO:
1,
2 comprising culturing the host cell of the invention in conditions wherein the antibody is expressed, and isolating the antibody.
The invention also provides for a method of treating a subject having an inflammatory disease, comprising administering to the subject in need thereof the isolated antibody of the invention for a time sufficient to treat the inflammatory disease.
The invention also provides for the antibody of the invention for use in therapy.
The invention also provides for an anti-idiotypic antibody binding to the antibody of the invention.
The invention also provides for a kit comprising the antibody of the invention.
Brief Description of the Drawings Figure 1 shows that C40B16 as wild-type IgG1 demonstrated comparable minimal agonism when compared to Fc effector silent Antibody D. Fc effector silent ASKP-1240, CFZ533 and BMS-986090 mAbs demonstrated higher level of agonism when compared to C40B16. Agonism was assessed in HEKB1ueTM CD4OL NF-KB activation assay.
Figure 2 shows that C40B16 does not induce agonism in an assay measuring antibody-mediated IL-12p40 production by human dendritic cells (DC), whereas ASKP-1240, CFZ533 and BMS-986090 induce IL-12p40 production. IL-12p40 production was evaluated at 6 different antibody concentrations, (350, 110, 35, 11, 3.5, and 1.1 nM) each represented by a separate column for each antibody in the Figure. DC+CD4OL:
positive control. DC only: negative control.
Figure 3A shows that 500 ng/ml concentrations of anti-CD40 antibodies C40B176, C40B179, C40B180 and C40B183 do not induce activation of dendritic cells (DC), whereas 350 nM ASKP-1240 induces IL-12p40 production. DC activation was assessed by IL-12p40 production by DCs in the presence of antibody. PP1B40:
IgGlsigma isotype control; CNT09412: IgG4_PAA isotype control.
Figure 3B shows that high concentrations of anti-CD40 antibodies C40B176, C40B179, C40B180 and C40B183 do not induce proliferation of B cells, whereas 500 nM
ASKP-1240 does. PP1B40: IgGlsigma isotype control; CNT09412: IgG4_PAA isotype control. Two separate dose response curves are shown for ASKP-1240.
The invention also provides for a method of treating a subject having an inflammatory disease, comprising administering to the subject in need thereof the isolated antibody of the invention for a time sufficient to treat the inflammatory disease.
The invention also provides for the antibody of the invention for use in therapy.
The invention also provides for an anti-idiotypic antibody binding to the antibody of the invention.
The invention also provides for a kit comprising the antibody of the invention.
Brief Description of the Drawings Figure 1 shows that C40B16 as wild-type IgG1 demonstrated comparable minimal agonism when compared to Fc effector silent Antibody D. Fc effector silent ASKP-1240, CFZ533 and BMS-986090 mAbs demonstrated higher level of agonism when compared to C40B16. Agonism was assessed in HEKB1ueTM CD4OL NF-KB activation assay.
Figure 2 shows that C40B16 does not induce agonism in an assay measuring antibody-mediated IL-12p40 production by human dendritic cells (DC), whereas ASKP-1240, CFZ533 and BMS-986090 induce IL-12p40 production. IL-12p40 production was evaluated at 6 different antibody concentrations, (350, 110, 35, 11, 3.5, and 1.1 nM) each represented by a separate column for each antibody in the Figure. DC+CD4OL:
positive control. DC only: negative control.
Figure 3A shows that 500 ng/ml concentrations of anti-CD40 antibodies C40B176, C40B179, C40B180 and C40B183 do not induce activation of dendritic cells (DC), whereas 350 nM ASKP-1240 induces IL-12p40 production. DC activation was assessed by IL-12p40 production by DCs in the presence of antibody. PP1B40:
IgGlsigma isotype control; CNT09412: IgG4_PAA isotype control.
Figure 3B shows that high concentrations of anti-CD40 antibodies C40B176, C40B179, C40B180 and C40B183 do not induce proliferation of B cells, whereas 500 nM
ASKP-1240 does. PP1B40: IgGlsigma isotype control; CNT09412: IgG4_PAA isotype control. Two separate dose response curves are shown for ASKP-1240.
3 Detailed Description of the Invention Definitions All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though fully set forth.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.
As used herein, the singular forms "a," "and," and "the" include plural reference unless the context clearly dictates otherwise.
Although any methods and materials similar or equivalent to those described herein may be used in the practice for testing of the present invention, exemplary materials and methods are described herein.
"Specific binding" or "specifically binds" or "binds" refers to antibody binding to human CD40 with greater affinity than for non-related antigens. Typically, the antibody binds to human CD40 with a dissociation constant (KD) of 1x10-8 M or less, for example 1x10-9 M or less, 1x101 M or less, 1x1011 M or less, or 1x1012 M or less, typically with a KD that is at least one hundred fold less than its KD for binding to a non-related antigen (for example, BSA, casein). The dissociation constant may be measured using standard procedures. Antibodies that specifically bind human CD40 may, however, have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca fascicularis (cynomolgus, cyno), Pan troglodytes (chimpanzee, chimp) or Callithrix jacchus (common marmoset, marmoset). While a monospecific antibody specifically binds one antigen or one epitope, a bispecific antibody specifically binds two distinct antigens or two distinct epitopes.
"Antibodies" is meant in a broad sense and includes immunoglobulin molecules including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, antigen-binding fragments, bispecific or multispecific antibodies, dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity. "Full length antibodies" are comprised of two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds as well as
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.
As used herein, the singular forms "a," "and," and "the" include plural reference unless the context clearly dictates otherwise.
Although any methods and materials similar or equivalent to those described herein may be used in the practice for testing of the present invention, exemplary materials and methods are described herein.
"Specific binding" or "specifically binds" or "binds" refers to antibody binding to human CD40 with greater affinity than for non-related antigens. Typically, the antibody binds to human CD40 with a dissociation constant (KD) of 1x10-8 M or less, for example 1x10-9 M or less, 1x101 M or less, 1x1011 M or less, or 1x1012 M or less, typically with a KD that is at least one hundred fold less than its KD for binding to a non-related antigen (for example, BSA, casein). The dissociation constant may be measured using standard procedures. Antibodies that specifically bind human CD40 may, however, have cross-reactivity to other related antigens, for example to the same antigen from other species (homologs), such as human or monkey, for example Macaca fascicularis (cynomolgus, cyno), Pan troglodytes (chimpanzee, chimp) or Callithrix jacchus (common marmoset, marmoset). While a monospecific antibody specifically binds one antigen or one epitope, a bispecific antibody specifically binds two distinct antigens or two distinct epitopes.
"Antibodies" is meant in a broad sense and includes immunoglobulin molecules including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, antigen-binding fragments, bispecific or multispecific antibodies, dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity. "Full length antibodies" are comprised of two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds as well as
4 multimers thereof (for example IgM). Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (comprised of domains CH1, hinge CH2 and CH3). Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The VH and the VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with framework regions (FR). Each VH and VL is composed of three CDRs and four FR segments, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
"Complementarity determining regions (CDR)" are "antigen binding sites" in an antibody. CDRs may be defined using various terms: (i) Complementarity Determining Regions (CDRs), three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL
(LCDR1, LCDR2, LCDR3) are based on sequence variability (Wu and Kabat, J Exp Med 132:211-50, 1970; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
(ii) "Hypervariable regions", "HVR", or "HV", three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3) refer to the regions of an antibody variable domains which are hypervariable in structure as defined by Chothia and Lesk (Chothia and Lesk, Mol Biol 196:901-17, 1987). The International ImMunoGeneTics (IMGT) database (http://www_imgt_org) provides a standardized numbering and definition of antigen-binding sites. The correspondence between CDRs, HVs and IMGT delineations is described in Lefranc et al., Dev Comparat Immunol 27:55-77, 2003. The term "CDR", "HCDR1", "HCDR2", "HCDR3", "LCDR1", "LCDR2" and "LCDR3" as used herein includes CDRs defined by any of the methods described supra, Kabat, Chothia or IMGT, unless otherwise explicitly stated in the specification.
Immunoglobulins may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG
are further sub-classified as the isotypes IgAi, IgA2, IgGi, IgG2, IgG3 and IgG4. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa (k) and lambda (2), based on the amino acid sequences of their constant domains.
"Antigen-binding fragment" refers to a portion of an immunoglobulin molecule that retains the antigen binding properties of the parental full length antibody. Exemplary antigen-binding fragments are as heavy chain complementarity determining regions (HCDR) 1, 2 and/or 3, light chain complementarity determining regions (LCDR) 1, 2 and/or 3, a heavy chain variable region (VH), or a light chain variable region (VL), Fab, F(ab')2, Fd and Fv fragments as well as domain antibodies (dAb) consisting of either one VH domain or one VL domain. VH and VL domains may be linked together via a synthetic linker to form various types of single chain antibody designs in which the VH/VL
domains pair intramolecularly, or intermolecularly in those cases when the VH
and VL
domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Int. Pat. Publ.
No.
W01998/44001, Int. Pat. Publ. No. W01988/01649; Int. Pat. Publ. No.
W01994/13804;
Int. Pat. Publ. No. W01992/01047.
"Monoclonal antibody" refers to an antibody population with single amino acid composition in each heavy and each light chain, except for possible well known alterations such as removal of C-terminal lysine from the antibody heavy chain. Monoclonal antibodies typically bind one antigenic epitope, except that multispecific monoclonal antibodies bind two or more distinct antigens or epitopes. Bispecific monoclonal antibodies bind two distinct antigenic epitopes. Monoclonal antibodies may have heterogeneous glycosylation within the antibody population. Monoclonal antibody may be monospecific or multispecific, or monovalent, bivalent or multivalent. A
multispecific antibody, such as a bispecific antibody or a trispecific antibody is included in the term monoclonal antibody.
"Isolated antibody" refers to an antibody or an antigen-binding fragment thereof that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody specifically binding human CD40 is substantially free of antibodies that specifically bind antigens other than human CD40). In case of a bispecific antibody, the bispecific antibody specifically binds two antigens of interest, and is substantially free of antibodies that specifically bind antigens other that the two antigens of interest. "Isolated antibody" encompasses antibodies that are isolated to a higher purity, such as antibodies that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% pure.
"Humanized antibodies" refers to antibodies in which the antigen binding sites are derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Humanized antibodies may include intentionally introduced mutations in the framework regions so that the framework may not be an exact copy of expressed human immunoglobulin or germline gene sequences.
"Human antibodies" refers to antibodies having heavy and light chain variable regions in which both the framework and the antigen binding site are derived from sequences of human origin. If the antibody contains a constant region or a portion of the constant region, the constant region also is derived from sequences of human origin.
A human antibody comprises heavy or light chain variable regions that are derived from sequences of human origin if the variable regions of the antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes.
Such exemplary systems are human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice or rats carrying human immunoglobulin loci as described herein. A human antibody typically contain amino acid differences when compared to the human germline or rearranged immunoglobulin sequences due to, for example naturally occurring somatic mutations, intentional introduction of substitutions into the framework or antigen binding site and amino acid changes introduced during cloning and VDJ recombination in non-human animals. Typically, a human antibody is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical in amino acid sequence to an amino acid sequence encoded by a human germline or rearranged immunoglobulin gene.
In some cases, a human antibody may contain consensus framework sequences derived from human framework sequence analyses, for example as described in Knappik et al., J
Mol Biol 296:57-86, 2000, or synthetic HCDR3 incorporated into human immunoglobulin gene libraries displayed on phage, for example as described in Shi et al., J
Mol Biol 397:385-96, 2010 and Int. Pat. Publ. No. W02009/085462.
Antibodies in which antigen binding sites are derived from a non-human species are not included in the definition of human antibody.
"Recombinant" includes antibodies and other proteins that are prepared, expressed, created or isolated by recombinant means.
"Epitope" refers to a portion of an antigen to which an antibody specifically binds.
Epitopes typically consist of chemically active (such as polar, non-polar or hydrophobic) surface groupings of moieties such as amino acids or polysaccharide side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope may be composed of contiguous and/or discontiguous amino acids that form a conformational spatial unit. For a discontiguous epitope, amino acids from differing portions of the linear sequence of the antigen come in close proximity in 3-dimensional space through the folding of the protein molecule.
"Multispecific" refers to an antibody that specifically binds at least two distinct antigens or two distinct epitopes within the antigens, for example three, four or five distinct antigens or epitopes.
"Bispecific" refers to an antibody that specifically binds two distinct antigens or two distinct epitopes within the same antigen. The bispecific antibody may have cross-reactivity to other related antigens or can bind an epitope that is shared between two or more distinct antigens.
"Variant" refers to a polypeptide or a polynucleotide that differs from a reference polypeptide or a reference polynucleotide by one or more modifications for example, substitutions, insertions or deletions.
"Vector" refers to a polynucleotide capable of being duplicated within a biological system or that can be moved between such systems. Vector polynucleotides typically contain elements, such as origins of replication, polyadenylation signal or selection markers, that function to facilitate the duplication or maintenance of these polynucleotides in a biological system. Examples of such biological systems may include a cell, virus, animal, plant, and reconstituted biological systems utilizing biological components capable of duplicating a vector. The polynucleotide comprising a vector may be DNA or RNA
molecules or a hybrid of these.
"Expression vector" refers to a vector that can be utilized in a biological system or in a reconstituted biological system to direct the translation of a polypeptide encoded by a polynucleotide sequence present in the expression vector.
"Polynucleotide" refers to a synthetic molecule comprising a chain of nucleotides covalently linked by a sugar-phosphate backbone or other equivalent covalent chemistry.
cDNA is a typical example of a polynucleotide.
"Polypeptide" or "protein" refers to a molecule that comprises at least two amino acid residues linked by a peptide bond to form a polypeptide. Small polypeptides of less than 50 amino acids may be referred to as "peptides".
"CD40" or "huCD40" refers to the human CD40 protein. CD40 is also known as Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), CD4OL receptor or CD154 receptor. The amino acid sequence of the full length human CD40 is shown in SEQ ID NO: 1. Human full length CD40 protein is a type I membrane protein with amino acids. The signal sequence spans residues 1-20, the extracellular domain spans residues 21-193, the transmembrane domain spans residues 194-215, and the cytoplasmic domain spans residues 216-277 of SEQ ID NO: 1. Throughout the specification, the extracellular domain of CD40, "CD40-ECD", refers to the CD40 fragment of residues 21-193 of SEQ ID NO: 1.
"Antagonist" or "antagonistic" refers to an antibody that specifically binds human CD40 and inhibits CD40 biological activity in the presence of CD4OL in cellular assays such as CD4OL-driven human B cell proliferation or CD4OL-driven IL-12p40 production by human dendritic cells. The antagonist may inhibit CD40 biological activity in a statistically significant manner when compared to a control sample without the antibody.
Alternatively, the antagonistic antibody specifically binding human CD40 may inhibit CD40 biological activity with an IC50 value of about 1 nM or less. CD4OL in the assays may be provided as a soluble form or membrane-bound (e.g. as cells expressing CD4OL, such as Jurkat cells).
"CD40 biological activity" refers to a measureable event in a cell occurring as a result of binding of CD4OL to CD40 on human cells. CD40 biological activity may be for example proliferation of human B cells or production of IL-12p40 by human dendritic cells, or downstream activation of CD40 signaling pathways. CD40 biological activity may be measured using known methods and methods described herein.
"About" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system.
Unless explicitly stated otherwise within the Examples or elsewhere in the Specification in the context of a particular assay, result or embodiment, "about" means within one standard deviation per practice in the art, or a range of up to 5%, whichever is larger.
"In combination with" means that two or more therapeutics can be administered to a subject together in a mixture, concurrently as single agents or sequentially as single agents in any order.
"Cross-linking" refers higher order multimerization of CD40 on cells induced by an antibody specifically binding human CD40 binding to FcyRIIb cis or trans, resulting in induction of CD40 agonistic activity.
Conventional one and three-letter amino acid codes are used herein as shown in Table 1.
Table 1.
Amino acid Three-letter code One-letter code Alanine Ala A
Arginine Arg Asparagine Asn Aspartate Asp Cysteine Cys Glutamate Gln Glutamine Glu Glycine Gly Histidine His Isoleucine Ile Lysine Lys Methionine Met Phenylalanine Phe Proline Pro Serine Ser Threonine Thr Tryptophan Trp Tyrosine Tyr Valine Val V
Antibodies of the invention The invention provides antagonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies, vectors, host cells and methods of using the antibodies.
The antibodies of the invention are potent inhibitors of CD40 and have minimal agonistic activity. It is documented that antagonistic anti-CD40 antibodies, albeit being antagonists, can also have agonistic activity as a result of Fc-dependent cross-linking (for example see US7,537,763) and therefore pose a potential safety risk when administered to subjects in which suppression of CD40 signaling is desired, such as patients with autoimmune disease. Preferable anti-CD40 antibodies for the treatment of conditions in which inhibition of CD40 biological function is desired are hence those that lack agonistic activity, or have minimal agonistic activity. Suitable therapeutic CD40 antibodies would thus be Fc-engineered to abolish FcyR binding, and as a result lack Fc-mediated cross-linking and potential for Fc-mediated agonism. Such effector silent Fc-engineered antibodies are for example ASKP-1240, CFZ533, BMS-986090 and Antibody D
("benchmark antibodies"). ASKP-1240 and CFZ533 are currently in clinical development for inflammatory or autoimmune diseases.
The antibodies of the invention demonstrate improved properties when compared to the benchmark antibodies. The antibody C40B16 of the invention has minimal agonistic activity and activates CD40 signaling to a lesser extend when compared to the benchmark antibodies ASKP-1240, CFZ533 and BMS-986090. As ASKP-1240, CFZ533 and BMS-986090 are Fc effector silent antibodies, the observed agonism of these antibodies may be epitope-dependent. C40B16 on the contrary is a wild-type IgG1 and therefore possesses neither epitope-dependent nor Fc-dependent agonism. Further, Fc engineered effector silent antibodies C40B176, C40B179, C40B180 and C40B183 of the invention demonstrate only minimal agonism but also up to 10-fold improved potency when compared to Antibody D.
The invention provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 5, a HCDR2 of SEQ
ID NO: 61, a HCDR3 of SEQ ID NO: 62, a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 63, a LCDR2 of SEQ ID NO: 9 and a LCDR3 of SEQ
ID
NO: 10.
SEQ ID NOs: 61, 62 and 63 represent the HCDR2, the HCDR3 and the LCDR1, genus sequences of antagonistic antibodies specifically binding CD40, the genera encompassing variants of a parental antibody C40B16 in which putative sites for post-translational modifications have been mutated. The antibodies within the genus are expected to display no shift in epitope, e.g. the antibodies comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 5, 61, 62, 63, 9 and 10 are expected to have similar characteristics when compared to the parental C40B16 antibody. Exemplary such antibodies are antibodies comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 or the VH and the VL
amino acid sequences of antibodies C40M141, C40M152, C40M142, C40M153, C40M144, C40M155, C40M148, C40M194, C40M198, C40M197, C40M201 or C40M126 as shown in Table 2 and Table 7.
SEQ ID NO: 61 Genus HCDR2 sequence:
TIX1X2X3GGGTYYADSVKG; wherein Xi is N, D or Q;
X2 is N, Q or A; and X3 is S or A.
SEQ ID NO: 62 genus HCDR3 sequence EGGKYYYYAXIDV; wherein XiisMorL
SEQ ID NO: 63 genus LCDR1 sequence SGDKLGDKYAXI; wherein X1 is C or A.
Table 2.
SEQ ID NO:
mAb In some embodiments, the antibody competes for binding to human CD40 of SEQ
ID NO: 1 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody binds to the same epitope on human CD40 of SEQ ID NO: 1 to which the antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 binds to.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x101 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01%
polysorbate 20 (PS-20) and 100 ug/m1 bovine serum albumin.
In some embodiments, the antibody inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about lx10-9 M.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x101 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 ug/m1 bovine serum albumin, inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M and inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody is an IgGl, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the antibody is an IgG1 isotype.
In some embodiments, the antibody is an IgG2 isotype.
In some embodiments, the antibody is an IgG3 isotype.
In some embodiments, the antibody is an IgG4 isotype.
In some embodiments, the antibody is an IgGl isotype, optionally comprising a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a S228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the S228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype comprising the S228P
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a S228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is a multispecific antibody, such as a bispecific antibody.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease.
The antibody is suitable for use in therapy, for example in treating Addinson's disease.
The antibody is suitable for use in therapy, for example in treating an ankylosing spondylitis.
The antibody is suitable for use in therapy, for example in treating an atherosclerosis.
The antibody is suitable for use in therapy, for example in treating an autoimmune hepatitis.
The antibody is suitable for use in therapy, for example in treating an autoimmune diabetes.
The antibody is suitable for use in therapy, for example in treating Graves' disease.
The antibody is suitable for use in therapy, for example in treating Buillain-Barre syndrome.
The antibody is suitable for use in therapy, for example in treating Hashimoto's disease.
The antibody is suitable for use in therapy, for example in treating, an idiopathic thrombocytopenia.
The antibody is suitable for use in therapy, for example in treating an inflammatory bowel disease (IBD).
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus.
The antibody is suitable for use in therapy, for example in treating a multiple sclerosis.
The antibody is suitable for use in therapy, for example in treating a myasthenia gravis.
The antibody is suitable for use in therapy, for example in treating a psoriasis.
The antibody is suitable for use in therapy, for example in treating an arthritis.
The antibody is suitable for use in therapy, for example in treating a scleroderma.
The antibody is suitable for use in therapy, for example in treating Sjogren's syndrome.
The antibody is suitable for use in therapy, for example in treating a systemic sclerosis.
The antibody is suitable for use in therapy, for example in treating a transplantation.
The antibody is suitable for use in therapy, for example in treating a kidney transplantation.
The antibody is suitable for use in therapy, for example in treating a skin transplantation.
The antibody is suitable for use in therapy, for example in treating a bone marrow transplantation.
The antibody is suitable for use in therapy, for example in treating a graft versus host disease (GVHD).
The antibody is suitable for use in therapy, for example in treating a type I
diabetes.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis.
The antibody is suitable for use in therapy, for example in treating a juvenile arthritis.
The antibody is suitable for use in therapy, for example in treating a psoriatic arthritis.
The antibody is suitable for use in therapy, for example in treating Reiter's syndrome.
The antibody is suitable for use in therapy, for example in treating a gouty arthritis.
The antibody is suitable for use in therapy, for example in treating Crohn's disease.
The antibody is suitable for use in therapy, for example in treating an ulcerative colitis.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus in combination with a second therapeutic agent.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 6, 7, 8, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 11 and 12, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 13 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 14.
In some embodiments, the antibody comprises a heavy chain of SEQ ID NO: 35 and a light chain of SEQ ID NO: 47.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 65 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 77.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 15, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 21 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 28 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 36 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 66 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 37 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 67 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 16, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 22 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 29 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 38 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 68 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 39 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 69 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 17, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 23 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 30 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 40 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 70 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 41 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 71 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 18, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 24 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 31 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 42 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 72 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 18, 19, 20, 9 and 10, respectively.
In some embodiments, the antibody competes for binding to human CD40 of SEQ
ID NO: 1 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody binds to the same epitope on human CD40 of SEQ ID NO: 1 to which the antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 binds to.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin.
In some embodiments, the antibody inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about lx10-9 M.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin, inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M and inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 25 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 32 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody is an IgGl, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the antibody is an IgG1 isotype.
In some embodiments, the antibody is an IgG2 isotype.
In some embodiments, the antibody is an IgG3 isotype.
In some embodiments, the antibody is an IgG4 isotype.
In some embodiments, the antibody is an IgGl isotype, optionally comprising a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG15, isotype comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG45, isotype comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG4/2, isotype comprising the S228P/F234A/L235A
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 43 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 73 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 44 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 74 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody is a multispecific antibody, such as a bispecific antibody.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease.
The antibody is suitable for use in therapy, for example in treating Addinson's disease.
The antibody is suitable for use in therapy, for example in treating an ankylosing spondylitis.
The antibody is suitable for use in therapy, for example in treating an atherosclerosis.
The antibody is suitable for use in therapy, for example in treating an autoimmune hepatitis.
The antibody is suitable for use in therapy, for example in treating an autoimmune diabetes.
The antibody is suitable for use in therapy, for example in treating Graves' disease.
The antibody is suitable for use in therapy, for example in treating Buillain-Barre syndrome.
The antibody is suitable for use in therapy, for example in treating Hashimoto's disease.
The antibody is suitable for use in therapy, for example in treating, an idiopathic thrombocytopenia.
The antibody is suitable for use in therapy, for example in treating an inflammatory bowel disease (IBD).
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus.
The antibody is suitable for use in therapy, for example in treating a multiple sclerosis.
The antibody is suitable for use in therapy, for example in treating a myasthenia gravis.
The antibody is suitable for use in therapy, for example in treating a psoriasis.
The antibody is suitable for use in therapy, for example in treating an arthritis.
The antibody is suitable for use in therapy, for example in treating a scleroderma.
The antibody is suitable for use in therapy, for example in treating Sjogren's syndrome.
The antibody is suitable for use in therapy, for example in treating a systemic sclerosis.
The antibody is suitable for use in therapy, for example in treating a transplantation.
The antibody is suitable for use in therapy, for example in treating a kidney transplantation.
The antibody is suitable for use in therapy, for example in treating a skin transplantation.
The antibody is suitable for use in therapy, for example in treating a bone marrow transplantation.
The antibody is suitable for use in therapy, for example in treating a graft versus host disease (GVHD).
The antibody is suitable for use in therapy, for example in treating a type I
diabetes.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis.
The antibody is suitable for use in therapy, for example in treating a juvenile arthritis.
The antibody is suitable for use in therapy, for example in treating a psoriatic arthritis.
The antibody is suitable for use in therapy, for example in treating Reiter's syndrome.
The antibody is suitable for use in therapy, for example in treating a gouty arthritis.
The antibody is suitable for use in therapy, for example in treating Crohn's disease.
The antibody is suitable for use in therapy, for example in treating an ulcerative colitis.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease, in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease, in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus in combination with a second therapeutic agent.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 17, 19, 20, 9 and 10, respectively.
In some embodiments, the antibody competes for binding to human CD40 of SEQ
ID NO: 1 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody binds to the same epitope on human CD40 of SEQ ID NO: 1 to which the antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 binds to.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin.
In some embodiments, the antibody inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about lx10-9 M.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin, inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M and inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 26 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 33 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody is an IgGl, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the antibody is an IgG1 isotype.
In some embodiments, the antibody is an IgG2 isotype.
In some embodiments, the antibody is an IgG3 isotype.
In some embodiments, the antibody is an IgG4 isotype.
In some embodiments, the antibody is an IgGl isotype, optionally comprising a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG15, isotype comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG45, isotype comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG4/2, isotype comprising the S228P/F234A/L235A
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 45 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 75 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 46 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 76 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody is a multispecific antibody, such as a bispecific antibody.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease.
The antibody is suitable for use in therapy, for example in treating Addinson's disease.
The antibody is suitable for use in therapy, for example in treating an ankylosing spondylitis.
The antibody is suitable for use in therapy, for example in treating an atherosclerosis.
The antibody is suitable for use in therapy, for example in treating an autoimmune hepatitis.
The antibody is suitable for use in therapy, for example in treating an autoimmune diabetes.
The antibody is suitable for use in therapy, for example in treating Graves' disease.
The antibody is suitable for use in therapy, for example in treating Buillain-Barre syndrome.
The antibody is suitable for use in therapy, for example in treating Hashimoto's disease.
The antibody is suitable for use in therapy, for example in treating, an idiopathic thrombocytopenia.
The antibody is suitable for use in therapy, for example in treating an inflammatory bowel disease (IBD).
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus.
The antibody is suitable for use in therapy, for example in treating a multiple sclerosis.
The antibody is suitable for use in therapy, for example in treating a myasthenia gravis.
The antibody is suitable for use in therapy, for example in treating a psoriasis.
The antibody is suitable for use in therapy, for example in treating an arthritis.
The antibody is suitable for use in therapy, for example in treating a scleroderma.
The antibody is suitable for use in therapy, for example in treating Sjogren's syndrome.
The antibody is suitable for use in therapy, for example in treating a systemic sclerosis.
The antibody is suitable for use in therapy, for example in treating a transplantation.
The antibody is suitable for use in therapy, for example in treating a kidney transplantation.
The antibody is suitable for use in therapy, for example in treating a skin transplantation.
The antibody is suitable for use in therapy, for example in treating a bone marrow transplantation.
The antibody is suitable for use in therapy, for example in treating a graft versus host disease (GVHD).
The antibody is suitable for use in therapy, for example in treating a type I
diabetes.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis.
The antibody is suitable for use in therapy, for example in treating a juvenile arthritis.
The antibody is suitable for use in therapy, for example in treating a psoriatic arthritis.
The antibody is suitable for use in therapy, for example in treating Reiter's syndrome.
The antibody is suitable for use in therapy, for example in treating a gouty arthritis.
The antibody is suitable for use in therapy, for example in treating Crohn's disease.
The antibody is suitable for use in therapy, for example in treating an ulcerative colitis.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus in combination with a second therapeutic agent.
Competition between binding to human CD40 with antibodies of the invention comprising certain VH and VL sequences may be assayed in vitro using following protocol: His-tagged recombinant soluble human CD40 (CD40-ECD-his) is used in the assay. 5 uL of anti-his mAb (10 jtg/mL, R&D Systems, MAB050) is directly coated on MSD HighBind plates for 2 hours at room temperature and then blocked with 5%
MSD
Blocker A buffer for an additional 2 hours at room temperature. 25 uL of 10 ug/mL CD40-ECD-his protein is added to be captured by anti-his mAb. After incubation with gentle shaking at room temperature 2 hours, plates are washed 3x with 0.1 M HEPES
buffer, pH
7.4, followed by the addition of the mixture of 10 nM Ruthenium (Ru)-labeled reference anti-CD40 mAb or a Fab portion thereof which is pre-incubated at room temperature for 30 minutes with different concentrations, from 2 uM to 1 nM, of a test anti-CD40 antibody.
After incubation with gentle shaking at room temperature 1 hours, plates are washed 3x with 0.1M HEPES buffer (pH 7.4). MSD Read Buffer T is diluted with distilled water (4-fold) and dispensed into each well then analyzed with a SECTOR Imager 6000 (Meso Scale Discovery, Gaithersburg, MD). The test antibody competes for binding to human CD40 with a reference antibody (e.g. an antibody comprising the VH of SEQ ID
NO: 11 and the VL of SEQ ID NO: 12, the antibody comprising the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 or the antibody comprising the VH of SEQ ID NO: 26 and the VL
of SEQ DI NO: 27) when the test antibody reduces the MDS signal obtained in the above assay using the Ru-labeled reference antibody or a Fab portion thereof by more than 90%.
Antibodies that compete for binding to CD40 with an antibody comprising the VH
of SEQ
ID NO: 11 and the VL of SEQ ID NO: 12, the VH of SEQ ID NO: 25 and the VL of SEQ
ID NO: 27 or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 may be generated by isolating antibodies specifically binding human CD40 using phage display libraries, and screening the generated antibodies for their ability to compete for binding to CD40 with the aforementioned antibodies.
The CD40 epitope the antibody of the invention binds to may be resolved for example using hydrogen/deuterium exchange (HID exchange) or by analyzing a crystal structure of the antibody in complex with CD40. Two CD40 antibodies "bind the same epitope on CD40" when 80% or more CD40 amino acid residues protected by the antibody by at least 5% difference in deuteration levels through HID exchange are identical between the two antibodies, or when 80% or more CD40 surface exposed amino acid residues determined to bind the antibody in a crystal structure of a complex of the antibody and CD40 are identical between the two antibodies. In the crystal structure of a complex of the antibody and CD40, the epitope residues are those CD40 residues that reside within 4 A
distance or less from any of the antibody CDR residues.
In an HID exchange assay, CD40 protein is incubated in the presence or absence of the antibody in deuterated water for predetermined times resulting in deuterium incorporation at exchangeable hydrogen atoms which are unprotected by the antibody, followed by protease digestion of the protein and analyses of the peptide fragments using LC-MS. In an exemplary assay, 5 u.L of the test antibody ( 10 u.g) or 5 u.L of the complex of CD40 and the test antibody ( 10 & 7.35 ug, respectively) is incubated with 120 u.L
deuterium oxide labeling buffer (50mM phosphate, 100mM sodium chloride at pH
7.4) for 0 sec, 60 sec, 300 sec, 1800 sec, 7200 sec, and 14400 sec. Deuterium exchange is quenched by adding 63 [IL of 5 M guanidine hydrochloride and final pH is 2.5.
The quenched sample is subjected to on-column pepsin/protease type XIII digestion and LC-MS analysis. For pepsin/protease type XIII digestion, 5 lag of the samples in 125 [IL
control buffer (50mM phosphate, 100mM sodium chloride at pH 7.4) are denatured by adding 63 [IL of 5 M guanidine hydrochloride (final pH is 2.5) and incubating the mixture for 3 min. Then, the mixture is subjected to on-column pepsin/protease type XIII digestion and the resultant peptides analyzed using an UPLC-MS system comprised of a Waters Acquity UPLC coupled to a Q ExactiveTm Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo). Raw MS data is processed using HDX WorkBench, software for the analysis of HID exchange MS data. The deuterium levels are calculated using the average mass difference between the deuteriated peptide and its native form (to). Peptide identification is done through searching MS/MS data against the CD40 sequence with Mascot. The mass tolerance for the precursor and product ions is 20 ppm and 0.05 Da, respectively.
For X-ray crystallography, CD40 and the test antibody are expressed and purified using standard protocols. The CD40/test antibody complex is incubated overnight at 4 C, concentrated, and separated from the uncomplexed species using size-exclusion chromatography. The complex is crystallized by the vapor-diffusion method from various known test solutions for example solutions containing PEG3350, ammonium citrate and 2-(N-morpholino)ethanesulfonic acid (MES).
Antibodies binding the same epitope on CD40 as a reference antibody may be generated by isolating antibodies binding CD40 using phage display libraries, selecting those antibodies that compete with the reference antibody for binding to CD40 by 100%, and identifying the antibody epitope by HID exchange or by X-ray crystallography.
Alternatively, mice or rabbits may be immunized using peptides encompassing the epitope residues, and the generated antibodies may be evaluated for their binding within the recited region.
The affinity of an antibody to human or cyno CD40 may be determined experimentally using any suitable method. An exemplary method utilizes ProteOn XPR36, Biacore 3000 or KinExA instrumentation, ELISA or competitive binding assays known to those skilled in the art. The measured affinity of a particular antibody to CD40 may vary if measured under different conditions (e.g., osmolarity, pH). Thus, measurements of affinity and other binding parameters (e.g., KD, Koo, and Koff) are typically made with standardized conditions and a standardized buffer, such as the buffer described herein.
Skilled in the art will appreciate that the internal error for affinity measurements for example using Biacore 3000 or ProteOn (measured as standard deviation, SD) can typically be within 5-33% for measurements within the typical limits of detection. Therefore the term "about" reflects the typical standard deviation in the assay. For example, the typical SD for a KD
of 1x10-9 M is up to +0.33x10-9 M.
In the B cell proliferation assay, 1x105 human tonsil B cells may be cultured in RPMI medium containing glutamax, 10% FBS and 1% Pen/Strep, titrations of each of the antibodies specifically binding human CD40 may be added to the cells, followed by addition of 0.5 ug/m1 soluble human CD154. Cells may be cultured for 48 hours at 37 C, pulsed with 3H-thymidine (luCi/well) in 50 ul medium and cultured for 16-18 hours before harvest and counting.
In the DC IL-12p40 production assay, human DCs may be generated by culturing purified human monocytes (2.5x106/well 6-well plates) for 6 days in 3m1 RPMI
medium containing glutamax, 25mM HEPES, 10% FBS, 1% Pen/Strep and 5Ong each GM-CSF
and IL-4. On day 3, lml of the medium may be removed and replaced with 2m1 fresh medium containing 50 ng/ml each of GM-CSF and IL-4. On day 6, DCs may be plated into 96-well plates (100,000 cells/well) followed by titrations of each of the antibodies specifically binding human CD40 and addition of 1ug/m1 of soluble human CD154 to the cultures. Cells may be cultured for 48 hours before collecting and analyzing supernatants for IL-12p40 by MSD.
Immune effector properties of the antibodies of the invention may be enhanced or silenced through Fc modifications. For example, Fc effector functions such as Clq binding, complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. may be provided and/or controlled by modifying residues in the Fc responsible for these activities.
In some embodiments, the antibody of the invention has reduced binding to FeyRI, FeyRIIa, FeyRIIb, FeyRIIIa or FeyRIIIb.
"Reduced binding" refers to reduced binding of the antibody of the invention having at least one mutation in the Fc region to an Fey receptor (FcyR) when compared to the binding of the parental antibody without the mutation to the same FeyR.
"Reduced binding" may be at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or at least about 20,000-fold reduced binding. In practice, antibodies exhibiting "reduced binding" to a particular FcyR refer to antibodies that have statistically insignificant effector function mediated by the particular FcyR.
In some embodiments, the antibody of the invention comprises at least one mutation in the Fc region that reduces binding of the antibody to an FcyR.
In some embodiments, the FcyR is FcyRI, FcyRIIa or FcyRIIIa or FcyRIIIb.
In some embodiments, the at least one mutation in the Fc region is a L234A
mutation, a L235A mutation, a G237A mutation, a P238S mutation, a M252Y
mutation, a S254T mutation, a T256E mutation, a H268A mutation, a A330S mutation or a mutation, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the at least one mutation in the Fc region is a V234A
mutation, a G237A mutation, a P238S mutation, a M252Y mutation , a 5254T
mutation, a T256E mutation, a H268A mutation, a V309L mutation, an A3305 mutation or a mutation, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a V234A/G237A/
P2385/H268AN309L/A3305/P3315 mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a 5228P mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a F234A mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a L235A mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a 5228P/F234A/L235A mutation, wherein residue numbering is according to the EU
Index.
Binding of the antibodies of the invention to FcyRI, FcyRIIa, FcyRIIb, FcyRIIIa and FcyRIIIb may be evaluated using recombinant soluble forms or cell-associated forms of the Fcy receptors. For example, direct or indirect, e.g., competitive binding, measurements may be applied for assessing relative affinities and avidities of the antibodies of the invention to various FcyR. In an exemplary assay, a test antibody binding to soluble FcyR captured on a plate is evaluated using competitive binding between 1 [Tim' biotinylated human IgG1 and serial dilutions of the test antibody pre-complexed with antigen.
In some embodiments, the antibody of the invention comprising at least one mutation in the Fc region has reduced antibody dependent cellular cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis, ("ADCP") and/or reduced complement dependent cytotoxicity (CDC).
"Antibody-dependent cellular cytotoxicity", "antibody-dependent cell-mediated cytotoxicity" or "ADCC" is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells with effector cells possessing lytic activity, such as natural killer cells, monocytes, macrophages and neutrophils via Fc gamma receptors (FcyR) expressed on effector cells. For example, NK cells express FcyRIIIa, whereas monocytes express FcyRI, FcyRII and FcyRIIIa. To assess ADCC activity of the antibodies of the invention, the antibody may be added to target cells in combination with immune effector cells, which may be activated by the antigen antibody complexes resulting in cytolysis of the target cell. Cytolysis is generally detected by the release of label (e.g.
radioactive substrates, fluorescent dyes or natural intracellular proteins) from the lysed cells. Exemplary effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells. Exemplary target cells include cells expressing CD40.
"Antibody-dependent cellular phagocytosis" ("ADCP") refers to a mechanism of elimination of antibody-coated target cells by internalization by phagocytic cells, such as macrophages or dendritic cells. ADCP may be evaluated using monocyte-derived macrophages as effector cells and cells expressing CD40 engineered to express GFP or other labeled molecule as target cells. Effector:target cell ratio may be for example 4:1.
Effector cells may be incubated with target cells for 4 hours with or without the test CD40 antibody. After incubation, cells may be detached using accutase. Macrophages may be identified with anti-CD1 lb and anti-CD14 antibodies coupled to a fluorescent label, and percent phagocytosis may be determined based on % GFP fluorescent in the CD11+CD14+
macrophages using standard methods.
"Complement-dependent cytotoxicity", or "CDC", refers to a mechanism for inducing cell death in which an Fc effector domain of a target-bound antibody binds and activates complement component Clq which in turn activates the complement cascade leading to target cell death. Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes. CDC of CD40-expressing cells may be measured for example by plating cells expressing CD40 in an appropriate medium, adding anti-CD4Oantibodies into the mixture, followed by addition of pooled human serum. After incubation period, percentage (%) lysed cells may be detected as % propidium iodide stained cells in FACS assay using standard methods.
"Reduced ADCC", "reduced CDC" and "reduced ADCP" refers to a statistically significant reduction in ADCC, CDC and/or ADCP mediated by the antibody of the invention comprising at least one mutation in the Fc region when compared to the same antibody without the mutation. ADCC, CDC and/or ADCP, such as assays described herein and in assays described in U.S. Pat. No. 8,871,204.
Variants of the antibodies of the invention comprising the VH or the VL amino acid sequences shown in Table 7 are within the scope of the invention. For example, variants may comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions in the VH
and/or the VL that do not adversely affect the characteristics of the antibodies. In some embodiments, the sequence identity may be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%
to the antibody VH or the VL amino acid sequence of the invention.
The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity =# of identical positions/total #
of positions x100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The percent identity between two amino acid sequences may be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences may be determined using the Needleman and Wunsch (1 Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://_www_gcg_com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
In some embodiments, the antibody of the invention comprises the VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the VH
of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the VL of SEQ ID NOs:
or 27, wherein the antibody exhibits one or more of the following properties:
inhibits 0.5 [tg/m1 human soluble CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M;
inhibits 1 [tg/m1 human soluble CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M; or binds to human CD40 with a dissociation constant (KD) of about 5x10-9 M or less, when the KD is measured using ProteOn XPR36 system using experimental design described in Example 4.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 11 and the VL of SEQ ID NO: 12.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 21 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 22 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 23 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 24 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 11 and the VL of SEQ ID NO: 12, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions and the antibody exhibits one or more of the following properties:
inhibits 0.5 [tg/m1 human soluble CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M;
inhibits 1 [tg/m1 human soluble CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M; or binds to human CD40 with a dissociation constant (KD) of about 5x10-9 M or less, when the KD is measured using ProteOn XPR36 system using experimental design described in Example 4.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 11 and the VL of SEQ ID NO: 12, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 21 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 22 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 23 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 24 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 25 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 26 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
"Conservative modification" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequences. Conservative modifications include amino acid substitutions, additions and deletions. Conservative amino acid substitutions are those in which the amino acid is replaced with an amino acid residue having a similar side chain. The families of amino acid residues having similar side chains are well defined and include amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), basic side chains (e.g., lysine, arginine, histidine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), uncharged polar side chains (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine, tryptophan), aromatic side chains (e.g., phenylalanine, tryptophan, histidine, tyrosine), aliphatic side chains (e.g., glycine, alanine, valine, leucine, isoleucine, serine, threonine), amide (e.g., asparagine, glutamine), beta-branched side chains (e.g., threonine, valine, isoleucine) and sulfur-containing side chains (cysteine, methionine). Furthermore, any native residue in the polypeptide may be substituted with alanine, as has been previously described for alanine scanning mutagenesis (MacLennan et al., Acta Physiol. Scand. Suppl. 643:55-67, 1998;
Sasaki et al., Adv. Biophys. 35:1-24, 1998). Amino acid substitutions to the antibodies of the invention may be made by well-known methods for example by PCR mutagenesis (US
Pat.
No. 4,683,195). Alternatively, libraries of variants may be generated using known methods, for example using random (NNK) or non-random codons, for example DVK
codons, which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp). The resulting antibody variants may be tested for their characteristics using assays described herein.
Although the embodiments illustrated in the Examples comprise pairs of variable regions, one from a heavy chain and one from a light chain, a skilled artisan will recognize that alternative embodiments may comprise single heavy or light chain variable regions.
The single variable region may be used to screen for variable domains capable of forming a two-domain specific antigen-binding fragment capable of for example specifically binding to human CD40. The screening may be accomplished by phage display screening methods using for example hierarchical dual combinatorial approach disclosed in Int.
Pat. Publ. No.
W01992/01047.
Antibodies of the invention may be generated using various technologies. For example, the hybridoma method of Kohler and Milstein, Nature 256:495, 1975 may be used to generate monoclonal antibodies. In the hybridoma method, a mouse or other host animal, such as a hamster, rat, rabbit or monkey, is immunized with human, marmoset or cyno CD40 or fragments of CD40, such as soluble form of CD40, followed by fusion of spleen cells from immunized animals with myeloma cells using standard methods to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-(Academic Press, 1986)). Colonies arising from single immortalized hybridoma cells are screened for production of antibodies with desired properties, such as specificity of binding, cross-reactivity or lack thereof, and affinity for the antigen.
Various host animals may be used to produce the antibodies of the invention.
For example, Balb/c mice may be used to generate antibodies. The antibodies made in Balb/c mice and other non-human animals may be humanized using various technologies to generate more human-like sequences. Exemplary humanization techniques including selection of human acceptor frameworks are known and include CDR grafting (U.S. Pat.
No. 5,225,539), SDR grafting (U.S. Pat. No. 6,818,749), Resurfacing (Padlan, Mol Immunol 28:489-499, 1991), Specificity Determining Residues Resurfacing (U.S.
Pat.
Publ. No. 20100261620), human-adaptation (or human framework adaptation) (U.S.
Pat.
Publ. No. U52009/0118127), Superhumanization (U.S. Pat. No. 7,709, 226) and guided selection (Osbourn et al (2005) Methods 36:61-68, 2005; U.S. Pat. No.
"Complementarity determining regions (CDR)" are "antigen binding sites" in an antibody. CDRs may be defined using various terms: (i) Complementarity Determining Regions (CDRs), three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL
(LCDR1, LCDR2, LCDR3) are based on sequence variability (Wu and Kabat, J Exp Med 132:211-50, 1970; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
(ii) "Hypervariable regions", "HVR", or "HV", three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3) refer to the regions of an antibody variable domains which are hypervariable in structure as defined by Chothia and Lesk (Chothia and Lesk, Mol Biol 196:901-17, 1987). The International ImMunoGeneTics (IMGT) database (http://www_imgt_org) provides a standardized numbering and definition of antigen-binding sites. The correspondence between CDRs, HVs and IMGT delineations is described in Lefranc et al., Dev Comparat Immunol 27:55-77, 2003. The term "CDR", "HCDR1", "HCDR2", "HCDR3", "LCDR1", "LCDR2" and "LCDR3" as used herein includes CDRs defined by any of the methods described supra, Kabat, Chothia or IMGT, unless otherwise explicitly stated in the specification.
Immunoglobulins may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG
are further sub-classified as the isotypes IgAi, IgA2, IgGi, IgG2, IgG3 and IgG4. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa (k) and lambda (2), based on the amino acid sequences of their constant domains.
"Antigen-binding fragment" refers to a portion of an immunoglobulin molecule that retains the antigen binding properties of the parental full length antibody. Exemplary antigen-binding fragments are as heavy chain complementarity determining regions (HCDR) 1, 2 and/or 3, light chain complementarity determining regions (LCDR) 1, 2 and/or 3, a heavy chain variable region (VH), or a light chain variable region (VL), Fab, F(ab')2, Fd and Fv fragments as well as domain antibodies (dAb) consisting of either one VH domain or one VL domain. VH and VL domains may be linked together via a synthetic linker to form various types of single chain antibody designs in which the VH/VL
domains pair intramolecularly, or intermolecularly in those cases when the VH
and VL
domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in Int. Pat. Publ.
No.
W01998/44001, Int. Pat. Publ. No. W01988/01649; Int. Pat. Publ. No.
W01994/13804;
Int. Pat. Publ. No. W01992/01047.
"Monoclonal antibody" refers to an antibody population with single amino acid composition in each heavy and each light chain, except for possible well known alterations such as removal of C-terminal lysine from the antibody heavy chain. Monoclonal antibodies typically bind one antigenic epitope, except that multispecific monoclonal antibodies bind two or more distinct antigens or epitopes. Bispecific monoclonal antibodies bind two distinct antigenic epitopes. Monoclonal antibodies may have heterogeneous glycosylation within the antibody population. Monoclonal antibody may be monospecific or multispecific, or monovalent, bivalent or multivalent. A
multispecific antibody, such as a bispecific antibody or a trispecific antibody is included in the term monoclonal antibody.
"Isolated antibody" refers to an antibody or an antigen-binding fragment thereof that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody specifically binding human CD40 is substantially free of antibodies that specifically bind antigens other than human CD40). In case of a bispecific antibody, the bispecific antibody specifically binds two antigens of interest, and is substantially free of antibodies that specifically bind antigens other that the two antigens of interest. "Isolated antibody" encompasses antibodies that are isolated to a higher purity, such as antibodies that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% pure.
"Humanized antibodies" refers to antibodies in which the antigen binding sites are derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Humanized antibodies may include intentionally introduced mutations in the framework regions so that the framework may not be an exact copy of expressed human immunoglobulin or germline gene sequences.
"Human antibodies" refers to antibodies having heavy and light chain variable regions in which both the framework and the antigen binding site are derived from sequences of human origin. If the antibody contains a constant region or a portion of the constant region, the constant region also is derived from sequences of human origin.
A human antibody comprises heavy or light chain variable regions that are derived from sequences of human origin if the variable regions of the antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes.
Such exemplary systems are human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice or rats carrying human immunoglobulin loci as described herein. A human antibody typically contain amino acid differences when compared to the human germline or rearranged immunoglobulin sequences due to, for example naturally occurring somatic mutations, intentional introduction of substitutions into the framework or antigen binding site and amino acid changes introduced during cloning and VDJ recombination in non-human animals. Typically, a human antibody is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical in amino acid sequence to an amino acid sequence encoded by a human germline or rearranged immunoglobulin gene.
In some cases, a human antibody may contain consensus framework sequences derived from human framework sequence analyses, for example as described in Knappik et al., J
Mol Biol 296:57-86, 2000, or synthetic HCDR3 incorporated into human immunoglobulin gene libraries displayed on phage, for example as described in Shi et al., J
Mol Biol 397:385-96, 2010 and Int. Pat. Publ. No. W02009/085462.
Antibodies in which antigen binding sites are derived from a non-human species are not included in the definition of human antibody.
"Recombinant" includes antibodies and other proteins that are prepared, expressed, created or isolated by recombinant means.
"Epitope" refers to a portion of an antigen to which an antibody specifically binds.
Epitopes typically consist of chemically active (such as polar, non-polar or hydrophobic) surface groupings of moieties such as amino acids or polysaccharide side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope may be composed of contiguous and/or discontiguous amino acids that form a conformational spatial unit. For a discontiguous epitope, amino acids from differing portions of the linear sequence of the antigen come in close proximity in 3-dimensional space through the folding of the protein molecule.
"Multispecific" refers to an antibody that specifically binds at least two distinct antigens or two distinct epitopes within the antigens, for example three, four or five distinct antigens or epitopes.
"Bispecific" refers to an antibody that specifically binds two distinct antigens or two distinct epitopes within the same antigen. The bispecific antibody may have cross-reactivity to other related antigens or can bind an epitope that is shared between two or more distinct antigens.
"Variant" refers to a polypeptide or a polynucleotide that differs from a reference polypeptide or a reference polynucleotide by one or more modifications for example, substitutions, insertions or deletions.
"Vector" refers to a polynucleotide capable of being duplicated within a biological system or that can be moved between such systems. Vector polynucleotides typically contain elements, such as origins of replication, polyadenylation signal or selection markers, that function to facilitate the duplication or maintenance of these polynucleotides in a biological system. Examples of such biological systems may include a cell, virus, animal, plant, and reconstituted biological systems utilizing biological components capable of duplicating a vector. The polynucleotide comprising a vector may be DNA or RNA
molecules or a hybrid of these.
"Expression vector" refers to a vector that can be utilized in a biological system or in a reconstituted biological system to direct the translation of a polypeptide encoded by a polynucleotide sequence present in the expression vector.
"Polynucleotide" refers to a synthetic molecule comprising a chain of nucleotides covalently linked by a sugar-phosphate backbone or other equivalent covalent chemistry.
cDNA is a typical example of a polynucleotide.
"Polypeptide" or "protein" refers to a molecule that comprises at least two amino acid residues linked by a peptide bond to form a polypeptide. Small polypeptides of less than 50 amino acids may be referred to as "peptides".
"CD40" or "huCD40" refers to the human CD40 protein. CD40 is also known as Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), CD4OL receptor or CD154 receptor. The amino acid sequence of the full length human CD40 is shown in SEQ ID NO: 1. Human full length CD40 protein is a type I membrane protein with amino acids. The signal sequence spans residues 1-20, the extracellular domain spans residues 21-193, the transmembrane domain spans residues 194-215, and the cytoplasmic domain spans residues 216-277 of SEQ ID NO: 1. Throughout the specification, the extracellular domain of CD40, "CD40-ECD", refers to the CD40 fragment of residues 21-193 of SEQ ID NO: 1.
"Antagonist" or "antagonistic" refers to an antibody that specifically binds human CD40 and inhibits CD40 biological activity in the presence of CD4OL in cellular assays such as CD4OL-driven human B cell proliferation or CD4OL-driven IL-12p40 production by human dendritic cells. The antagonist may inhibit CD40 biological activity in a statistically significant manner when compared to a control sample without the antibody.
Alternatively, the antagonistic antibody specifically binding human CD40 may inhibit CD40 biological activity with an IC50 value of about 1 nM or less. CD4OL in the assays may be provided as a soluble form or membrane-bound (e.g. as cells expressing CD4OL, such as Jurkat cells).
"CD40 biological activity" refers to a measureable event in a cell occurring as a result of binding of CD4OL to CD40 on human cells. CD40 biological activity may be for example proliferation of human B cells or production of IL-12p40 by human dendritic cells, or downstream activation of CD40 signaling pathways. CD40 biological activity may be measured using known methods and methods described herein.
"About" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system.
Unless explicitly stated otherwise within the Examples or elsewhere in the Specification in the context of a particular assay, result or embodiment, "about" means within one standard deviation per practice in the art, or a range of up to 5%, whichever is larger.
"In combination with" means that two or more therapeutics can be administered to a subject together in a mixture, concurrently as single agents or sequentially as single agents in any order.
"Cross-linking" refers higher order multimerization of CD40 on cells induced by an antibody specifically binding human CD40 binding to FcyRIIb cis or trans, resulting in induction of CD40 agonistic activity.
Conventional one and three-letter amino acid codes are used herein as shown in Table 1.
Table 1.
Amino acid Three-letter code One-letter code Alanine Ala A
Arginine Arg Asparagine Asn Aspartate Asp Cysteine Cys Glutamate Gln Glutamine Glu Glycine Gly Histidine His Isoleucine Ile Lysine Lys Methionine Met Phenylalanine Phe Proline Pro Serine Ser Threonine Thr Tryptophan Trp Tyrosine Tyr Valine Val V
Antibodies of the invention The invention provides antagonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies, vectors, host cells and methods of using the antibodies.
The antibodies of the invention are potent inhibitors of CD40 and have minimal agonistic activity. It is documented that antagonistic anti-CD40 antibodies, albeit being antagonists, can also have agonistic activity as a result of Fc-dependent cross-linking (for example see US7,537,763) and therefore pose a potential safety risk when administered to subjects in which suppression of CD40 signaling is desired, such as patients with autoimmune disease. Preferable anti-CD40 antibodies for the treatment of conditions in which inhibition of CD40 biological function is desired are hence those that lack agonistic activity, or have minimal agonistic activity. Suitable therapeutic CD40 antibodies would thus be Fc-engineered to abolish FcyR binding, and as a result lack Fc-mediated cross-linking and potential for Fc-mediated agonism. Such effector silent Fc-engineered antibodies are for example ASKP-1240, CFZ533, BMS-986090 and Antibody D
("benchmark antibodies"). ASKP-1240 and CFZ533 are currently in clinical development for inflammatory or autoimmune diseases.
The antibodies of the invention demonstrate improved properties when compared to the benchmark antibodies. The antibody C40B16 of the invention has minimal agonistic activity and activates CD40 signaling to a lesser extend when compared to the benchmark antibodies ASKP-1240, CFZ533 and BMS-986090. As ASKP-1240, CFZ533 and BMS-986090 are Fc effector silent antibodies, the observed agonism of these antibodies may be epitope-dependent. C40B16 on the contrary is a wild-type IgG1 and therefore possesses neither epitope-dependent nor Fc-dependent agonism. Further, Fc engineered effector silent antibodies C40B176, C40B179, C40B180 and C40B183 of the invention demonstrate only minimal agonism but also up to 10-fold improved potency when compared to Antibody D.
The invention provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 5, a HCDR2 of SEQ
ID NO: 61, a HCDR3 of SEQ ID NO: 62, a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 63, a LCDR2 of SEQ ID NO: 9 and a LCDR3 of SEQ
ID
NO: 10.
SEQ ID NOs: 61, 62 and 63 represent the HCDR2, the HCDR3 and the LCDR1, genus sequences of antagonistic antibodies specifically binding CD40, the genera encompassing variants of a parental antibody C40B16 in which putative sites for post-translational modifications have been mutated. The antibodies within the genus are expected to display no shift in epitope, e.g. the antibodies comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID NOs: 5, 61, 62, 63, 9 and 10 are expected to have similar characteristics when compared to the parental C40B16 antibody. Exemplary such antibodies are antibodies comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 or the VH and the VL
amino acid sequences of antibodies C40M141, C40M152, C40M142, C40M153, C40M144, C40M155, C40M148, C40M194, C40M198, C40M197, C40M201 or C40M126 as shown in Table 2 and Table 7.
SEQ ID NO: 61 Genus HCDR2 sequence:
TIX1X2X3GGGTYYADSVKG; wherein Xi is N, D or Q;
X2 is N, Q or A; and X3 is S or A.
SEQ ID NO: 62 genus HCDR3 sequence EGGKYYYYAXIDV; wherein XiisMorL
SEQ ID NO: 63 genus LCDR1 sequence SGDKLGDKYAXI; wherein X1 is C or A.
Table 2.
SEQ ID NO:
mAb In some embodiments, the antibody competes for binding to human CD40 of SEQ
ID NO: 1 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody binds to the same epitope on human CD40 of SEQ ID NO: 1 to which the antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 binds to.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x101 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01%
polysorbate 20 (PS-20) and 100 ug/m1 bovine serum albumin.
In some embodiments, the antibody inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about lx10-9 M.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x101 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 ug/m1 bovine serum albumin, inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M and inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody is an IgGl, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the antibody is an IgG1 isotype.
In some embodiments, the antibody is an IgG2 isotype.
In some embodiments, the antibody is an IgG3 isotype.
In some embodiments, the antibody is an IgG4 isotype.
In some embodiments, the antibody is an IgGl isotype, optionally comprising a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a S228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the S228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype comprising the S228P
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a S228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is a multispecific antibody, such as a bispecific antibody.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease.
The antibody is suitable for use in therapy, for example in treating Addinson's disease.
The antibody is suitable for use in therapy, for example in treating an ankylosing spondylitis.
The antibody is suitable for use in therapy, for example in treating an atherosclerosis.
The antibody is suitable for use in therapy, for example in treating an autoimmune hepatitis.
The antibody is suitable for use in therapy, for example in treating an autoimmune diabetes.
The antibody is suitable for use in therapy, for example in treating Graves' disease.
The antibody is suitable for use in therapy, for example in treating Buillain-Barre syndrome.
The antibody is suitable for use in therapy, for example in treating Hashimoto's disease.
The antibody is suitable for use in therapy, for example in treating, an idiopathic thrombocytopenia.
The antibody is suitable for use in therapy, for example in treating an inflammatory bowel disease (IBD).
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus.
The antibody is suitable for use in therapy, for example in treating a multiple sclerosis.
The antibody is suitable for use in therapy, for example in treating a myasthenia gravis.
The antibody is suitable for use in therapy, for example in treating a psoriasis.
The antibody is suitable for use in therapy, for example in treating an arthritis.
The antibody is suitable for use in therapy, for example in treating a scleroderma.
The antibody is suitable for use in therapy, for example in treating Sjogren's syndrome.
The antibody is suitable for use in therapy, for example in treating a systemic sclerosis.
The antibody is suitable for use in therapy, for example in treating a transplantation.
The antibody is suitable for use in therapy, for example in treating a kidney transplantation.
The antibody is suitable for use in therapy, for example in treating a skin transplantation.
The antibody is suitable for use in therapy, for example in treating a bone marrow transplantation.
The antibody is suitable for use in therapy, for example in treating a graft versus host disease (GVHD).
The antibody is suitable for use in therapy, for example in treating a type I
diabetes.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis.
The antibody is suitable for use in therapy, for example in treating a juvenile arthritis.
The antibody is suitable for use in therapy, for example in treating a psoriatic arthritis.
The antibody is suitable for use in therapy, for example in treating Reiter's syndrome.
The antibody is suitable for use in therapy, for example in treating a gouty arthritis.
The antibody is suitable for use in therapy, for example in treating Crohn's disease.
The antibody is suitable for use in therapy, for example in treating an ulcerative colitis.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus in combination with a second therapeutic agent.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 6, 7, 8, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 11 and 12, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 13 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 14.
In some embodiments, the antibody comprises a heavy chain of SEQ ID NO: 35 and a light chain of SEQ ID NO: 47.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 65 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 77.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 15, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 21 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 28 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 36 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 66 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 37 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 67 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 16, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 22 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 29 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 38 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 68 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 39 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 69 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 17, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 23 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 30 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 40 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 70 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 41 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 71 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 18, 7, 20, 9 and 10, respectively.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 24 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 31 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 42 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 72 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
The invention also provides for an isolated antagonistic or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 18, 19, 20, 9 and 10, respectively.
In some embodiments, the antibody competes for binding to human CD40 of SEQ
ID NO: 1 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody binds to the same epitope on human CD40 of SEQ ID NO: 1 to which the antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 binds to.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin.
In some embodiments, the antibody inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about lx10-9 M.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin, inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M and inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 25 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 32 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody is an IgGl, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the antibody is an IgG1 isotype.
In some embodiments, the antibody is an IgG2 isotype.
In some embodiments, the antibody is an IgG3 isotype.
In some embodiments, the antibody is an IgG4 isotype.
In some embodiments, the antibody is an IgGl isotype, optionally comprising a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG15, isotype comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG45, isotype comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 and is an IgG4/2, isotype comprising the S228P/F234A/L235A
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 43 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 73 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 44 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 74 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody is a multispecific antibody, such as a bispecific antibody.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease.
The antibody is suitable for use in therapy, for example in treating Addinson's disease.
The antibody is suitable for use in therapy, for example in treating an ankylosing spondylitis.
The antibody is suitable for use in therapy, for example in treating an atherosclerosis.
The antibody is suitable for use in therapy, for example in treating an autoimmune hepatitis.
The antibody is suitable for use in therapy, for example in treating an autoimmune diabetes.
The antibody is suitable for use in therapy, for example in treating Graves' disease.
The antibody is suitable for use in therapy, for example in treating Buillain-Barre syndrome.
The antibody is suitable for use in therapy, for example in treating Hashimoto's disease.
The antibody is suitable for use in therapy, for example in treating, an idiopathic thrombocytopenia.
The antibody is suitable for use in therapy, for example in treating an inflammatory bowel disease (IBD).
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus.
The antibody is suitable for use in therapy, for example in treating a multiple sclerosis.
The antibody is suitable for use in therapy, for example in treating a myasthenia gravis.
The antibody is suitable for use in therapy, for example in treating a psoriasis.
The antibody is suitable for use in therapy, for example in treating an arthritis.
The antibody is suitable for use in therapy, for example in treating a scleroderma.
The antibody is suitable for use in therapy, for example in treating Sjogren's syndrome.
The antibody is suitable for use in therapy, for example in treating a systemic sclerosis.
The antibody is suitable for use in therapy, for example in treating a transplantation.
The antibody is suitable for use in therapy, for example in treating a kidney transplantation.
The antibody is suitable for use in therapy, for example in treating a skin transplantation.
The antibody is suitable for use in therapy, for example in treating a bone marrow transplantation.
The antibody is suitable for use in therapy, for example in treating a graft versus host disease (GVHD).
The antibody is suitable for use in therapy, for example in treating a type I
diabetes.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis.
The antibody is suitable for use in therapy, for example in treating a juvenile arthritis.
The antibody is suitable for use in therapy, for example in treating a psoriatic arthritis.
The antibody is suitable for use in therapy, for example in treating Reiter's syndrome.
The antibody is suitable for use in therapy, for example in treating a gouty arthritis.
The antibody is suitable for use in therapy, for example in treating Crohn's disease.
The antibody is suitable for use in therapy, for example in treating an ulcerative colitis.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease, in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease, in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus in combination with a second therapeutic agent.
The invention also provides for an isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of SEQ ID
NOs: 5, 17, 19, 20, 9 and 10, respectively.
In some embodiments, the antibody competes for binding to human CD40 of SEQ
ID NO: 1 with an antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody binds to the same epitope on human CD40 of SEQ ID NO: 1 to which the antibody comprising a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27, or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 binds to.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin.
In some embodiments, the antibody inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about lx10-9 M.
In some embodiments, the antibody binds human CD40 with a dissociation constant (KD) of about 1.5x10-1 M or less, when the KD is measured using ProteOn XPR36 system at 25 C in Dulbecco's phosphate buffered saline containing 0.01% PS-20 and 100 pg/m1 bovine serum albumin, inhibits soluble human CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M and inhibits soluble human CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M.
In some embodiments, the antibody comprises the VH and the VL of SEQ ID
NOs: 26 and 27, respectively.
In some embodiments, the VH is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 33 and the VL is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 34.
In some embodiments, the antibody is an IgGl, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the antibody is an IgG1 isotype.
In some embodiments, the antibody is an IgG2 isotype.
In some embodiments, the antibody is an IgG3 isotype.
In some embodiments, the antibody is an IgG4 isotype.
In some embodiments, the antibody is an IgGl isotype, optionally comprising a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG15, isotype, optionally comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG15, isotype comprising the L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation when compared to the wild-type IgGl.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG45, isotype comprising the 5228P mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG4 isotype, optionally comprising a 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG45, isotype, optionally comprising the 5228P/F234A/L235A mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 and is an IgG4/2, isotype comprising the S228P/F234A/L235A
mutation when compared to the wild-type IgG4.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 45 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 75 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody comprises the heavy chain of SEQ ID NO: 46 and the light chain of SEQ ID NO: 48.
In some embodiments, the heavy chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 76 and the light chain is encoded by a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 78.
In some embodiments, the antibody is a multispecific antibody, such as a bispecific antibody.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease.
The antibody is suitable for use in therapy, for example in treating Addinson's disease.
The antibody is suitable for use in therapy, for example in treating an ankylosing spondylitis.
The antibody is suitable for use in therapy, for example in treating an atherosclerosis.
The antibody is suitable for use in therapy, for example in treating an autoimmune hepatitis.
The antibody is suitable for use in therapy, for example in treating an autoimmune diabetes.
The antibody is suitable for use in therapy, for example in treating Graves' disease.
The antibody is suitable for use in therapy, for example in treating Buillain-Barre syndrome.
The antibody is suitable for use in therapy, for example in treating Hashimoto's disease.
The antibody is suitable for use in therapy, for example in treating, an idiopathic thrombocytopenia.
The antibody is suitable for use in therapy, for example in treating an inflammatory bowel disease (IBD).
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus.
The antibody is suitable for use in therapy, for example in treating a multiple sclerosis.
The antibody is suitable for use in therapy, for example in treating a myasthenia gravis.
The antibody is suitable for use in therapy, for example in treating a psoriasis.
The antibody is suitable for use in therapy, for example in treating an arthritis.
The antibody is suitable for use in therapy, for example in treating a scleroderma.
The antibody is suitable for use in therapy, for example in treating Sjogren's syndrome.
The antibody is suitable for use in therapy, for example in treating a systemic sclerosis.
The antibody is suitable for use in therapy, for example in treating a transplantation.
The antibody is suitable for use in therapy, for example in treating a kidney transplantation.
The antibody is suitable for use in therapy, for example in treating a skin transplantation.
The antibody is suitable for use in therapy, for example in treating a bone marrow transplantation.
The antibody is suitable for use in therapy, for example in treating a graft versus host disease (GVHD).
The antibody is suitable for use in therapy, for example in treating a type I
diabetes.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis.
The antibody is suitable for use in therapy, for example in treating a juvenile arthritis.
The antibody is suitable for use in therapy, for example in treating a psoriatic arthritis.
The antibody is suitable for use in therapy, for example in treating Reiter's syndrome.
The antibody is suitable for use in therapy, for example in treating a gouty arthritis.
The antibody is suitable for use in therapy, for example in treating Crohn's disease.
The antibody is suitable for use in therapy, for example in treating an ulcerative colitis.
The antibody is suitable for use in therapy, for example in treating an inflammatory disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating an autoimmune disease in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a rheumatoid arthritis in combination with a second therapeutic agent.
The antibody is suitable for use in therapy, for example in treating a systemic lupus erythematosus in combination with a second therapeutic agent.
Competition between binding to human CD40 with antibodies of the invention comprising certain VH and VL sequences may be assayed in vitro using following protocol: His-tagged recombinant soluble human CD40 (CD40-ECD-his) is used in the assay. 5 uL of anti-his mAb (10 jtg/mL, R&D Systems, MAB050) is directly coated on MSD HighBind plates for 2 hours at room temperature and then blocked with 5%
MSD
Blocker A buffer for an additional 2 hours at room temperature. 25 uL of 10 ug/mL CD40-ECD-his protein is added to be captured by anti-his mAb. After incubation with gentle shaking at room temperature 2 hours, plates are washed 3x with 0.1 M HEPES
buffer, pH
7.4, followed by the addition of the mixture of 10 nM Ruthenium (Ru)-labeled reference anti-CD40 mAb or a Fab portion thereof which is pre-incubated at room temperature for 30 minutes with different concentrations, from 2 uM to 1 nM, of a test anti-CD40 antibody.
After incubation with gentle shaking at room temperature 1 hours, plates are washed 3x with 0.1M HEPES buffer (pH 7.4). MSD Read Buffer T is diluted with distilled water (4-fold) and dispensed into each well then analyzed with a SECTOR Imager 6000 (Meso Scale Discovery, Gaithersburg, MD). The test antibody competes for binding to human CD40 with a reference antibody (e.g. an antibody comprising the VH of SEQ ID
NO: 11 and the VL of SEQ ID NO: 12, the antibody comprising the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27 or the antibody comprising the VH of SEQ ID NO: 26 and the VL
of SEQ DI NO: 27) when the test antibody reduces the MDS signal obtained in the above assay using the Ru-labeled reference antibody or a Fab portion thereof by more than 90%.
Antibodies that compete for binding to CD40 with an antibody comprising the VH
of SEQ
ID NO: 11 and the VL of SEQ ID NO: 12, the VH of SEQ ID NO: 25 and the VL of SEQ
ID NO: 27 or the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27 may be generated by isolating antibodies specifically binding human CD40 using phage display libraries, and screening the generated antibodies for their ability to compete for binding to CD40 with the aforementioned antibodies.
The CD40 epitope the antibody of the invention binds to may be resolved for example using hydrogen/deuterium exchange (HID exchange) or by analyzing a crystal structure of the antibody in complex with CD40. Two CD40 antibodies "bind the same epitope on CD40" when 80% or more CD40 amino acid residues protected by the antibody by at least 5% difference in deuteration levels through HID exchange are identical between the two antibodies, or when 80% or more CD40 surface exposed amino acid residues determined to bind the antibody in a crystal structure of a complex of the antibody and CD40 are identical between the two antibodies. In the crystal structure of a complex of the antibody and CD40, the epitope residues are those CD40 residues that reside within 4 A
distance or less from any of the antibody CDR residues.
In an HID exchange assay, CD40 protein is incubated in the presence or absence of the antibody in deuterated water for predetermined times resulting in deuterium incorporation at exchangeable hydrogen atoms which are unprotected by the antibody, followed by protease digestion of the protein and analyses of the peptide fragments using LC-MS. In an exemplary assay, 5 u.L of the test antibody ( 10 u.g) or 5 u.L of the complex of CD40 and the test antibody ( 10 & 7.35 ug, respectively) is incubated with 120 u.L
deuterium oxide labeling buffer (50mM phosphate, 100mM sodium chloride at pH
7.4) for 0 sec, 60 sec, 300 sec, 1800 sec, 7200 sec, and 14400 sec. Deuterium exchange is quenched by adding 63 [IL of 5 M guanidine hydrochloride and final pH is 2.5.
The quenched sample is subjected to on-column pepsin/protease type XIII digestion and LC-MS analysis. For pepsin/protease type XIII digestion, 5 lag of the samples in 125 [IL
control buffer (50mM phosphate, 100mM sodium chloride at pH 7.4) are denatured by adding 63 [IL of 5 M guanidine hydrochloride (final pH is 2.5) and incubating the mixture for 3 min. Then, the mixture is subjected to on-column pepsin/protease type XIII digestion and the resultant peptides analyzed using an UPLC-MS system comprised of a Waters Acquity UPLC coupled to a Q ExactiveTm Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo). Raw MS data is processed using HDX WorkBench, software for the analysis of HID exchange MS data. The deuterium levels are calculated using the average mass difference between the deuteriated peptide and its native form (to). Peptide identification is done through searching MS/MS data against the CD40 sequence with Mascot. The mass tolerance for the precursor and product ions is 20 ppm and 0.05 Da, respectively.
For X-ray crystallography, CD40 and the test antibody are expressed and purified using standard protocols. The CD40/test antibody complex is incubated overnight at 4 C, concentrated, and separated from the uncomplexed species using size-exclusion chromatography. The complex is crystallized by the vapor-diffusion method from various known test solutions for example solutions containing PEG3350, ammonium citrate and 2-(N-morpholino)ethanesulfonic acid (MES).
Antibodies binding the same epitope on CD40 as a reference antibody may be generated by isolating antibodies binding CD40 using phage display libraries, selecting those antibodies that compete with the reference antibody for binding to CD40 by 100%, and identifying the antibody epitope by HID exchange or by X-ray crystallography.
Alternatively, mice or rabbits may be immunized using peptides encompassing the epitope residues, and the generated antibodies may be evaluated for their binding within the recited region.
The affinity of an antibody to human or cyno CD40 may be determined experimentally using any suitable method. An exemplary method utilizes ProteOn XPR36, Biacore 3000 or KinExA instrumentation, ELISA or competitive binding assays known to those skilled in the art. The measured affinity of a particular antibody to CD40 may vary if measured under different conditions (e.g., osmolarity, pH). Thus, measurements of affinity and other binding parameters (e.g., KD, Koo, and Koff) are typically made with standardized conditions and a standardized buffer, such as the buffer described herein.
Skilled in the art will appreciate that the internal error for affinity measurements for example using Biacore 3000 or ProteOn (measured as standard deviation, SD) can typically be within 5-33% for measurements within the typical limits of detection. Therefore the term "about" reflects the typical standard deviation in the assay. For example, the typical SD for a KD
of 1x10-9 M is up to +0.33x10-9 M.
In the B cell proliferation assay, 1x105 human tonsil B cells may be cultured in RPMI medium containing glutamax, 10% FBS and 1% Pen/Strep, titrations of each of the antibodies specifically binding human CD40 may be added to the cells, followed by addition of 0.5 ug/m1 soluble human CD154. Cells may be cultured for 48 hours at 37 C, pulsed with 3H-thymidine (luCi/well) in 50 ul medium and cultured for 16-18 hours before harvest and counting.
In the DC IL-12p40 production assay, human DCs may be generated by culturing purified human monocytes (2.5x106/well 6-well plates) for 6 days in 3m1 RPMI
medium containing glutamax, 25mM HEPES, 10% FBS, 1% Pen/Strep and 5Ong each GM-CSF
and IL-4. On day 3, lml of the medium may be removed and replaced with 2m1 fresh medium containing 50 ng/ml each of GM-CSF and IL-4. On day 6, DCs may be plated into 96-well plates (100,000 cells/well) followed by titrations of each of the antibodies specifically binding human CD40 and addition of 1ug/m1 of soluble human CD154 to the cultures. Cells may be cultured for 48 hours before collecting and analyzing supernatants for IL-12p40 by MSD.
Immune effector properties of the antibodies of the invention may be enhanced or silenced through Fc modifications. For example, Fc effector functions such as Clq binding, complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. may be provided and/or controlled by modifying residues in the Fc responsible for these activities.
In some embodiments, the antibody of the invention has reduced binding to FeyRI, FeyRIIa, FeyRIIb, FeyRIIIa or FeyRIIIb.
"Reduced binding" refers to reduced binding of the antibody of the invention having at least one mutation in the Fc region to an Fey receptor (FcyR) when compared to the binding of the parental antibody without the mutation to the same FeyR.
"Reduced binding" may be at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or at least about 20,000-fold reduced binding. In practice, antibodies exhibiting "reduced binding" to a particular FcyR refer to antibodies that have statistically insignificant effector function mediated by the particular FcyR.
In some embodiments, the antibody of the invention comprises at least one mutation in the Fc region that reduces binding of the antibody to an FcyR.
In some embodiments, the FcyR is FcyRI, FcyRIIa or FcyRIIIa or FcyRIIIb.
In some embodiments, the at least one mutation in the Fc region is a L234A
mutation, a L235A mutation, a G237A mutation, a P238S mutation, a M252Y
mutation, a S254T mutation, a T256E mutation, a H268A mutation, a A330S mutation or a mutation, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a L234A/L235A/G237A/P238S/H268A/A330S/P331S mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the at least one mutation in the Fc region is a V234A
mutation, a G237A mutation, a P238S mutation, a M252Y mutation , a 5254T
mutation, a T256E mutation, a H268A mutation, a V309L mutation, an A3305 mutation or a mutation, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a V234A/G237A/
P2385/H268AN309L/A3305/P3315 mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a 5228P mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a F234A mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a L235A mutation in the Fc region, wherein residue numbering is according to the EU Index.
In some embodiments, the antibody of the invention comprises a 5228P/F234A/L235A mutation, wherein residue numbering is according to the EU
Index.
Binding of the antibodies of the invention to FcyRI, FcyRIIa, FcyRIIb, FcyRIIIa and FcyRIIIb may be evaluated using recombinant soluble forms or cell-associated forms of the Fcy receptors. For example, direct or indirect, e.g., competitive binding, measurements may be applied for assessing relative affinities and avidities of the antibodies of the invention to various FcyR. In an exemplary assay, a test antibody binding to soluble FcyR captured on a plate is evaluated using competitive binding between 1 [Tim' biotinylated human IgG1 and serial dilutions of the test antibody pre-complexed with antigen.
In some embodiments, the antibody of the invention comprising at least one mutation in the Fc region has reduced antibody dependent cellular cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis, ("ADCP") and/or reduced complement dependent cytotoxicity (CDC).
"Antibody-dependent cellular cytotoxicity", "antibody-dependent cell-mediated cytotoxicity" or "ADCC" is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells with effector cells possessing lytic activity, such as natural killer cells, monocytes, macrophages and neutrophils via Fc gamma receptors (FcyR) expressed on effector cells. For example, NK cells express FcyRIIIa, whereas monocytes express FcyRI, FcyRII and FcyRIIIa. To assess ADCC activity of the antibodies of the invention, the antibody may be added to target cells in combination with immune effector cells, which may be activated by the antigen antibody complexes resulting in cytolysis of the target cell. Cytolysis is generally detected by the release of label (e.g.
radioactive substrates, fluorescent dyes or natural intracellular proteins) from the lysed cells. Exemplary effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells. Exemplary target cells include cells expressing CD40.
"Antibody-dependent cellular phagocytosis" ("ADCP") refers to a mechanism of elimination of antibody-coated target cells by internalization by phagocytic cells, such as macrophages or dendritic cells. ADCP may be evaluated using monocyte-derived macrophages as effector cells and cells expressing CD40 engineered to express GFP or other labeled molecule as target cells. Effector:target cell ratio may be for example 4:1.
Effector cells may be incubated with target cells for 4 hours with or without the test CD40 antibody. After incubation, cells may be detached using accutase. Macrophages may be identified with anti-CD1 lb and anti-CD14 antibodies coupled to a fluorescent label, and percent phagocytosis may be determined based on % GFP fluorescent in the CD11+CD14+
macrophages using standard methods.
"Complement-dependent cytotoxicity", or "CDC", refers to a mechanism for inducing cell death in which an Fc effector domain of a target-bound antibody binds and activates complement component Clq which in turn activates the complement cascade leading to target cell death. Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes. CDC of CD40-expressing cells may be measured for example by plating cells expressing CD40 in an appropriate medium, adding anti-CD4Oantibodies into the mixture, followed by addition of pooled human serum. After incubation period, percentage (%) lysed cells may be detected as % propidium iodide stained cells in FACS assay using standard methods.
"Reduced ADCC", "reduced CDC" and "reduced ADCP" refers to a statistically significant reduction in ADCC, CDC and/or ADCP mediated by the antibody of the invention comprising at least one mutation in the Fc region when compared to the same antibody without the mutation. ADCC, CDC and/or ADCP, such as assays described herein and in assays described in U.S. Pat. No. 8,871,204.
Variants of the antibodies of the invention comprising the VH or the VL amino acid sequences shown in Table 7 are within the scope of the invention. For example, variants may comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid substitutions in the VH
and/or the VL that do not adversely affect the characteristics of the antibodies. In some embodiments, the sequence identity may be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%
to the antibody VH or the VL amino acid sequence of the invention.
The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity =# of identical positions/total #
of positions x100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The percent identity between two amino acid sequences may be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences may be determined using the Needleman and Wunsch (1 Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://_www_gcg_com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
In some embodiments, the antibody of the invention comprises the VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the VH
of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the VL of SEQ ID NOs:
or 27, wherein the antibody exhibits one or more of the following properties:
inhibits 0.5 [tg/m1 human soluble CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M;
inhibits 1 [tg/m1 human soluble CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M; or binds to human CD40 with a dissociation constant (KD) of about 5x10-9 M or less, when the KD is measured using ProteOn XPR36 system using experimental design described in Example 4.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 11 and the VL of SEQ ID NO: 12.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 21 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 22 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 23 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 24 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH and the VL
which are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%
identical to the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 11 and the VL of SEQ ID NO: 12, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions and the antibody exhibits one or more of the following properties:
inhibits 0.5 [tg/m1 human soluble CD4OL-driven human tonsillar B cell proliferation with an IC50 value of less than about 1x10-9 M;
inhibits 1 [tg/m1 human soluble CD4OL-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10-9 M; or binds to human CD40 with a dissociation constant (KD) of about 5x10-9 M or less, when the KD is measured using ProteOn XPR36 system using experimental design described in Example 4.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 11 and the VL of SEQ ID NO: 12, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 21 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 22 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 23 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 24 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 25 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
In some embodiments, the antibody of the invention comprises the VH of SEQ ID
NO: 26 and the VL of SEQ ID NO: 27, wherein the VH, the VL or both the VH and the VL comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen conservative amino acid substitutions.
"Conservative modification" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequences. Conservative modifications include amino acid substitutions, additions and deletions. Conservative amino acid substitutions are those in which the amino acid is replaced with an amino acid residue having a similar side chain. The families of amino acid residues having similar side chains are well defined and include amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), basic side chains (e.g., lysine, arginine, histidine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), uncharged polar side chains (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine, tryptophan), aromatic side chains (e.g., phenylalanine, tryptophan, histidine, tyrosine), aliphatic side chains (e.g., glycine, alanine, valine, leucine, isoleucine, serine, threonine), amide (e.g., asparagine, glutamine), beta-branched side chains (e.g., threonine, valine, isoleucine) and sulfur-containing side chains (cysteine, methionine). Furthermore, any native residue in the polypeptide may be substituted with alanine, as has been previously described for alanine scanning mutagenesis (MacLennan et al., Acta Physiol. Scand. Suppl. 643:55-67, 1998;
Sasaki et al., Adv. Biophys. 35:1-24, 1998). Amino acid substitutions to the antibodies of the invention may be made by well-known methods for example by PCR mutagenesis (US
Pat.
No. 4,683,195). Alternatively, libraries of variants may be generated using known methods, for example using random (NNK) or non-random codons, for example DVK
codons, which encode 11 amino acids (Ala, Cys, Asp, Glu, Gly, Lys, Asn, Arg, Ser, Tyr, Trp). The resulting antibody variants may be tested for their characteristics using assays described herein.
Although the embodiments illustrated in the Examples comprise pairs of variable regions, one from a heavy chain and one from a light chain, a skilled artisan will recognize that alternative embodiments may comprise single heavy or light chain variable regions.
The single variable region may be used to screen for variable domains capable of forming a two-domain specific antigen-binding fragment capable of for example specifically binding to human CD40. The screening may be accomplished by phage display screening methods using for example hierarchical dual combinatorial approach disclosed in Int.
Pat. Publ. No.
W01992/01047.
Antibodies of the invention may be generated using various technologies. For example, the hybridoma method of Kohler and Milstein, Nature 256:495, 1975 may be used to generate monoclonal antibodies. In the hybridoma method, a mouse or other host animal, such as a hamster, rat, rabbit or monkey, is immunized with human, marmoset or cyno CD40 or fragments of CD40, such as soluble form of CD40, followed by fusion of spleen cells from immunized animals with myeloma cells using standard methods to form hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-(Academic Press, 1986)). Colonies arising from single immortalized hybridoma cells are screened for production of antibodies with desired properties, such as specificity of binding, cross-reactivity or lack thereof, and affinity for the antigen.
Various host animals may be used to produce the antibodies of the invention.
For example, Balb/c mice may be used to generate antibodies. The antibodies made in Balb/c mice and other non-human animals may be humanized using various technologies to generate more human-like sequences. Exemplary humanization techniques including selection of human acceptor frameworks are known and include CDR grafting (U.S. Pat.
No. 5,225,539), SDR grafting (U.S. Pat. No. 6,818,749), Resurfacing (Padlan, Mol Immunol 28:489-499, 1991), Specificity Determining Residues Resurfacing (U.S.
Pat.
Publ. No. 20100261620), human-adaptation (or human framework adaptation) (U.S.
Pat.
Publ. No. U52009/0118127), Superhumanization (U.S. Pat. No. 7,709, 226) and guided selection (Osbourn et al (2005) Methods 36:61-68, 2005; U.S. Pat. No.
5,565,332). In these methods, CDRs of parental antibodies are transferred onto human frameworks that may be selected based on their overall homology to the parental frameworks, based on framework CDR length, homology or canonical structure information, or a combination thereof Humanized antibodies may be further optimized to improve their selectivity or affinity to a desired antigen by incorporating altered framework support residues to preserve binding affinity (backmutations) by techniques such as those disclosed as described in Int. Pat. Publ. No. W090/007861 and in Int. Pat. Publ. No.
W092/22653, or by introducing variation to any of the CDRs to improve for example affinity of the antibody.
Transgenic mice carrying human immunoglobulin (Ig) loci in their genome may be used to generate human antibodies against a target protein, and are described in for example Int. Pat. Publ. No. W090/04036, U.S. Pat. No. 6150584, Int. Pat. Publ.
No.
W099/45962, Int. Pat. Publ. No. W002/066630, Int. Pat. Publ. No. W002/43478, Lonberg et al (1994) Nature 368:856-9; Green et al (1994) Nature Genet. 7:13-21; Green &
Jakobovits (1998) Exp. Med. 188:483-95; Lonberg and Huszar (1995) Int. Rev.
Immunol.
13:65-93; Bruggemann et al (1991) Eur. 1 Immunol. 21:1323- 1326; Fishwild et al (1996) Nat. Biotechnol. 14:845-851; Mendez et al (1997) Nat. Genet. 15:146-156; Green (1999)1 Immunol. Methods 231:11-23; Yang et al (1999) Cancer Res. 59:1236-1243;
Briiggemann and Taussig (1997) Curr. Opin. Biotechnol. 8:455-458; Int. Pat. Publ. No.
W002/043478).
The endogenous immunoglobulin loci in such mice may be disrupted or deleted, and at least one complete or partial human immunoglobulin locus may be inserted into the mouse genome using homologous or non-homologous recombination, using transchromosomes, or using minigenes. Companies such as Regeneron (http://_www_regeneron_com), Harbour Antibodies (http://_www_harbourantibodies_com), Open Monoclonal Technology, Inc.
(OMT) (http://_www_omtinc_net), KyMab (http://_www_kymab_com), Trianni (http://_www.trianni_com) and Ablexis (http://_www_ablexis_com) may be engaged to provide human antibodies directed against a selected antigen using technology as described above.
Human antibodies may be selected from a phage display library, where the phage is engineered to express human immunoglobulins or portions thereof such as Fabs, single
W092/22653, or by introducing variation to any of the CDRs to improve for example affinity of the antibody.
Transgenic mice carrying human immunoglobulin (Ig) loci in their genome may be used to generate human antibodies against a target protein, and are described in for example Int. Pat. Publ. No. W090/04036, U.S. Pat. No. 6150584, Int. Pat. Publ.
No.
W099/45962, Int. Pat. Publ. No. W002/066630, Int. Pat. Publ. No. W002/43478, Lonberg et al (1994) Nature 368:856-9; Green et al (1994) Nature Genet. 7:13-21; Green &
Jakobovits (1998) Exp. Med. 188:483-95; Lonberg and Huszar (1995) Int. Rev.
Immunol.
13:65-93; Bruggemann et al (1991) Eur. 1 Immunol. 21:1323- 1326; Fishwild et al (1996) Nat. Biotechnol. 14:845-851; Mendez et al (1997) Nat. Genet. 15:146-156; Green (1999)1 Immunol. Methods 231:11-23; Yang et al (1999) Cancer Res. 59:1236-1243;
Briiggemann and Taussig (1997) Curr. Opin. Biotechnol. 8:455-458; Int. Pat. Publ. No.
W002/043478).
The endogenous immunoglobulin loci in such mice may be disrupted or deleted, and at least one complete or partial human immunoglobulin locus may be inserted into the mouse genome using homologous or non-homologous recombination, using transchromosomes, or using minigenes. Companies such as Regeneron (http://_www_regeneron_com), Harbour Antibodies (http://_www_harbourantibodies_com), Open Monoclonal Technology, Inc.
(OMT) (http://_www_omtinc_net), KyMab (http://_www_kymab_com), Trianni (http://_www.trianni_com) and Ablexis (http://_www_ablexis_com) may be engaged to provide human antibodies directed against a selected antigen using technology as described above.
Human antibodies may be selected from a phage display library, where the phage is engineered to express human immunoglobulins or portions thereof such as Fabs, single
6 chain antibodies (scFv), or unpaired or paired antibody variable regions (Knappik et al., J.Mol Biol 296:57-86, 2000; Krebs et al., J Immunol Meth 254:67-84,2001;
Vaughan et al., Nature Biotechnology 14:309-314, 1996; Sheets et al., PITAS (USA) 95:6157-6162, 1998;
Hoogenboom and Winter, J Mol Biol 227:381,1991; Marks et al., J Mol Biol 222:581, 1991). The antibodies of the invention may be isolated for example from phage display libraries expressing antibody heavy and light chain variable regions as fusion proteins with bacteriophage pIX coat protein as described in Shi et al., J Mol Biol 397:385-96, 2010 and Int. Pat. Publ. No. W009/085462). The libraries may be screened for phage binding to human and/or cyno CD40 and the obtained positive clones may be further characterized, the Fabs isolated from the clone lysates, and expressed as full length IgGs.
Such phage display methods for isolating human antibodies are described in for example:
U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al.; U.S. Patent Nos.
5,427,908 and 5, 580,717 to Dower et al.;U U.S. Patent Nos. 5,969,108 and 6,172,197 to McCafferty et al.;
and U.S. Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths et al.
Preparation of immunogenic antigens and monoclonal antibody production may be performed using any suitable technique, such as recombinant protein production. The immunogenic antigens may be administered to an animal in the form of purified protein, or protein mixtures including whole cells or cell or tissue extracts, or the antigen may be formed de novo in the animal's body from nucleic acids encoding said antigen or a portion thereof The antibodies of the invention may be human or humanized.
In some embodiments, the antibody of the invention comprises a VH framework derived from human germline gene VH3_3-23 (SEQ ID NO: 49).
In some embodiments, the antibody of the invention comprises a VL framework derived from human germline gene VL3_3R (IGLV3-1) (SEQ ID NO: 50).
The antibodies of the invention may be of IgA, IgD, IgE, IgG or IgM type. The antibodies of the invention may be of IgGl, IgG2, IgG3, IgG4 type.
The antibodies of the invention may further be engineered to generate modified antibodies with similar or altered properties when compared to the parental antibodies. The VH, the VL, the VH and the VL, the constant regions, VH framework, VL
framework, or any or all of the six CDRs may be engineered in the antibodies of the invention.
The antibodies of the invention may be engineered by CDR grafting. One or more CDR sequences of the antibodies of the invention may be grafted to a different framework sequence. CDR grafting may be done using methods described herein. In some embodiments, the antibodies of the invention comprise a VH that comprises the HDCR1 of SEQ ID NO: 5, the HCDR2 of SEQ ID NO: 6, 15, 16, 17 or 18, the HCDR3 of SEQ ID
NOs: 7 or 19, and theVL that comprises the LCDR1 of SEQ ID NOs: 8 or 20, the of SEQ ID NO: 9 and/or the LCDR3 of SEQ ID NO: 10, wherein the VH framework is not derived from VH3 3-23 (SEQ ID NO: 49) and the VL framework is not derived from VL3 3R (IGLV3-1) (SEQ ID NO: 50). The framework sequences to be used may be obtained from public DNA databases or published references that include germline antibody gene sequences. For example, germline DNA and the encoded protein sequences for human heavy and light chain variable region genes can be found at IMGTO, the international ImMunoGeneTics information system http://_www-imgt_org.
Framework sequences that may be used to replace the existing framework sequences in the antibodies of the invention are those that show the highest percent identity to C40B16, C40B124, C40B135, C40B125, C40B136, C40B127, C40B138, C40B131, C40B176, C40B180, C40B179 or C40B183 VH or VL at amino acid level.
The framework sequences of the parental and engineered antibodies may further be modified, for example by backmutations to restore and/or improve binding of the resulting antibody to the antigen as described for example in U.S. Pat No. 6,180,370.
The framework sequences of the parental and engineered antibodies may further be modified by mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T-cell epitopes to thereby reduce the potential immunogenicity of the antibody. This approach is also referred to as "deimmunization" and described in further detail in U.S. Pat. Publ. No. 20030153043.
The CDR residues of the antibodies of the invention may be mutated to improve one or more binding properties of the antibody of interest. Site-directed mutagenesis or PCR-mediated mutagenesis may be performed to introduce the mutation(s) and the effect on antibody binding, or other functional property of interest, may be evaluated in in vitro or in vivo assays as described herein and provided in the Examples. Exemplary substitutions that may be introduced are conservative modifications as discussed supra.
Moreover, typically no more than one, two, three, four or five residues within a CDR
region are altered.
Antibodies of the invention may be post-translationally modified by processes such as glycosylation, isomerization, deglycosylation or non-naturally occurring covalent modification such as the addition of polyethylene glycol moieties (pegylation) and lipidation. Such modifications may occur in vivo or in vitro. For example, the antibodies of the invention may be conjugated to polyethylene glycol (PEGylated) to improve their pharmacokinetic profiles. Conjugation may be carried out by techniques known to those skilled in the art. Conjugation of therapeutic antibodies with PEG has been shown to enhance pharmacodynamics while not interfering with function (Knigh et al., Platelets 15:409-18, 2004; Leong et al., Cytokine 16:106-19, 2001; Yang et al., Protein Eng. 16:761-70, 2003).
Antibodies or antigen-binding fragments thereof of the invention may be modified to improve stability, selectivity, cross-reactivity, affinity, immunogenicity or other desirable biological or biophysical property are within the scope of the invention. Stability of an antibody is influenced by a number of factors, including core packing of individual domains that affects their intrinsic stability, protein/protein interface interactions that have impact upon the HC and LC pairing, burial of polar and charged residues, (4) H-bonding network for polar and charged residues; and surface charge and polar residue distribution among other intra- and inter-molecular forces (Worn et al., J Mol Biol 305:989-1010, 2001). Potential structure destabilizing residues may be identified based upon the crystal structure of the antibody or by molecular modeling in certain cases, and the effect of the residues on antibody stability may be tested by generating and evaluating variants harboring mutations in the identified residues. One of the ways to increase antibody stability is to raise the thermal transition midpoint (Tm) as measured by differential scanning calorimetry (DSC). In general, the protein Tm is correlated with its stability and inversely correlated with its susceptibility to unfolding and denaturation in solution and the degradation processes that depend on the tendency of the protein to unfold (Remmele et al., Biopharm 13:36-46, 2000). A number of studies have found correlation between the ranking of the physical stability of formulations measured as thermal stability by DSC and physical stability measured by other methods (Gupta et al., AAPS PharmSci 5E8, 2003;
Zhang et al., J Pharm Sci 93:3076-89, 2004; Maa et al., Int J Pharm 140:155-68, 1996;
Bedu-Addo et al., Pharm Res 21:1353-61, 2004; Remmele et al., Pharm Res 15:200-8, 1997). Formulation studies suggest that a Fab Tm has implication for long-term physical stability of a corresponding mAb.
In some embodiments, the antibody of the invention is a multispecific antibody.
In some embodiments, the antibody of the invention is a bispecific antibody.
The monospecific antagonistic antibodies specifically binding CD40 of the invention may be engineered into bispecific antibodies which are also encompassed within the scope of the invention.
Full length bispecific antibodies may be generated for example using Fab arm exchange (e.g., half-molecule exchange, exchanging one heavy chain-light chain pair) between two monospecific bivalent antibodies by introducing substitutions at the heavy chain CH3 interface in each half molecule to favor heterodimer formation of two antibody half molecules having distinct specificity either in vitro in cell-free environment or using co-expression. The Fab arm exchange reaction is the result of a disulfide-bond isomerization reaction and dissociation-association of CH3 domains. The heavy chain disulfide bonds in the hinge regions of the parental monospecific antibodies are reduced.
The resulting free cysteines of one of the parental monospecific antibodies form an inter heavy-chain disulfide bond with cysteine residues of a second parental monospecific antibody molecule and simultaneously CH3 domains of the parental antibodies release and reform by dissociation-association. The CH3 domains of the Fab arms may be engineered to favor heterodimerization over homodimerization. The resulting product is a bispecific antibody having two Fab arms or half molecules which each bind a distinct epitope.
Bispecific antibodies may also be generated using designs such as the Triomab/Quadroma (Trion Pharma/Fresenius Biotech), Knob-in-Hole (Genentech), CrossMAbs (Roche) and the electrostatically-induced CH3 interaction (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), the Biclonic (Merus) and as DuoBody0 Products (Genmab A/S).
The Triomab quadroma technology may be used to generate full length bispecific antibodies of the invention. Triomab technology promotes Fab arm exchange between two parental chimeric antibodies, one parental mAb having IgG2a and the second parental mAb having rat IgG2b constant regions, yielding chimeric bispecific antibodies.
The "knob-in-hole" strategy (see, e.g., Intl. Publ. No. WO 2006/028936) may be used to generate full length bispecific antibodies. Briefly, selected amino acids forming the interface of the CH3 domains in human IgG can be mutated at positions affecting CH3 domain interactions to promote heterodimer formation. An amino acid with a small side chain (hole) is introduced into a heavy chain of an antibody specifically binding a first antigen and an amino acid with a large side chain (knob) is introduced into a heavy chain of an antibody specifically binding a second antigen. After co-expression of the two antibodies, a heterodimer is formed as a result of the preferential interaction of the heavy chain with a "hole" with the heavy chain with a "knob". Exemplary CH3 substitution pairs forming a knob and a hole are (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_L368A_Y407V.
The CrossMAb technology may be used to generate full length bispecific antibodies of the invention. CrossMAbs, in addition to utilizing the "knob-in-hole"
strategy to promoter Fab arm exchange, have in one of the half arms the CH1 and the CL
domains exchanged to ensure correct light chain pairing of the resulting bispecific antibody (see e.g. U.S. Patent No. 8,242,247).
Other cross-over strategies may be used to generate full length bispecific antibodies by exchanging variable or constant, or both domains between the heavy chain and the light chain or within the heavy chain in the bispecific antibodies, either in one or both arms. These exchanges include for example VH-CH1 with VL-CL, VH with VL, CH3 with CL and CH3 with CH1 as described in Int. Patent Publ. Nos.
W02009/080254, W02009/080251, W02009/018386 and W02009/080252.
Other strategies such as promoting heavy chain heterodimerization using electrostatic interactions by substituting positively charged residues at one CH3 surface and negatively charged residues at a second CH3 surface may be used, as described in US
Patent Publ. No. U52010/0015133; US Patent Publ. No. U52009/0182127; US Patent Publ.
No. U52010/028637 or US Patent Publ. No. US2011/0123532. In other strategies, heterodimerization may be promoted by following substitutions (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): L351Y_F405A_Y407V/T394W, T366I K392M T394W/F405A Y407V, T366L K392M T394W/F405A Y407V, L351Y Y407A/T366A K409F, L351Y Y407A/T366V K409F, Y407A/T366A K409F, or T350V L351Y F405A Y407V/T350V T366L K392L T394W as described in U.S.
Patent Publ. No. US2012/0149876 or U.S. Patent Publ. No. US2013/0195849.
LUZ-Y technology may be utilized to generate bispecific antibodies. In this technology, a leucine zipper is added into the C terminus of the CH3 domains to drive the heterodimer assembly from parental mAbs that is removed post-purification as described in Wranik et al., (2012) J Biol Chem 287(52): 42221-9.
SEEDbody technology may be utilized to generate bispecific antibodies.
SEEDbodies have, in their constant domains, select IgG residues substituted with IgA
residues to promote heterodimerization as described in U.S. Patent No.
U520070287170.
Bispecific antibodies may be generated in vitro in a cell-free environment by introducing asymmetrical mutations in the CH3 regions of two monospecific homodimeric antibodies and forming the bispecific heterodimeric antibody from two parent monospecific homodimeric antibodies in reducing conditions to allow disulfide bond isomerization according to methods described in Int.Patent Publ. No. W02011/131746. In the methods, the first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have certain substitutions at the CH3 domain that promoter heterodimer stability; the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization;
thereby generating the bispecific antibody by Fab arm exchange. Substitutions that may be used are F405L in one heavy chain and K409R in the other heavy chain. The incubation conditions may optimally be restored to non-reducing. Exemplary reducing agents that may be used are 2- mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and beta-mercaptoethanol. For example, incubation for at least 90 min at a temperature of at least 20 C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM
dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
Substitutions are typically made at the DNA level to a molecule such as the constant domain of the antibody using standard methods.
The antibodies of the invention may be engineered into various well known antibody forms.
In some embodiments, the bispecific antibodies include recombinant IgG-like dual targeting molecules, wherein the two sides of the molecule each contain the Fab fragment or part of the Fab fragment of at least two different antibodies; IgG fusion molecules, wherein full length IgG antibodies are fused to an extra Fab fragment or parts of Fab fragment; Fc fusion molecules, wherein single chain Fv molecules or stabilized diabodies are fused to heavy-chain constant-domains, Fc-regions or parts thereof; Fab fusion molecules, wherein different Fab-fragments are fused together; ScFv- and diabody-based and heavy chain antibodies (e.g., domain antibodies, nanobodies) wherein different single chain Fv molecules or different diabodies or different heavy-chain antibodies (e.g. domain antibodies, nanobodies) are fused to each other or to another protein or carrier molecule.
Polynucleotides, vectors, host cells The invention also provides for an isolated polynucleotide encoding any of the antibody heavy chain variable regions, any of the antibody light chain variable regions, or any of the antibody heavy chains and/or the antibody light chains of the invention.
The invention also provides for an isolated polynucleotide encoding the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26.
The invention also provides for an isolated polynucleotide encoding the VL of SEQ ID NOs: 12 or 27.
The invention also provides for an isolated polynucleotide encoding the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL of SEQ ID NOs: 12 or 27.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 13, 14, 28, 29, 30, 31, 32, 33, or 34.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46.
The invention also provides for an isolated polynucleotide encoding the light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46 and a light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 77 or 78.
The polynucleotide sequences encoding the VH or the VL or a fragment thereof of the antibodies of the invention or the heavy chain and the light chain of the antibodies of the invention may be operably linked to one or more regulatory elements, such as a promoter or enhancer, that allow expression of the nucleotide sequence in the intended host cell. The polynucleotide may be a cDNA.
The invention also provides for a vector comprising the polynucleotide of the invention. Such vectors may be plasmid vectors, viral vectors, vectors for baculovirus expression, transposon based vectors or any other vector suitable for introduction of the synthetic polynucleotide of the invention into a given organism or genetic background by any means. For example, polynucleotides encoding light and/or heavy chain variable regions of the antibodies of the invention, optionally linked to constant regions, are inserted into expression vectors. The light and/or heavy chains may be cloned in the same or different expression vectors. The DNA segments encoding immunoglobulin chains may be operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides. Such control sequences include signal sequences, promoters (e.g. naturally associated or heterologous promoters), enhancer elements, and transcription termination sequences, and are chosen to be compatible with the host cell chosen to express the antibody. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the proteins encoded by the incorporated polynucleotides.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 13 and the polynucleotide of SEQ ID NO: 14.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 28 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 29 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 30 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 31 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 32 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 33 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 65 and the polynucleotide of SEQ ID NO: 77.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 66 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 67 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 68 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 69 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 70 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 71 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 72 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 73 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 74 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 75 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 76 and the polynucleotide of SEQ ID NO: 78.
Suitable expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers such as ampicillin-resistance, hygromycin-resistance, tetracycline resistance, kanamycin resistance or neomycin resistance to permit detection of those cells transformed with the desired DNA sequences.
Suitable promoter and enhancer elements are known in the art. For expression in a eukaryotic cell, exemplary promoters include light and/or heavy chain immunoglobulin gene promoter and enhancer elements; cytomegalovirus immediate early promoter;
herpes simplex virus thymidine kinase promoter; early and late SV40 promoters;
promoter present in long terminal repeats from a retrovirus; mouse metallothionein-I promoter;
and various art-known tissue specific promoters. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
Large numbers of suitable vectors and promoters are known to those of skill in the art; many are commercially available for generating a subject recombinant constructs. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA); pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia, Uppsala, Sweden). Eukaryotic: pWLneo, pSV2cat, p0G44, PXR1, pSG (Stratagene) pSVK3, pBPV, pMSG and pSVL (Pharmacia).
The invention also provides for a host cell comprising one or more vectors of the invention. "Host cell" refers to a cell into which a vector has been introduced. It is understood that the term host cell is intended to refer not only to the particular subject cell but to the progeny of such a cell, and also to a stable cell line generated from the particular subject cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not be identical to the parent cell, but are still included within the scope of the term "host cell"
as used herein.
Such host cells may be eukaryotic cells, prokaryotic cells, plant cells or archeal cells.
Escherichia coli, bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species are examples of prokaryotic host cells. Other microbes, such as yeast, are also useful for expression.
Saccharomyces (e.g., S. cerevisiae) and Pichia are examples of suitable yeast host cells.
Exemplary eukaryotic cells may be of mammalian, insect, avian or other animal origins.
Mammalian eukaryotic cells include immortalized cell lines such as hybridomas or myeloma cell lines such as 5P2/0 (American Type Culture Collection (ATCC), Manassas, VA, CRL-1581), NSO (European Collection of Cell Cultures (ECACC), Salisbury, Wiltshire, UK, ECACC No. 85110503), FO (ATCC CRL-1646) and Ag653 (ATCC CRL-1580) murine cell lines. An exemplary human myeloma cell line is U266 (ATTC
CRL-TIB-196). Other useful cell lines include those derived from Chinese Hamster Ovary (CHO) cells such as CHO-K1SV (Lonza Biologics, Walkersville, MD), CHO-K1 (ATCC
CRL-61) or DG44.
The invention also provides for a method of producing the antibody of the invention comprising culturing the host cell of the invention in conditions that the antibody is expressed, and recovering the antibody produced by the host cell. Methods of making antibodies and purifying them are known. Once synthesized (either chemically or recombinantly), the whole antibodies, their dimers, individual light and/or heavy chains, or other antibody fragments such as VH and/ or VL, may be purified according to standard procedures, including ammonium sulfate precipitation, affinity columns, column chromatography, high performance liquid chromatography (HPLC) purification, gel electrophoresis, and the like (see generally Scopes, Protein Purification (Springer- Verlag, N.Y., (1982)). A subject antibody may be substantially pure, e.g., at least about 80% to 85% pure, at least about 85% to 90% pure, at least about 90% to 95% pure, or at least about 98% to 99%, or more, pure, e.g., free from contaminants such as cell debris, macromolecules, etc. other than the subject antibody.
The invention also provides for a method for producing an antagonistic antibody specifically binding CD40 of SEQ ID NO: 1, comprising:
incorporating the first polynucleotide encoding the VH of the antibody and the second polynucleotide encoding the VL of the antibody into an expression vector;
transforming a host cell with the expression vector;
culturing the host cell in culture medium under conditions wherein the VL and the VH are expressed and form the antibody; and recovering the antibody from the host cell or culture medium.
The polynucleotides encoding certain VH or VL sequences of the invention may be incorporated into vectors using standard molecular biology methods. Host cell transformation, culture, antibody expression and purification are done using well known methods.
Methods of Treatment Antagonistic antibodies specifically binding CD40 of the invention, for example antibodies C40B16, C40B124, C40B135, C40B125, C40B136, C40B127, C40B138, C40B131, C40B176, C40B180, C40B179 or C40B183, may be used for the treatment and/or prevention of any condition or disease wherein antagonizing the effects of CD40 may be therapeutically effective and may reduce the symptoms of the disease.
Examples thereof include the treatment of inflammatory diseases such as autoimmune diseases wherein the induction of tolerance and/or the suppression of humoral immunity are therapeutically desirable. Diseases that may be treated with the antibodies of the invention are autoimmune diseases, Addison's disease, an ankylosing spondylitis, an atherosclerosis, an autoimmune hepatitis, an autoimmune diabetes, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, an idiopathic thrombocytopenia, an inflammatory bowel disease (IBD), a systemic lupus erythematosus, a multiple sclerosis, a myasthenia gravis, a psoriasis, an arthritis, a scleroderma, Sjogren's syndrome, a systemic sclerosis, a transplantation, a kidney transplantation, a skin transplantation, a bone marrow transplantation, a graft versus host disease (GVHD), a type I diabetes, a rheumatoid arthritis, a juvenile arthritis, a psoriatic arthritis, Reiter's syndrome, an ankylosing spondylitis, or a gouty arthritis, Crohn's disease or an ulcerative colitis.
The invention also provides for a method of treating an arthritis, comprising administering a therapeutically effective amount of the antibody of the invention to a subject in need thereof for a time sufficient to treat the arthritis.
In some embodiments, the arthritis is a juvenile arthritis, a rheumatoid arthritis, a psoriatic arthritis, Reiter's syndrome, an ankylosing spondylitis, or a gouty arthritis.
The invention also provides for a method of treating a lupus, comprising administering a therapeutically effective amount of the antibody of the invention to a subject in need thereof for a time sufficient to treat the lupus.
In some embodiments, the lupus is a systemic lupus erythematosus (SLE) or a cutaneous lupus erythematosus (CLE).
In some embodiments, the subject has lupus nephritis.
In some embodiments, the subject has a cutaneous lupus erythematosus.
The invention also provides for a method of treating an inflammatory bowel disease, comprising administering a therapeutically effective amount of the antibody of the invention to a subject in need thereof for a time sufficient to treat the inflammatory bowel disease.
In some embodiments, the inflammatory bowel disease is Crohn's disease.
In some embodiments, the inflammatory bowel disease is an ulcerative colitis.
"Treatment" or "treat" refers to therapeutic treatment. Subjects in need of treatment include those subjects diagnosed with the disorder or experiencing at least one of the symptoms of the disease. Subjects that may be treated also include those prone to or susceptible to have the disorder, or those in which the disorder is to be prevented.
Beneficial or desired clinical results include alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. Beneficial treatment result include, in a subject who has received treatment, reduction in the levels of inflammatory cytokines, adhesion molecules, proteases, immunoglobulins, combinations thereof, increased production of anti- inflammatory proteins, a reduction in the number of autoreactive cells, an increase in immune tolerance, inhibition of autoreactive cell survival, and/or a decrease in one or more symptoms mediated by stimulation of CD40-expressing cells by CD154.
Clinical response may be assessed using screening techniques such as magnetic resonance imaging (MRI) scan, x-radiographic imaging, computed tomographic (CT) scan, flow cytometry or fluorescence-activated cell sorter (FACS) analysis, histology, gross pathology, and blood chemistry, including but not limited to changes detectable by ELISA, RIA, chromatography, and the like.
The methods of the invention may be used to treat a subject belonging to any animal classification. Examples of subjects that may be treated include mammals such as humans, rodents, dogs, cats and farm animals.
The antibodies of the invention may be useful in the preparation of a medicament for such treatment, wherein the medicament is prepared for administration in dosages defined herein.
The antibodies of the invention may be administered in combination with a second therapeutic agent.
The second therapeutic agent may be any known therapy for inflammatory diseases, such as autoimmune diseases, including any agent or combination of agents that are known to be useful, or which have been used or are currently in use for treatment. Such therapies and therapeutic agents include surgery or surgical procedures (e.g.
splenectomy, lymphadenectomy, thyroidectomy, plasmapheresis, leukophoresis, cell, tissue, or organ transplantation, intestinal procedures, organ perfusion, and the like), therapy such as steroid therapy and non-steroidal therapy, hormone therapy, cytokine therapy, therapy with dermatological agents (for example, topical agents used to treat skin conditions such as allergies, contact dermatitis, and psoriasis), immunosuppressive therapy, and other anti-inflammatory drugs including monoclonal antibodies.
The second therapeutic agent may be a corticosteroid, an immunosuppressant, a cytotoxic drug, or a B-cell modulator.
In some embodiments, the antibodies of the invention are administered in combination with a second therapeutic agent. Exemplary second therapeutic agents are corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, hydroxychloroquine, sulfasalazine, cytotoxic drugs, immunosuppressive drugs immunomodulatory antibodies, methotrexate, cyclophosphamide, mizoribine, chlorambucil, cyclosporine, tacrolimus (FK506 ; ProGrafrM), mycophenolate mofetil, and azathioprine (6-mercaptopurine), sirolimus (rapamycin), deoxyspergualin, leflunomide and its malononitriloamide analogs; anti-CTLA4 antibodies and Ig fusions, anti-B
lymphocyte stimulator antibodies (e.g., LYMPHOSTAT-BTM) and CTLA4-Ig fusions, anti-CD80 antibodies, anti-T cell antibodies such as anti-CD3 (OKT3), anti-CD4, corticosteroids such as, for example, clobetasol, halobetasol, hydrocortisone, triamcinolone, betamethasone, fluocinole, fluocinonide, prednisone, prednisolone, methylprednisolone; non-steroidal anti-inflammatory drugs (NSAIDs) such as, for example, sulfasalazine, medications containing mesalamine (known as 5-ASA agents), celecoxib, diclofenac, etodolac, fenprofen, flurbiprofen, ibuprofen, ketoprofen, meclofamate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, salicylates, sulindac, and tolmetin;
phosphodiesterase-4 inhibitors, anti-TNFa antibodies REMICADEO (infliximab), SIMPONIO (golimumab) and HUMIRAO (adalimumab), thalidomide or its analogs such as lenalidomide.
The antibodies of the invention may be administered in combination with a second therapeutic agent simultaneously, sequentially or separately.
Treatment effectiveness or RA may be assessed using effectiveness as measured by clinical responses defined by the American College of Rheumatology criteria, the European League of Rheumatism criteria, or any other criteria. See for example, Felson et al. (1995) Arthritis Rheum. 38: 727-35 and van Gestel et al. (1996) Arthritis Rheum. 39:
34-40.
Administration/Pharmaceutical Compositions The invention also provides for pharmaceutical compositions of the antagonistic antibodies specifically binding CD40 of the invention and a pharmaceutically acceptable carrier. For therapeutic use, the antibodies the invention may be prepared as pharmaceutical compositions containing an effective amount of the antibody as an active ingredient in a pharmaceutically acceptable carrier. "Carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the active compound is administered. Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. For example, 0.4% saline and 0.3% glycine may be used. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, thickening, lubricating and coloring agents, etc. The concentration of the antibodies of the invention in such pharmaceutical compositions may vary widely, i.e., from less than about 0.5%, usually to at least about 1%
to as much as 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight and will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the particular mode of administration selected. Suitable vehicles and formulations, including other human proteins, e.g., human serum albumin, are described, for example, in e.g. Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D.B.
ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing pp 691-1092, See especially pp. 958-989.
The mode of administration of the antibodies of the invention in the methods of the invention may be any suitable route such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, transmucosal (oral, intranasal, intravaginal, and rectal) or other means appreciated by the skilled artisan, as well known in the art.
The antibodies of the invention may be administered to the subject by any suitable route, for example parentally by intravenous (i.v.) infusion or bolus injection, intramuscularly or subcutaneously or intraperitoneally. i.v. infusion may be given over for, example, 15, 30, 60, 90, 120, 180, or 240 minutes, or over 1, 2, 3, 4, 5, 6,
Vaughan et al., Nature Biotechnology 14:309-314, 1996; Sheets et al., PITAS (USA) 95:6157-6162, 1998;
Hoogenboom and Winter, J Mol Biol 227:381,1991; Marks et al., J Mol Biol 222:581, 1991). The antibodies of the invention may be isolated for example from phage display libraries expressing antibody heavy and light chain variable regions as fusion proteins with bacteriophage pIX coat protein as described in Shi et al., J Mol Biol 397:385-96, 2010 and Int. Pat. Publ. No. W009/085462). The libraries may be screened for phage binding to human and/or cyno CD40 and the obtained positive clones may be further characterized, the Fabs isolated from the clone lysates, and expressed as full length IgGs.
Such phage display methods for isolating human antibodies are described in for example:
U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al.; U.S. Patent Nos.
5,427,908 and 5, 580,717 to Dower et al.;U U.S. Patent Nos. 5,969,108 and 6,172,197 to McCafferty et al.;
and U.S. Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths et al.
Preparation of immunogenic antigens and monoclonal antibody production may be performed using any suitable technique, such as recombinant protein production. The immunogenic antigens may be administered to an animal in the form of purified protein, or protein mixtures including whole cells or cell or tissue extracts, or the antigen may be formed de novo in the animal's body from nucleic acids encoding said antigen or a portion thereof The antibodies of the invention may be human or humanized.
In some embodiments, the antibody of the invention comprises a VH framework derived from human germline gene VH3_3-23 (SEQ ID NO: 49).
In some embodiments, the antibody of the invention comprises a VL framework derived from human germline gene VL3_3R (IGLV3-1) (SEQ ID NO: 50).
The antibodies of the invention may be of IgA, IgD, IgE, IgG or IgM type. The antibodies of the invention may be of IgGl, IgG2, IgG3, IgG4 type.
The antibodies of the invention may further be engineered to generate modified antibodies with similar or altered properties when compared to the parental antibodies. The VH, the VL, the VH and the VL, the constant regions, VH framework, VL
framework, or any or all of the six CDRs may be engineered in the antibodies of the invention.
The antibodies of the invention may be engineered by CDR grafting. One or more CDR sequences of the antibodies of the invention may be grafted to a different framework sequence. CDR grafting may be done using methods described herein. In some embodiments, the antibodies of the invention comprise a VH that comprises the HDCR1 of SEQ ID NO: 5, the HCDR2 of SEQ ID NO: 6, 15, 16, 17 or 18, the HCDR3 of SEQ ID
NOs: 7 or 19, and theVL that comprises the LCDR1 of SEQ ID NOs: 8 or 20, the of SEQ ID NO: 9 and/or the LCDR3 of SEQ ID NO: 10, wherein the VH framework is not derived from VH3 3-23 (SEQ ID NO: 49) and the VL framework is not derived from VL3 3R (IGLV3-1) (SEQ ID NO: 50). The framework sequences to be used may be obtained from public DNA databases or published references that include germline antibody gene sequences. For example, germline DNA and the encoded protein sequences for human heavy and light chain variable region genes can be found at IMGTO, the international ImMunoGeneTics information system http://_www-imgt_org.
Framework sequences that may be used to replace the existing framework sequences in the antibodies of the invention are those that show the highest percent identity to C40B16, C40B124, C40B135, C40B125, C40B136, C40B127, C40B138, C40B131, C40B176, C40B180, C40B179 or C40B183 VH or VL at amino acid level.
The framework sequences of the parental and engineered antibodies may further be modified, for example by backmutations to restore and/or improve binding of the resulting antibody to the antigen as described for example in U.S. Pat No. 6,180,370.
The framework sequences of the parental and engineered antibodies may further be modified by mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T-cell epitopes to thereby reduce the potential immunogenicity of the antibody. This approach is also referred to as "deimmunization" and described in further detail in U.S. Pat. Publ. No. 20030153043.
The CDR residues of the antibodies of the invention may be mutated to improve one or more binding properties of the antibody of interest. Site-directed mutagenesis or PCR-mediated mutagenesis may be performed to introduce the mutation(s) and the effect on antibody binding, or other functional property of interest, may be evaluated in in vitro or in vivo assays as described herein and provided in the Examples. Exemplary substitutions that may be introduced are conservative modifications as discussed supra.
Moreover, typically no more than one, two, three, four or five residues within a CDR
region are altered.
Antibodies of the invention may be post-translationally modified by processes such as glycosylation, isomerization, deglycosylation or non-naturally occurring covalent modification such as the addition of polyethylene glycol moieties (pegylation) and lipidation. Such modifications may occur in vivo or in vitro. For example, the antibodies of the invention may be conjugated to polyethylene glycol (PEGylated) to improve their pharmacokinetic profiles. Conjugation may be carried out by techniques known to those skilled in the art. Conjugation of therapeutic antibodies with PEG has been shown to enhance pharmacodynamics while not interfering with function (Knigh et al., Platelets 15:409-18, 2004; Leong et al., Cytokine 16:106-19, 2001; Yang et al., Protein Eng. 16:761-70, 2003).
Antibodies or antigen-binding fragments thereof of the invention may be modified to improve stability, selectivity, cross-reactivity, affinity, immunogenicity or other desirable biological or biophysical property are within the scope of the invention. Stability of an antibody is influenced by a number of factors, including core packing of individual domains that affects their intrinsic stability, protein/protein interface interactions that have impact upon the HC and LC pairing, burial of polar and charged residues, (4) H-bonding network for polar and charged residues; and surface charge and polar residue distribution among other intra- and inter-molecular forces (Worn et al., J Mol Biol 305:989-1010, 2001). Potential structure destabilizing residues may be identified based upon the crystal structure of the antibody or by molecular modeling in certain cases, and the effect of the residues on antibody stability may be tested by generating and evaluating variants harboring mutations in the identified residues. One of the ways to increase antibody stability is to raise the thermal transition midpoint (Tm) as measured by differential scanning calorimetry (DSC). In general, the protein Tm is correlated with its stability and inversely correlated with its susceptibility to unfolding and denaturation in solution and the degradation processes that depend on the tendency of the protein to unfold (Remmele et al., Biopharm 13:36-46, 2000). A number of studies have found correlation between the ranking of the physical stability of formulations measured as thermal stability by DSC and physical stability measured by other methods (Gupta et al., AAPS PharmSci 5E8, 2003;
Zhang et al., J Pharm Sci 93:3076-89, 2004; Maa et al., Int J Pharm 140:155-68, 1996;
Bedu-Addo et al., Pharm Res 21:1353-61, 2004; Remmele et al., Pharm Res 15:200-8, 1997). Formulation studies suggest that a Fab Tm has implication for long-term physical stability of a corresponding mAb.
In some embodiments, the antibody of the invention is a multispecific antibody.
In some embodiments, the antibody of the invention is a bispecific antibody.
The monospecific antagonistic antibodies specifically binding CD40 of the invention may be engineered into bispecific antibodies which are also encompassed within the scope of the invention.
Full length bispecific antibodies may be generated for example using Fab arm exchange (e.g., half-molecule exchange, exchanging one heavy chain-light chain pair) between two monospecific bivalent antibodies by introducing substitutions at the heavy chain CH3 interface in each half molecule to favor heterodimer formation of two antibody half molecules having distinct specificity either in vitro in cell-free environment or using co-expression. The Fab arm exchange reaction is the result of a disulfide-bond isomerization reaction and dissociation-association of CH3 domains. The heavy chain disulfide bonds in the hinge regions of the parental monospecific antibodies are reduced.
The resulting free cysteines of one of the parental monospecific antibodies form an inter heavy-chain disulfide bond with cysteine residues of a second parental monospecific antibody molecule and simultaneously CH3 domains of the parental antibodies release and reform by dissociation-association. The CH3 domains of the Fab arms may be engineered to favor heterodimerization over homodimerization. The resulting product is a bispecific antibody having two Fab arms or half molecules which each bind a distinct epitope.
Bispecific antibodies may also be generated using designs such as the Triomab/Quadroma (Trion Pharma/Fresenius Biotech), Knob-in-Hole (Genentech), CrossMAbs (Roche) and the electrostatically-induced CH3 interaction (Chugai, Amgen, NovoNordisk, Oncomed), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), the Biclonic (Merus) and as DuoBody0 Products (Genmab A/S).
The Triomab quadroma technology may be used to generate full length bispecific antibodies of the invention. Triomab technology promotes Fab arm exchange between two parental chimeric antibodies, one parental mAb having IgG2a and the second parental mAb having rat IgG2b constant regions, yielding chimeric bispecific antibodies.
The "knob-in-hole" strategy (see, e.g., Intl. Publ. No. WO 2006/028936) may be used to generate full length bispecific antibodies. Briefly, selected amino acids forming the interface of the CH3 domains in human IgG can be mutated at positions affecting CH3 domain interactions to promote heterodimer formation. An amino acid with a small side chain (hole) is introduced into a heavy chain of an antibody specifically binding a first antigen and an amino acid with a large side chain (knob) is introduced into a heavy chain of an antibody specifically binding a second antigen. After co-expression of the two antibodies, a heterodimer is formed as a result of the preferential interaction of the heavy chain with a "hole" with the heavy chain with a "knob". Exemplary CH3 substitution pairs forming a knob and a hole are (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): T366Y/F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_L368A_Y407V.
The CrossMAb technology may be used to generate full length bispecific antibodies of the invention. CrossMAbs, in addition to utilizing the "knob-in-hole"
strategy to promoter Fab arm exchange, have in one of the half arms the CH1 and the CL
domains exchanged to ensure correct light chain pairing of the resulting bispecific antibody (see e.g. U.S. Patent No. 8,242,247).
Other cross-over strategies may be used to generate full length bispecific antibodies by exchanging variable or constant, or both domains between the heavy chain and the light chain or within the heavy chain in the bispecific antibodies, either in one or both arms. These exchanges include for example VH-CH1 with VL-CL, VH with VL, CH3 with CL and CH3 with CH1 as described in Int. Patent Publ. Nos.
W02009/080254, W02009/080251, W02009/018386 and W02009/080252.
Other strategies such as promoting heavy chain heterodimerization using electrostatic interactions by substituting positively charged residues at one CH3 surface and negatively charged residues at a second CH3 surface may be used, as described in US
Patent Publ. No. U52010/0015133; US Patent Publ. No. U52009/0182127; US Patent Publ.
No. U52010/028637 or US Patent Publ. No. US2011/0123532. In other strategies, heterodimerization may be promoted by following substitutions (expressed as modified position in the first CH3 domain of the first heavy chain/ modified position in the second CH3 domain of the second heavy chain): L351Y_F405A_Y407V/T394W, T366I K392M T394W/F405A Y407V, T366L K392M T394W/F405A Y407V, L351Y Y407A/T366A K409F, L351Y Y407A/T366V K409F, Y407A/T366A K409F, or T350V L351Y F405A Y407V/T350V T366L K392L T394W as described in U.S.
Patent Publ. No. US2012/0149876 or U.S. Patent Publ. No. US2013/0195849.
LUZ-Y technology may be utilized to generate bispecific antibodies. In this technology, a leucine zipper is added into the C terminus of the CH3 domains to drive the heterodimer assembly from parental mAbs that is removed post-purification as described in Wranik et al., (2012) J Biol Chem 287(52): 42221-9.
SEEDbody technology may be utilized to generate bispecific antibodies.
SEEDbodies have, in their constant domains, select IgG residues substituted with IgA
residues to promote heterodimerization as described in U.S. Patent No.
U520070287170.
Bispecific antibodies may be generated in vitro in a cell-free environment by introducing asymmetrical mutations in the CH3 regions of two monospecific homodimeric antibodies and forming the bispecific heterodimeric antibody from two parent monospecific homodimeric antibodies in reducing conditions to allow disulfide bond isomerization according to methods described in Int.Patent Publ. No. W02011/131746. In the methods, the first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have certain substitutions at the CH3 domain that promoter heterodimer stability; the antibodies are incubated together under reducing conditions sufficient to allow the cysteines in the hinge region to undergo disulfide bond isomerization;
thereby generating the bispecific antibody by Fab arm exchange. Substitutions that may be used are F405L in one heavy chain and K409R in the other heavy chain. The incubation conditions may optimally be restored to non-reducing. Exemplary reducing agents that may be used are 2- mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and beta-mercaptoethanol. For example, incubation for at least 90 min at a temperature of at least 20 C in the presence of at least 25 mM 2-MEA or in the presence of at least 0.5 mM
dithiothreitol at a pH of from 5-8, for example at pH of 7.0 or at pH of 7.4 may be used.
Substitutions are typically made at the DNA level to a molecule such as the constant domain of the antibody using standard methods.
The antibodies of the invention may be engineered into various well known antibody forms.
In some embodiments, the bispecific antibodies include recombinant IgG-like dual targeting molecules, wherein the two sides of the molecule each contain the Fab fragment or part of the Fab fragment of at least two different antibodies; IgG fusion molecules, wherein full length IgG antibodies are fused to an extra Fab fragment or parts of Fab fragment; Fc fusion molecules, wherein single chain Fv molecules or stabilized diabodies are fused to heavy-chain constant-domains, Fc-regions or parts thereof; Fab fusion molecules, wherein different Fab-fragments are fused together; ScFv- and diabody-based and heavy chain antibodies (e.g., domain antibodies, nanobodies) wherein different single chain Fv molecules or different diabodies or different heavy-chain antibodies (e.g. domain antibodies, nanobodies) are fused to each other or to another protein or carrier molecule.
Polynucleotides, vectors, host cells The invention also provides for an isolated polynucleotide encoding any of the antibody heavy chain variable regions, any of the antibody light chain variable regions, or any of the antibody heavy chains and/or the antibody light chains of the invention.
The invention also provides for an isolated polynucleotide encoding the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26.
The invention also provides for an isolated polynucleotide encoding the VL of SEQ ID NOs: 12 or 27.
The invention also provides for an isolated polynucleotide encoding the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL of SEQ ID NOs: 12 or 27.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 13, 14, 28, 29, 30, 31, 32, 33, or 34.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46.
The invention also provides for an isolated polynucleotide encoding the light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide encoding the heavy chain of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46 and a light chain of SEQ ID NOs: 77 or 78.
The invention also provides for an isolated polynucleotide comprising the polynucleotide sequence of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 77 or 78.
The polynucleotide sequences encoding the VH or the VL or a fragment thereof of the antibodies of the invention or the heavy chain and the light chain of the antibodies of the invention may be operably linked to one or more regulatory elements, such as a promoter or enhancer, that allow expression of the nucleotide sequence in the intended host cell. The polynucleotide may be a cDNA.
The invention also provides for a vector comprising the polynucleotide of the invention. Such vectors may be plasmid vectors, viral vectors, vectors for baculovirus expression, transposon based vectors or any other vector suitable for introduction of the synthetic polynucleotide of the invention into a given organism or genetic background by any means. For example, polynucleotides encoding light and/or heavy chain variable regions of the antibodies of the invention, optionally linked to constant regions, are inserted into expression vectors. The light and/or heavy chains may be cloned in the same or different expression vectors. The DNA segments encoding immunoglobulin chains may be operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides. Such control sequences include signal sequences, promoters (e.g. naturally associated or heterologous promoters), enhancer elements, and transcription termination sequences, and are chosen to be compatible with the host cell chosen to express the antibody. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the proteins encoded by the incorporated polynucleotides.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 13 and the polynucleotide of SEQ ID NO: 14.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 28 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 29 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 30 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 31 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 32 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 33 and the polynucleotide of SEQ ID NO: 34.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 65 and the polynucleotide of SEQ ID NO: 77.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 66 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 67 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 68 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 69 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 70 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 71 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 72 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 73 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 74 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 75 and the polynucleotide of SEQ ID NO: 78.
In some embodiments, the vector comprises the polynucleotide of SEQ ID NO: 76 and the polynucleotide of SEQ ID NO: 78.
Suitable expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers such as ampicillin-resistance, hygromycin-resistance, tetracycline resistance, kanamycin resistance or neomycin resistance to permit detection of those cells transformed with the desired DNA sequences.
Suitable promoter and enhancer elements are known in the art. For expression in a eukaryotic cell, exemplary promoters include light and/or heavy chain immunoglobulin gene promoter and enhancer elements; cytomegalovirus immediate early promoter;
herpes simplex virus thymidine kinase promoter; early and late SV40 promoters;
promoter present in long terminal repeats from a retrovirus; mouse metallothionein-I promoter;
and various art-known tissue specific promoters. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
Large numbers of suitable vectors and promoters are known to those of skill in the art; many are commercially available for generating a subject recombinant constructs. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA); pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia, Uppsala, Sweden). Eukaryotic: pWLneo, pSV2cat, p0G44, PXR1, pSG (Stratagene) pSVK3, pBPV, pMSG and pSVL (Pharmacia).
The invention also provides for a host cell comprising one or more vectors of the invention. "Host cell" refers to a cell into which a vector has been introduced. It is understood that the term host cell is intended to refer not only to the particular subject cell but to the progeny of such a cell, and also to a stable cell line generated from the particular subject cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not be identical to the parent cell, but are still included within the scope of the term "host cell"
as used herein.
Such host cells may be eukaryotic cells, prokaryotic cells, plant cells or archeal cells.
Escherichia coli, bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species are examples of prokaryotic host cells. Other microbes, such as yeast, are also useful for expression.
Saccharomyces (e.g., S. cerevisiae) and Pichia are examples of suitable yeast host cells.
Exemplary eukaryotic cells may be of mammalian, insect, avian or other animal origins.
Mammalian eukaryotic cells include immortalized cell lines such as hybridomas or myeloma cell lines such as 5P2/0 (American Type Culture Collection (ATCC), Manassas, VA, CRL-1581), NSO (European Collection of Cell Cultures (ECACC), Salisbury, Wiltshire, UK, ECACC No. 85110503), FO (ATCC CRL-1646) and Ag653 (ATCC CRL-1580) murine cell lines. An exemplary human myeloma cell line is U266 (ATTC
CRL-TIB-196). Other useful cell lines include those derived from Chinese Hamster Ovary (CHO) cells such as CHO-K1SV (Lonza Biologics, Walkersville, MD), CHO-K1 (ATCC
CRL-61) or DG44.
The invention also provides for a method of producing the antibody of the invention comprising culturing the host cell of the invention in conditions that the antibody is expressed, and recovering the antibody produced by the host cell. Methods of making antibodies and purifying them are known. Once synthesized (either chemically or recombinantly), the whole antibodies, their dimers, individual light and/or heavy chains, or other antibody fragments such as VH and/ or VL, may be purified according to standard procedures, including ammonium sulfate precipitation, affinity columns, column chromatography, high performance liquid chromatography (HPLC) purification, gel electrophoresis, and the like (see generally Scopes, Protein Purification (Springer- Verlag, N.Y., (1982)). A subject antibody may be substantially pure, e.g., at least about 80% to 85% pure, at least about 85% to 90% pure, at least about 90% to 95% pure, or at least about 98% to 99%, or more, pure, e.g., free from contaminants such as cell debris, macromolecules, etc. other than the subject antibody.
The invention also provides for a method for producing an antagonistic antibody specifically binding CD40 of SEQ ID NO: 1, comprising:
incorporating the first polynucleotide encoding the VH of the antibody and the second polynucleotide encoding the VL of the antibody into an expression vector;
transforming a host cell with the expression vector;
culturing the host cell in culture medium under conditions wherein the VL and the VH are expressed and form the antibody; and recovering the antibody from the host cell or culture medium.
The polynucleotides encoding certain VH or VL sequences of the invention may be incorporated into vectors using standard molecular biology methods. Host cell transformation, culture, antibody expression and purification are done using well known methods.
Methods of Treatment Antagonistic antibodies specifically binding CD40 of the invention, for example antibodies C40B16, C40B124, C40B135, C40B125, C40B136, C40B127, C40B138, C40B131, C40B176, C40B180, C40B179 or C40B183, may be used for the treatment and/or prevention of any condition or disease wherein antagonizing the effects of CD40 may be therapeutically effective and may reduce the symptoms of the disease.
Examples thereof include the treatment of inflammatory diseases such as autoimmune diseases wherein the induction of tolerance and/or the suppression of humoral immunity are therapeutically desirable. Diseases that may be treated with the antibodies of the invention are autoimmune diseases, Addison's disease, an ankylosing spondylitis, an atherosclerosis, an autoimmune hepatitis, an autoimmune diabetes, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, an idiopathic thrombocytopenia, an inflammatory bowel disease (IBD), a systemic lupus erythematosus, a multiple sclerosis, a myasthenia gravis, a psoriasis, an arthritis, a scleroderma, Sjogren's syndrome, a systemic sclerosis, a transplantation, a kidney transplantation, a skin transplantation, a bone marrow transplantation, a graft versus host disease (GVHD), a type I diabetes, a rheumatoid arthritis, a juvenile arthritis, a psoriatic arthritis, Reiter's syndrome, an ankylosing spondylitis, or a gouty arthritis, Crohn's disease or an ulcerative colitis.
The invention also provides for a method of treating an arthritis, comprising administering a therapeutically effective amount of the antibody of the invention to a subject in need thereof for a time sufficient to treat the arthritis.
In some embodiments, the arthritis is a juvenile arthritis, a rheumatoid arthritis, a psoriatic arthritis, Reiter's syndrome, an ankylosing spondylitis, or a gouty arthritis.
The invention also provides for a method of treating a lupus, comprising administering a therapeutically effective amount of the antibody of the invention to a subject in need thereof for a time sufficient to treat the lupus.
In some embodiments, the lupus is a systemic lupus erythematosus (SLE) or a cutaneous lupus erythematosus (CLE).
In some embodiments, the subject has lupus nephritis.
In some embodiments, the subject has a cutaneous lupus erythematosus.
The invention also provides for a method of treating an inflammatory bowel disease, comprising administering a therapeutically effective amount of the antibody of the invention to a subject in need thereof for a time sufficient to treat the inflammatory bowel disease.
In some embodiments, the inflammatory bowel disease is Crohn's disease.
In some embodiments, the inflammatory bowel disease is an ulcerative colitis.
"Treatment" or "treat" refers to therapeutic treatment. Subjects in need of treatment include those subjects diagnosed with the disorder or experiencing at least one of the symptoms of the disease. Subjects that may be treated also include those prone to or susceptible to have the disorder, or those in which the disorder is to be prevented.
Beneficial or desired clinical results include alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. Beneficial treatment result include, in a subject who has received treatment, reduction in the levels of inflammatory cytokines, adhesion molecules, proteases, immunoglobulins, combinations thereof, increased production of anti- inflammatory proteins, a reduction in the number of autoreactive cells, an increase in immune tolerance, inhibition of autoreactive cell survival, and/or a decrease in one or more symptoms mediated by stimulation of CD40-expressing cells by CD154.
Clinical response may be assessed using screening techniques such as magnetic resonance imaging (MRI) scan, x-radiographic imaging, computed tomographic (CT) scan, flow cytometry or fluorescence-activated cell sorter (FACS) analysis, histology, gross pathology, and blood chemistry, including but not limited to changes detectable by ELISA, RIA, chromatography, and the like.
The methods of the invention may be used to treat a subject belonging to any animal classification. Examples of subjects that may be treated include mammals such as humans, rodents, dogs, cats and farm animals.
The antibodies of the invention may be useful in the preparation of a medicament for such treatment, wherein the medicament is prepared for administration in dosages defined herein.
The antibodies of the invention may be administered in combination with a second therapeutic agent.
The second therapeutic agent may be any known therapy for inflammatory diseases, such as autoimmune diseases, including any agent or combination of agents that are known to be useful, or which have been used or are currently in use for treatment. Such therapies and therapeutic agents include surgery or surgical procedures (e.g.
splenectomy, lymphadenectomy, thyroidectomy, plasmapheresis, leukophoresis, cell, tissue, or organ transplantation, intestinal procedures, organ perfusion, and the like), therapy such as steroid therapy and non-steroidal therapy, hormone therapy, cytokine therapy, therapy with dermatological agents (for example, topical agents used to treat skin conditions such as allergies, contact dermatitis, and psoriasis), immunosuppressive therapy, and other anti-inflammatory drugs including monoclonal antibodies.
The second therapeutic agent may be a corticosteroid, an immunosuppressant, a cytotoxic drug, or a B-cell modulator.
In some embodiments, the antibodies of the invention are administered in combination with a second therapeutic agent. Exemplary second therapeutic agents are corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, hydroxychloroquine, sulfasalazine, cytotoxic drugs, immunosuppressive drugs immunomodulatory antibodies, methotrexate, cyclophosphamide, mizoribine, chlorambucil, cyclosporine, tacrolimus (FK506 ; ProGrafrM), mycophenolate mofetil, and azathioprine (6-mercaptopurine), sirolimus (rapamycin), deoxyspergualin, leflunomide and its malononitriloamide analogs; anti-CTLA4 antibodies and Ig fusions, anti-B
lymphocyte stimulator antibodies (e.g., LYMPHOSTAT-BTM) and CTLA4-Ig fusions, anti-CD80 antibodies, anti-T cell antibodies such as anti-CD3 (OKT3), anti-CD4, corticosteroids such as, for example, clobetasol, halobetasol, hydrocortisone, triamcinolone, betamethasone, fluocinole, fluocinonide, prednisone, prednisolone, methylprednisolone; non-steroidal anti-inflammatory drugs (NSAIDs) such as, for example, sulfasalazine, medications containing mesalamine (known as 5-ASA agents), celecoxib, diclofenac, etodolac, fenprofen, flurbiprofen, ibuprofen, ketoprofen, meclofamate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, salicylates, sulindac, and tolmetin;
phosphodiesterase-4 inhibitors, anti-TNFa antibodies REMICADEO (infliximab), SIMPONIO (golimumab) and HUMIRAO (adalimumab), thalidomide or its analogs such as lenalidomide.
The antibodies of the invention may be administered in combination with a second therapeutic agent simultaneously, sequentially or separately.
Treatment effectiveness or RA may be assessed using effectiveness as measured by clinical responses defined by the American College of Rheumatology criteria, the European League of Rheumatism criteria, or any other criteria. See for example, Felson et al. (1995) Arthritis Rheum. 38: 727-35 and van Gestel et al. (1996) Arthritis Rheum. 39:
34-40.
Administration/Pharmaceutical Compositions The invention also provides for pharmaceutical compositions of the antagonistic antibodies specifically binding CD40 of the invention and a pharmaceutically acceptable carrier. For therapeutic use, the antibodies the invention may be prepared as pharmaceutical compositions containing an effective amount of the antibody as an active ingredient in a pharmaceutically acceptable carrier. "Carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the active compound is administered. Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. For example, 0.4% saline and 0.3% glycine may be used. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, thickening, lubricating and coloring agents, etc. The concentration of the antibodies of the invention in such pharmaceutical compositions may vary widely, i.e., from less than about 0.5%, usually to at least about 1%
to as much as 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight and will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the particular mode of administration selected. Suitable vehicles and formulations, including other human proteins, e.g., human serum albumin, are described, for example, in e.g. Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D.B.
ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing pp 691-1092, See especially pp. 958-989.
The mode of administration of the antibodies of the invention in the methods of the invention may be any suitable route such as parenteral administration, e.g., intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous, transmucosal (oral, intranasal, intravaginal, and rectal) or other means appreciated by the skilled artisan, as well known in the art.
The antibodies of the invention may be administered to the subject by any suitable route, for example parentally by intravenous (i.v.) infusion or bolus injection, intramuscularly or subcutaneously or intraperitoneally. i.v. infusion may be given over for, example, 15, 30, 60, 90, 120, 180, or 240 minutes, or over 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11 or 12 hours.
The dose given to the subject is sufficient to alleviate or at least partially arrest the disease being treated ("therapeutically effective amount") and may be from about 0.005 mg/kg to about 100 mg/kg, for example about 0.05 mg/kg to about 20 mg/kg, about 0.1 mg/kg to about 20 mg/kg, about 1 mg to about 20 mg/kg, about 4 mg/kg, about 8 mg/kg, about 16 mg/kg or about 24 mg/kg , or, e.g., about 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/kg, but may even higher, for example about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90 or 100 mg/kg.
A fixed unit dose may also be given, for example, 50, 100, 200, 500 or 1000 mg, or the dose may be based on the patient's surface area, e.g., 500, 400, 300, 250, 200, or 100 mg/m2. Usually between 1 and 8 doses, (e.g., 1, 2, 3, 4, 5, 6, 7 or 8) may be administered to treat the inflammatory disease, such as an autoimmune disease such or a rheumatoid arthritis, but 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more doses may be given.
The administration of the antibodies of the invention may be repeated after one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months or longer. Repeated courses of treatment are also possible, as is chronic administration. The repeated administration may be at the same dose or at a different dose. For example, the antibodies of the invention may be administered at 0.1 mg/kg, at 1 mg/kg, at 5 mg/kg, at 8 mg/kg or at 16 mg/kg at weekly interval for 8 weeks, followed by administration at 8 mg/kg or at 16 mg/kg every two weeks for an additional 16 weeks, followed by administration at 8 mg/ kg or at 16 mg/kg every four weeks by intravenous infusion.
The antibodies of the invention may be provided by maintenance therapy, such as, e.g ., once a week, once a month, once in two months, once in three months, once in four months, once in five months, or once in six months over one or more years.
For example, the antibodies of the invention may be provided as a daily dosage in an amount of about 0.1-100 mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7,
The dose given to the subject is sufficient to alleviate or at least partially arrest the disease being treated ("therapeutically effective amount") and may be from about 0.005 mg/kg to about 100 mg/kg, for example about 0.05 mg/kg to about 20 mg/kg, about 0.1 mg/kg to about 20 mg/kg, about 1 mg to about 20 mg/kg, about 4 mg/kg, about 8 mg/kg, about 16 mg/kg or about 24 mg/kg , or, e.g., about 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/kg, but may even higher, for example about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90 or 100 mg/kg.
A fixed unit dose may also be given, for example, 50, 100, 200, 500 or 1000 mg, or the dose may be based on the patient's surface area, e.g., 500, 400, 300, 250, 200, or 100 mg/m2. Usually between 1 and 8 doses, (e.g., 1, 2, 3, 4, 5, 6, 7 or 8) may be administered to treat the inflammatory disease, such as an autoimmune disease such or a rheumatoid arthritis, but 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more doses may be given.
The administration of the antibodies of the invention may be repeated after one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, five weeks, six weeks, seven weeks, two months, three months, four months, five months, six months or longer. Repeated courses of treatment are also possible, as is chronic administration. The repeated administration may be at the same dose or at a different dose. For example, the antibodies of the invention may be administered at 0.1 mg/kg, at 1 mg/kg, at 5 mg/kg, at 8 mg/kg or at 16 mg/kg at weekly interval for 8 weeks, followed by administration at 8 mg/kg or at 16 mg/kg every two weeks for an additional 16 weeks, followed by administration at 8 mg/ kg or at 16 mg/kg every four weeks by intravenous infusion.
The antibodies of the invention may be provided by maintenance therapy, such as, e.g ., once a week, once a month, once in two months, once in three months, once in four months, once in five months, or once in six months over one or more years.
For example, the antibodies of the invention may be provided as a daily dosage in an amount of about 0.1-100 mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one of day 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively, at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 after initiation of treatment, or any combination thereof, using single or divided doses of every 24, 12, 8, 6, 4, or 2 hours, or any combination thereof The antibodies of the invention may also be administered prophylactically in order to reduce the risk of developing a disease and/or delay the onset of the disease to be treated.
An exemplary pharmaceutical composition of the invention for intramuscular injection may be prepared to contain 1 ml sterile buffered water, and between about 1 ng to about 100 mg/kg, e.g. about 50 ng to about 30 mg/kg or about 5 mg to about 25 mg/kg, of the antibody of the invention.
An exemplary pharmaceutical composition of the invention for intravenous infusion may be made up to contain about 200 ml of sterile Ringer's solution, and about 8 mg to about 2400 mg, about 400 mg to about 1600 mg, or about 400 mg to about 800 mg of the antibodies of the invention for administration to a 80 kg patient. Methods for preparing parenterally administrable compositions are well known and are described in more detail in, for example, "Remington's Pharmaceutical Science", 15th ed., Mack Publishing Company, Easton, PA.
"Therapeutically effective amount" of the antibodies of the invention effective in the treatment of a disease may be determined by standard research techniques.
For example, in vitro assays may be employed to help identify optimal dosage ranges.
Optionally, the dosage of the antibodies of the invention that may be effective in the treatment of a disease such as the inflammatory disease may be determined by administering the antibodies to relevant animal models well known in the art.
Selection of a particular effective dose may be determined (e.g., via clinical trials) by those skilled in the art based upon the consideration of several factors. Such factors include the disease to be treated or prevented, the symptoms involved, the patient's body mass, the patient's immune status and other factors known by the skilled artisan. The precise dose will also depend on the route of administration, and the severity of disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. The antibodies of the invention may be tested for their efficacy and effective dosage using any of the models described herein.
The antibodies of the invention may be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional protein preparations and well known lyophilization and reconstitution techniques can be employed.
Anti-idiotypic antibodies The present invention provides for an anti-idiotypic antibody binding to the antibody of the invention.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 11 and the VL or SEQ ID NO: 12.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 21 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 22 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 23 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 24 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 25 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 26 and the VL or SEQ ID NO: 27.
An anti-idiotypic (Id) antibody is an antibody which recognizes the antigenic determinants (e.g. the paratope or CDRs) of the antibody. The Id antibody may be antigen-blocking or non-blocking. The antigen-blocking Id may be used to detect the free antibody in a sample (e.g. CD40 antibody of the invention described herein). The non-blocking Id may be used to detect the total antibody (free, partially bond to antigen, or fully bound to antigen) in a sample. An Id antibody may be prepared by immunizing an animal with the antibody to which an anti-Id is being prepared.
An anti-Id antibody may also be used as an immunogen to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody.
An anti-anti-Id may be epitopically identical to the original mAb, which induced the anti-Id.
Thus, by using antibodies to the idiotypic determinants of a mAb, it is possible to identify other clones expressing antibodies of identical specificity. Anti-Id antibodies may be varied (thereby producing anti-Id antibody variants) and/or derivatized by any suitable technique.
Immunoconjugates An "immunoconjugate" refers to the antibody of the invention conjugated to one or more heterologous molecule(s).
In some embodiments, the antibody of the invention is conjugated to one or more cytotoxic agents or an imaging agent.
Exemplary cytotoxic agents include chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), and radionuclides.
The cytotoxic agent may be one or more drugs, such as to a mayatansinoid (see, e.g., U.S. Patent No. 5,208,020, 5,416,06), an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see, e.g., U.S. Patent Nos. 5,635,483 and 5,780,588, and 7,498,298), a dolastatin, a calicheamicin or derivative thereof (see, e.g., U.S. Patent Nos. 5,712,374, 5,714,586, 5,739, 116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., (1993) Cancer Res 53:3336-3342; and Lode et al.,(1998) Cancer Res 58:2925-2928); an anthracycline such as daunomycin or doxorubicin (see, e.g., Kratz et al., (2006) Current Med. Chem 13:477-523; Jeffrey et al., (2006) Bioorganic &Med Chem Letters 16:358-362; Torgov et al., (2005) Bioconj Chem 16:717-721; Nagy et al., (2000) Proc Natl Acad Sci USA 97:829-834; Dubowchik et al, Bioorg. &
Med. Chem. Letters 12: 1529-1532 (2002); King et al., (2002) J Med Chem 45:4336-4343;
and U.S. Patent No. 6,630,579), methotrexate, vindesine, a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel.
The cytotoxic agent may also be an enzymatically active toxin or fragment thereof, such as diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A
chain (from Pseudomonas aeruginosa), ricin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
The cytotoxic agent or an imaging agent may also be a radionuclide. Exemplary radionuclides include Ac-225, At-211, 1-131, 1-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, Pb-212 and radioactive isotopes of Lu. When the radioconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc-99m or 1-123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as 1-123, 1-131, In-111, F-19, C-13, N-15 or 0-17.
Conjugates of the antibodies of the invention and the heterologous molecule may be made using a variety of bifunctional protein coupling agents such as N-succinimidy1-3-(2-pyridyldithio) propionate (SPDP), succinimidy1-4-(N-maleimidomethyl) cyclohexane-l-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HQ), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoy1)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin may be prepared as described in Vitetta et al., (1987) Science 238: 1098. Carbon- 14-labeled 1-isothiocyanatobenzy1-3-methyldiethylene triaminepentaacetic acid (MX- DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody.
See, e.g., W094/11026. The linker may be a "cleavable linker" facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., (1992) Cancer Res 52:
127-131; U.S. Patent No. 5,208,020) may be used.
Conjugates of the antibodies of the invention and the heterologous molecule may be prepared with cross-linker reagents such as BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo- SMPB, and SVSB
(succinimidy1-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).
The invention also provides for an immunoconjugate comprising the antibody specifically binding CD40 of SEQ ID NO: 1 of the invention linked to a therapeutic agent or an imaging agent.
Diagnostic uses and kits Kits The invention also provides for a kit comprising the antagonistic antibody specifically binding human CD40 of the invention.
The kit may be used for therapeutic uses and as diagnostic kits.
The kit may be used to detect the presence of CD40 in a biological sample.
In some embodiments, the kit comprises the antagonistic antibody specifically binding human CD40 of the invention and reagents for detecting the antibody.
The kit can include one or more other elements including: instructions for use; other reagents, e.g., a label, a therapeutic agent, or an agent useful for chelating, or otherwise coupling, an antibody to a label or therapeutic agent, or a radioprotective composition;
devices or other materials for preparing the antibody for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to a subject.
In some embodiments, the kit comprises the antibody of the invention in a container and instructions for use of the kit.
In some embodiments, the antibody in the kit is labeled.
In some embodiments, the kit comprises the antibody C40B16, C40B124, C40B135, C40B125, C40B136, C40B127, C40B138, C40B131, C40B176, C40B180, C40B179 or C40B183.
Methods of detecting CD40 The invention also provides for a method of detecting CD40 in a sample, comprising obtaining the sample, contacting the sample with the antibody of the invention, and detecting the antibody bound to CD40 in the sample.
In some embodiments, the sample may be derived from urine, blood, serum, plasma, saliva, ascites, circulating cells, circulating tumor cells, cells that are not tissue associated (i.e., free cells), tissues (e.g., surgically resected tumor tissue, biopsies, including fine needle aspiration), histological preparations, and the like.
The antibodies of the invention may be detected using known methods. Exemplary methods include direct labeling of the antibodies using fluorescent or chemiluminescent labels, or radiolabels, or attaching to the antibodies of the invention a moiety which is readily detectable, such as biotin, enzymes or epitope tags. Exemplary labels and moieties are ruthenium, In-DOTA, diethylenetriaminepentaacetic acid (DTPA), horseradish peroxidase, alkaline phosphatase and beta-galactosidase, poly-histidine (HIS
tag), acridine dyes, cyanine dyes, fluorone dyes, oxazin dyes, phenanthridine dyes, rhodamine dyes and Alexafluor0 dyes.
The antibodies of the invention may be used in a variety of assays to detect in the sample. Exemplary assays are western blot analysis, radioimmunoassay, surface plasmon resonance, immunoprecipitation, equilibrium dialysis, immunodiffusion, electrochemiluminescence (ECL) immunoassay, and immunohistochemistry, fluorescence-activated cell sorting (FACS) or ELISA assay.
The present invention will now be described with reference to the following specific, non-limiting examples.
General Materials and Methods Generation of antigens used in the studies Cloning, expression and purification of the antigens was done using standard methods. The amino acid sequences of the proteins used are shown below.
Full length human CD40 (huCD40); SEQ ID NO: 1 MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTE
TECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHC
TSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCE
TKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNK
APHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
Human CD40 extracellular domain (huCD40-ECD); SEQ ID NO: 2 EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHC
HQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVK
QIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGP
QDRLR
Macaca fascicularis (cynomolgous, herein referred to as cyno) CD40 (cCD40);
SEQ ID
NO: 3 MVRLPLQCVLWGCLLTAVYPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTE
TECLPCSESEFLDTWNRETRCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGLHCM
SESCESCVPHRSCLPGFGVKQIATGVSDTICEPCPVGFF SNVS SAFEKCRPWTSCETK
DLVVQQAGTNKTDVVCGPQDRQRALVVIPICLGILFVILLLVLVFIKKVAKKPNDK
APHPKQEPQEINFLDDLPGSNPAAPVQETLHGCQPVTQEDGKESRISVQERQ
Cyno CD40 extracellular domain (cCD40-ECD); SEQ ID NO: 4 EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECL
PCSESEFLDTWNRETRCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGLHCMSESC
ESCVPHRSCLPGFGVKQIATGVSDTICEPCPVGFF SNVS SAFEKCRPWTSCETKDLV
VQQAGTNKTDVVCGPQDRQR
Soluble human CD154; SEQ ID NO: 60 MQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQ
GLYYIYAQVTFCSNREAS SQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIH
LGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
Full length human CD154; SEQ ID NO: 64 MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDER
NLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEM
QKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQG
LYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHL
GGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLL
Binding assay in primary human and cyno Dendritic Cells (DCs) Human monocytes were isolated from either frozen/fresh PBMC using CD14 negative isolation kit per manufacturer's protocol (MACS Miltenyi). Cyno monocytes were isolated from fresh PBMC using CD14 positive isolation kit per manufacturer's protocol (MACS Miltenyi). To generate DCs, monocytes were cultured for 5 days in complete RPMI medium (Invitrogen) in the presence of 10Ong/m1 human GM-CSF and human IL-4 (Peprotech) and medium was replenished every 2 days. On day 5, DCs were stimulated with 10Ong/m1LPS (Sigma) for 24 hours. Cells were then stained with each of the tested CD40 antibodies at different concentration in flow cytometry buffer (PBS + 1%
FBS; BD Bioscience) in 100 IA volume for 30 minutes on ice followed with two washes with flow buffer. Cells were then stained for an additional 30 minutes on ice with APC-conjugated anti human IgG (Jackson ImmunoResearch) at the recommended dilution (1:100) and washed twice with flow buffer. Cells were analyzed for percent positive and Mean Fluorescence Intensity (MFI) to determine the antibody binding using Fortessa (BD
Bioscience).
Binding assay in Raji (B cells lymphoma cell line) and HEK-B1ueTM CD4OL NF-KB
cell lines Raji cells were obtained from ATCC and HEKB1ueTM CD4OL NF-KB cell line was obtained from Invivogen. Cells were cultured in complete RPMI medium per company's recommendation. Staining was done as described above for binding assay in primary human and cyno DCs.
Human DC IL-12p40 production assay Human DCs were generated by culturing purified human monocytes (2.5x106/well 6-well plates) for 6 days in 3m1 RPMI medium containing glutamax, 25mM HEPES, 10%
FBS, 1% Pen/Strep and 5Ong each GM-CSF and IL-4. On day 3, lml of the medium was removed and replaced with 2m1 fresh medium containing 5Ong/m1 each of GM-CSF
and IL-4. For agonist assays, day 6 DCs were plated into 96-well plates (100,000 cells/well) followed by titrations of each of the CD40 antibodies. For antagonist assays, day 6 DCs were plated into 96-well plates (100,000 cells/well) followed by titrations of each of the CD40 antibodies and addition of 1ug/m1 of soluble human CD154 (R&D Systems) to the cultures. For both assays, cells were cultured for 48 hours before collecting and analyzing supernatants for IL-12p40 by MSD (according to manufacturer's directions). For Jurkat D1.1 (ATCC) antagonist assays, day 6 DCs were plated into 96-well plates (10,000 cells/well) followed by titrations of each of the CD40 antibodies, after which irradiated Jurkat D1.1 cells (1,000 rads; 100,000/well) were added to the cultures. Cells were cultured for 24 hours before collecting and analyzing supernatants for IL-12p40 by MSD.
Human B cell proliferation assay Human tonsillar B cells were plated into 96-well plates (100,000 cells/well) in RPMI medium containing glutamax, 10% FBS and 1% Pen/Strep. For agonist assays, titrations of each of the CD40 antibodies were added to the cells and cultured for 48 hours.
For antagonist assays, titrations of each of the CD40 antibodies were added to the cells, followed by addition of 0.5 [tg/m1 soluble human CD154 (R&D Systems). Cells were cultured for 48 hours at 37C. For Jurkat D1.1 antagonist assays, titrations of each of the CD40 antibodies were added to the cells along with IL-21 (10Ong/m1 final, Thermo Fisher Scientific)), after which irradiated Jurkat D1.1. cells (5,000 rads;
100,000/well) were added to the cultures and incubated at 37C for 48 hours. For all assays, after 48 hours cells were pulsed with 3H-thymidine (luCi/well) in 50 1 medium and cultured for 16-18 hours before harvest and counting.
Cyno B cell proliferation assay Cyno spleen cells were plated into 96-well plates (100,000 cells/well) in RPMI
medium containing glutamax, 10% FBS and 1% Pen/Strep. Titrations of each of the CD40 antibodies were added to the cells, followed by addition of 0.5 [tg/ml soluble human CD154 (R&D Systems). Cells were cultured for 48 hours at 37C. After 48 hours, cells were pulsed with 3H-thymidine (luCi/well) in 50 1 medium and cultured for 16-18 hours before harvest and counting.
HEK-B1ueTM CD4OL NF-KB activation assay HEKB1ueTM CD4OL cell lines stably express human CD40 and NF-KB-inducible secreted embryonic alkaline phosphatase (SEAP). Activation of CD40 on HEKB1ueTM
CD4OL cells induce downstream signaling events leading to activation of NF-KB
and secretion of SEAP, which can be measured by QUANTI-BlueTm substrate conversion.
These cells were used to assess the ability of the antibodies to either block (antagonize) CD4O-CD154 interaction or activate (agonize) CD40.
Inhibition of CD40 Dependent NF-kB Activation in HEK-Blue CD4OL Cell Line HEKB1ueTM CD4OL cells (Invivogen), which were maintained according to the vendor's protocol, were seeded into 96 well tissue culture plates in 100 [11 volume (2.5 x 104 cells/well). The assay plates were covered and incubated overnight (37 C, 5% CO2) to allow the cells to recover. On the following day, a 4X solution of rhCD154-ECD-His (80 ng/ml final concentration) and 4X solution of CD40 antibodies, or Fabs, (1 ¨
25 ps/m1 final concentration) were pre-mixed and the resulting 2X solution added to the 96 well assay plates containing the cells (200 [11/we11 final volumes). After 16-24 h incubation (37 C, 5% CO2), 40 IA aliquots of the supernatants were mixed with 160 [11 of pre-warmed QUANTI-Blue TM (Invivogen) solution and incubated for 30-60 minutes prior to obtaining absorbance readings at 650 nm.
CD40 Dependent NF-kB Activation in HEK-Blue CD4OL NFkB-SEAP Cell Line HEKB1ueTM CD4OL cells were seeded as described above and recovered overnight. On the following day, 2X CD40 antibody solutions (1 ¨ 25 pg/m1 final concentration) were added to the plate at 100 [d/well and incubated overnight (37 C, 5%
CO2). After 16-24 h incubation (37 C, 5% CO2), 40 [11 aliquots of the supernatants were analyzed as described above.
Example 1. Isolation of antibodies specifically binding human CD40 using rats expressing human immunoglobulin loci Antibodies were generated using transgenic rats expressing human immunoglobulin loci, the OmniRat0; OMT, Inc. The OmniRatO endogenous immunoglobulin loci are replaced by human Igk and IgX loci and a chimeric human/rat IgH locus with V, D and J segments of human origin linked to the rat CH locus.
The IgH
locus contains 22 human VHS, all human D and .JH segments in natural configuration linked to the rat CH locus. Generation and characterization of the OmniRatO is described in Osborn, et al. J Immunol 190: 1481-1490, 2013; and Int. Pat. Publ. No. WO
14/093908.
Separate cohorts of five rats were immunized with recombinant human and cyno CD40 ECD-His or human and cyno CD40 ECD-Fc proteins. Following a 31-34 day immunization regimen, lymph nodes were harvested from two rats and used to generate hybridomas. The generated hybridomas were screened for binding to both human and cyno CD40-ECD. Hybridomas exhibiting statistically significant binding to both human and cyno CD40-ECD following one-way ANOVA with a Dunnett's mean comparison post-test were cloned and their V regions sequenced using standard procedures Example 2. Engineering of C40B16 C40B16 was generated by using the OmniRatO and identified having antagonist activity in the HEK-Blue TM CD4OL NF-KB activation assay based on the criteria that an antagonist had a signal that is lower than the 3 x standard deviation of the mean signal of HEKB1ueTM CD4OL cells treated with rhCD154-ECD-his alone.
C40B16 VH and VL were sequenced using standard methods and the framework sequences compared to the closest germline gene sequences in order to identify potential immunogenicity risks. C40B16 VH amino acid sequence was most homologous to IGHV3-23 (SEQ ID NO: 49) with 2 amino acid changes in the framework. C40B16 VL
framework was identical to that of IGLV3-1 (SEQ ID NO: 50).
The variable regions of C40B16 were engineered to reduce possible immunogenicity and/or developability risk(s) by generating mutations at positions R43, H82, N52, S54 and/or M108 in the VH (residue numbering according to SEQ ID NO:
11) and at position C33 in the VL (residue numbering according to SEQ ID NO: 12) to eliminate potential heterogeneity caused by unpaired cysteines. The generated VH/VL
domains were cloned as effector silent Fc isoforms IgGlsigma or IgG4PAA.
IgGlsigma contains mutations L234A, L235A, G237A, P238S, H268A, A3305, and P331S when compared to the wild-type IgGl. IgG4PAA contains mutations 5228P, F234A and when compared to the wild-type IgG4. Residue numbering is according to the EU
Index.
Table 3 shows the generated antibodies and introduced mutations when compared to the parental C40B16 mAb. A C33A mutation was engineered in the VL of all generated antibodies when compared to the parental C40B16 VL.
Table 4 shows the HCDR1 and the HCDR2 amino acid sequences of the antibodies.
Table 5 shows the HCDR3 and the LCDR1 amino acid sequences of the antibodies.
Table 6 shows the LCDR2 and the LCDR3 amino acid sequences of the antibodies.
Table 7 shows the SEQ ID NOs: of the amino acid and cDNA sequences of the VH and the VL regions of the antibodies.
Table 8 shows the SEQ ID NOs: of the amino acid sequences of the heavy chains and the light chains of the antibodies.
Table 9 shows the amino acid or polynucleotide sequences corresponding to SEQ
ID NOs: 11-14, 21-52 and 65-78.
Table 3.
VH Mutation compared to mAb C40B16 Isotype C40B16 parental IgG1 C40B124 R43K,H82Q,N52D,554A IgGl Sigma C40B135 R43K,H82Q,N52D,554A IgG4PAA
C40B125 R43K,H82Q,N52Q,554A IgGl Sigma C40B136 R43K,H82Q,N52Q,554A IgG4PAA
C40B127 R43K,H82Q,N53Q,554A IgGl Sigma C40B138 R43K,H82Q,N53Q,554A IgG4PAA
C4OB 131 R43K,H82Q,N53A,554A IgG4PAA
C40B176 R43K,H82Q,N53A,554A, M108L IgGl Sigma C40B180 R43K,H82Q,N53A,554A, M108L IgG4PAA
C40B179 R43K,H82Q,N53Q,554A, M108L IgGl Sigma C40B183 R43K,H82Q,N53Q,554A, M108L IgG4PAA
Table 4.
mAb Sequence SEQ Sequence SEQ ID
ID NO: NO:
Table 5.
mAb Sequence SEQ Sequence SEQ ID
ID NO: NO:
Table 6.
mAb Sequence SEQ Sequence SEQ ID
ID NO: NO:
Table 7.
VH
amino VH DNA VLVL DNA
mAb VH name acid SEQ ID VL aminoSEQ ID
acid SEQ
SEQ ID NO: name NO:
ID NO:
NO:
Table 8.
HC HC DNA LC protein LC DNA
protein SEQ ID SEQ ID SEQ ID
mAb SEQ NO: NO: NO:
ID NO:
Table 9.
Protein Sequence SEQ ID
NO:
C40B16 VH protein EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 11 AMSWVRQAPGRGLEWVSTINNSGGGTYYAD
SVKGRFTISRDNSKNTLYLHMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40B16 VL protein SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 12 CWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWASSTV
VFGGGTKLTVL
CTGGTGCAGCCTGGCGGCAGCCTGAGACTG
TCTTGTGCCGCCAGCGGCTTCACCTTCAGCA
GCTACGCTATGAGCTGGGTCCGACAGGCCC
CTGGCAGAGGACTCGAGTGGGTGTCCACCA
TCAACAACAGCGGCGGAGGCACCTACTACG
CCGACAGCGTGAAGGGCAGATTCACCATCA
GCCGGGACAACAGCAAGAACACCCTGTACC
TGCACATGAACAGCCTGCGGGCCGAGGACA
CCGCCGTGTACTATTGTGCCAAAGAGGGCG
GCAAGTACTACTACTATGCCATGGACGTGT
GGGGCCAGGGCACCACCGTGACAGTGTCAT
CT
CTGTGTCTCCTGGCCAGACCGCCAGCATCAC
CTGTAGCGGCGACAAGCTGGGCGATAAGTA
CGCCTGCTGGTATCAGCAGAAGCCCGGCCA
GAGCCCCGTGCTGGTCATCTACCAGGACAG
CAGAAGGCCCAGCGGCATCCCCGAGAGATT
CAGCGGCAGCAACAGCGGCAATACCGCCAC
CCTGACCATCAGCGGCACCCAGGCCATGGA
CGAGGCCGATTACTATTGTCAGGCCTGGGC
CAGCAGCACCGTGGTGTTTGGCGGCGGAAC
AAAGCTGACCGTGCTG
C40H60 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 21 AMSWVRQAPGKGLEWVSTIDNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H61 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 22 AMSWVRQAPGKGLEWVSTIQNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H63 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 23 AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H56 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 24 AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H83 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 25 AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVSS
C40H86 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 26 AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVSS
C40L71 protein SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 27 AWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWASSTV
VFGGGTKLTVL
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCGACAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCCAGAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
AGCGTGAGCCCCGGCCAGACCGCCAGCATC
ACCTGCAGCGGCGACAAGCTGGGCGACAAG
TACGCCGCCTGGTACCAGCAGAAGCCCGGC
CAGAGCCCCGTGCTGGTGATCTACCAGGAC
AGCCGGCGGCC CAGCGGCATC CC CGAGCGG
TTCAGCGGCAGCAACAGCGGCAACACCGCC
ACC CTGACCATCAGCGGCACC CAGGCCATG
GACGAGGCCGACTACTACTGCCAGGCCTGG
GCCAGCAGCACCGTGGTGTTCGGCGGCGGC
ACCAAGCTGACCGTGCTG
C4 OB 1 6 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFS SY 3 5 protein AMSWVRQAPGRGLEWVSTINNSGGGTYYAD
SVKGRFTI SRDNSKNTLYLHMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVS SAS
TKGPSVFPLAP S SKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQ S SGLYSLS
SVVTVP S S SLGTQTYICNVNHKPSNTKVDKKV
EPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDV SHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B124 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 36 protein AMSWVRQAPGKGLEWVSTIDNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVP SS SLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B135 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 37 protein AMSWVRQAPGKGLEWVSTIDNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C4OB 125 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 38 protein AMSWVRQAPGKGLEWVSTIQNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVP SS SLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B136 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 39 protein AMSWVRQAPGKGLEWVSTIQNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGK
C40B127 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 40 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B138 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 41 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGK
C40B131 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 42 protein AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTV S SA S
TKGP SVFPLAP C S RS TSE S TAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MI SRTPEVTCVVVDV S QEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPP S QEEMTKNQV SLTCLVKGFYP SD I
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C4OB 176 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFSSY 43 protein AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLS
SVVTVP SS SLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVF SC SVMHEALHNH
YTQKSLSLSPGK
C4OB 180 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFSSY 44 protein AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGP SVFPLAP C S RS TSE S TAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MI SRTPEVTCVVVDV S QEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPP S QEEMTKNQV SLTCLVKGFYP SD I
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C4OB 179 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFS SY 45 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVF SC SVMHEALHNH
YTQKSLSLSPGK
C4OB 183 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFS SY 46 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGP SVFPLAP C S RS TSE S TAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C40B16 light chain SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 47 protein CWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWASSTV
VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQA
NKATLVCLISDFYPGAVTVAWKADSSPVKAG
VETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
C40B124, C40B135, SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 48 C40B125, C40B136, AWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
C40B127, C40B138, NSGNTATLTISGTQAMDEADYYCQAWASSTV
C40B131, C40B176, VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQA
C40B180. C40B179, NKATLVCLISDFYPGAVTVAWKADSSPVKAG
Light chain protein YSCQVTHEGSTVEKTVAPTECS
AMSWVRQAPGKGLEWVSAISGSGGSTYYADS
VKGRFTISRDNSKNTLYLQMNSLRAEDTAVY
YCAK
CWYQQKPGQSPVLVIYQDSKRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWDS STA
IgGlsigma Fc ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 51 FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LS SVVTVP S S SLGTQTYICNVNHKPSNTKVDK
KVEPKSCDKTHTCPPCPAPEAAGASSVFLFPP
KPKDTLMISRTPEVTCVVVDVSAEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPSSIEKTISK
AKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYP SDIAVEWESNGQPENNYKTTPPVLD SD
GSFFLYSKLTVDKSRWQQGNVFS CSVMHEAL
HNHYTQKSLSLSPGK
IgG4PAA ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF 52 PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKR
VESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSD
IAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
RLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
KSLSLSLGK
CTGGTGCAGCCTGGCGGCAGCCTGAGACTG
TCTTGTGCCGCCAGCGGCTTCACCTTCAGCA
GCTACGCTATGAGCTGGGTCCGACAGGCCC
CTGGCAGAGGACTCGAGTGGGTGTCCACCA
TCAACAACAGCGGCGGAGGCACCTACTACG
CCGACAGCGTGAAGGGCAGATTCACCATCA
GCCGGGACAACAGCAAGAACACCCTGTACC
TGCACATGAACAGCCTGCGGGCCGAGGACA
CCGCCGTGTACTATTGTGCCAAAGAGGGCG
GCAAGTACTACTACTATGCCATGGACGTGT
GGGGCCAGGGCACCACCGTGACAGTGTCAT
CTGCCTCCACCAAGGGCCCATCGGTCTTCCC
C40B16 heavy chain CCTGGCACCCTCCTCCAAGAGCACCTCTGGG
DNA GGCACAGCGGCCCTGGGCTGCCTGGTCAAG
GACTACTTCCCCGAACCGGTGACGGTGTCGT
GGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGG
ACTCTACTCCCTCAGCAGCGTGGTGACCGTG
CCCTCCAGCAGCTTGGGCACCCAGACCTAC
ATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAAAGTTGAGCCCAAA
TCTTGTGACAAAACTCACACATGCCCACCGT
GCCCAGCACCTGAACTCCTGGGGGGACCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGA
CACCCTCATGATCTCCCGGACCCCTGAGGTC
ACATGCGTGGTGGTGGACGTGAGCCACGAA
GACCCTGAGGTCAAGTTCAACTGGTACGTG
GACGGCGTGGAGGTGCATAATGCCAAGACA
AAGCCGCGGGAGGAGCAGTACAACAGCAC
GTACCGTGTGGTCAGCGTCCTCACCGTCCTG
CACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCA
GCCCCCATCGAGAAAACCATCTCCAAAGCC
AAAGGGCAGCCCCGAGAACCACAGGTGTAC
ACC CTGCC CC CATCC CGGGAGGAGATGACC
AAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTATCCCAGCGACATCGCCGTG
GAGTGGGAGAGCAATGGGCAGCCGGAGAA
CAACTACAAGACCACGCCTCCCGTGCTGGA
CTCCGACGGCTCCTTCTTCCTCTACAGCAAG
CTCACCGTGGACAAGAGCAGGTGGCAGCAG
GGGAACGTCTTCTCATGCTCCGTGATGCATG
AGGCTCTGCACAACCACTACACGCAGAAGA
GCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCGACAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
C40B124 heaw chain GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
' 1 GGACTACTTC CC CGAA CCGGTGACGGTGTC
DNA
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTCCCATCCTCCATCGAGAAAACCATCTCCA
AAGCCAAAGGGCAGCCCCGAGAACCACAG
GTGTACACCCTGCCCCCATCCCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCGACAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CCCTGGCGCCCTGCTCCAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
C4OB 135 heavy chain CGTGGAACTCAGGCGCCCTGACCAGCGGCG
DNA TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCATGCCCA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCCCCCCAAAACCCAAGGACACTC
TCATGATCTCCCGGACCCCTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGCTGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCCAGAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
C40B125 heaw chain GCACACCTTCCCGGCTGTCCTACAGTCCTCA
' 1 GGACTCTACTCCCTCAGCAGCGTGGTGACC
DNA
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCCAGAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CC CTGGCGC CCTGCTC CAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
C40B136 heavy chain CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
DNA CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCC CC CATGCC CAC CATGCC CA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCC CC C CAAAAC C CAAGGACACTC
TCATGATCTC CCGGAC CC CTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGCTGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
C40B127 heaw chain TACATCTGCAACGTGAATCACAAGCCCAGC
DNA
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CC CTGGCGC CCTGCTC CAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTC CC CGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
A. C ACACCAAGGTGGACAAGAGAGTTGAGTC
C4OB 138 heavy chain CAAATATGGTCC CC CATGCC CAC CATGCC CA
DNA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCC CC C CAAAAC C CAAGGACACTC
TCATGATCTC CCGGAC CC CTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGCTGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CC CTGTCTCTGGGTAAA
C4OB 131 heavy chain GAGGTGCAGCTGGTGGAGAGCGGCGGCGGC 72 DNA CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CCCTGGCGCCCTGCTCCAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCATGCCCA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCCCCCCAAAACCCAAGGACACTC
TCATGATCTCCCGGACCCCTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CCCCCATCCCAGGAGGAGATGACCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
C4OB 176 heavy chain CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
DNA AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
C40B180 heaw chain AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
DNA
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CCCTGGCGCCCTGCTCCAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCATGCCCA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCCCCCCAAAACCCAAGGACACTC
TCATGATCTCCCGGACCCCTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CCCCCATCCCAGGAGGAGATGACCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
C4OB 179 heavy chain CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
DNA ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
C4OB 1 83 heaw chain ATCAACCAGGCCGGCGGCGGCACCTACTAC
' 1 GCCGACAGCGTGAAGGGCCGGTTCACCATC
DNA
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CC CTGGCGC CC TGCTC CAGGAGCACC TCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAAC TCAGGCGC C CTGAC CA GCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCC CC CA TGCC CAC CATGCC CA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCC TGTTCC CC C CAAAAC C CAAGGACAC TC
TCATGAT CTC CCGGAC CC CTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGC TGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
C4OB 16 light chain TCCTACGAGCTGACCCAGCCTCCCTCCGTGT 77 DNA CTGTGTCTCCTGGCCAGACCGCCAGCATCAC
CTGTAGCGGCGACAAGCTGGGCGATAAGTA
CGC CTGCTGGTATCAGCAGAAGC CCGGC CA
GAGC CC CGTGCTGGTCATCTAC CAGGACAG
CAGAAGGCCCAGCGGCATCCCCGAGAGATT
CAGCGGCAGCAACAGCGGCAATACCGCCAC
CCTGACCATCAGCGGCACCCAGGCCATGGA
CGAGGCCGATTACTATTGTCAGGCCTGGGC
CAGCAGCACCGTGGTGTTTGGCGGCGGAAC
AAAGCTGACCGTGCTGGGTCAGCCCAAGGC
TGCACCCAGTGTCACTCTGTTCCCGCCCTCC
TCTGAGGAGCTTCAAGCCAACAAGGCCACA
CTGGTGTGTCTCATAAGTGACTTCTACCCGG
GAGCCGTGACAGTGGCCTGGAAGGCCGATA
GCAGC CC CGTCAA GGCGGGAGTGGAGAC CA
CCACACCCTCCAAACAAAGCAACAACAAGT
ACGCGGCCAGCAGCTATCTGAGCCTGACGC
CTGAGCAGTGGAAGTCCCACAGAAGCTACA
GCTGCCAGGTCACGCATGAAGGGAGCACCG
TGGAGAAGACAGTGGCCCCTACAGAATGTT
CA
C40B124, C40B135, AGCTACGAGCTGACCCAGCCCCCCAGCGTG 78 AGCGTGAGCCCCGGCCAGACCGCCAGCATC
C40B125, C40B136, ACCTGCAGCGGCGACAAGCTGGGCGACAAG
C4 OB127, C4 OB 138, TACGCCGCCTGGTACCAGCAGAAGCCCGGC
, , AGCCGGCGGCCCAGCGGCATCCCCGAGCGG
C40B180. C40B179, TTCAGCGGCAGCAACAGCGGCAACACCGCC
ACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCCAGGCCTGG
Light chain DNA GCCAGCAGCACCGTGGTGTTCGGCGGCGGC
ACCAAGCTGACCGTGCTGGGTCAGCCCAAG
GCTGCACCCAGTGTCACTCTGTTCCCGCCCT
CCTCTGAGGAGCTTCAAGCCAACAAGGCCA
CACTGGTGTGTCTCATAAGTGACTTCTACCC
GGGAGCCGTGACAGTGGCCTGGAAGGCCGA
TAGCAGCCCCGTCAAGGCGGGAGTGGAGAC
CACCACACCCTCCAAACAAAGCAACAACAA
GTACGCGGCCAGCAGCTATCTGAGCCTGAC
GCCTGAGCAGTGGAAGTCCCACAGAAGCTA
CAGCTGCCAGGTCACGCATGAAGGGAGCAC
CGTGGAGAAGACAGTGGCCCCTACAGAATG
TTCA
Example 3. Characterization of antagonistic anti-CD40 antibodies The parental C40B16 and the engineered variants were tested for their antagonistic activity in a spectrum of assays including ability of the antibodies to inhibit human soluble CD4OL (sCD4OL) or membrane-bound CD4OL (mCD4OL)-mediated proliferation of human or cyno B cells, and inhibition of IL-12p40 production by human DCs. The experiments were conducted according to protocols described in Example 1.
Membrane-bound CD4OL was provided on Jurkat cells in the assays.
All antibodies demonstrated antagonism in the assays performed.
Table 10 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven B cell proliferation. Table 11 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven IL-12p40 production by human dendritic cells.
Table 10.
B-cell proliferation 1050 nM +/- SD
sCD4OL-driven mCD4OL-driven sCD4OL-driven mAb human B-cell human B-cell cyno B-cell proliferation proliferation proliferation C40B124 0.118 +1-0.003 (4) C40B135 0.056 +/-0.040 (3) 0.131 +/-0.012 (4) 0.077 +/-0.024 (2) C40B125 0.088 +/-0.025 (6) 0.128 +/-0.019 (6) 0.083 +/-0.029 (2) C40B136 0.087 +/-0.056 (6) 0.122 +/-0.013 (4) 0.065 +/-0.038 (2) C40B127 0.073 +/-0.010 (2) 0.111 +/-0.009 (4) 0.066 +/-0.002 (2) C40B138 0.048 +/-0.035 (2) 0.106 +/-0.000 (2) 0.075 +/-0.050 (2) C40B131 0.099 +/-0.003 (4) C40B176 0.132 +/-0.105 (4) 0.181 +/-0.054 (4) 0.108 +/-0.029 (4) C40B180 0.092 +/-0.047 (4) 0.136 +/-0.071 (4) 0.109 +/-0.047 (4) C40B179 0.132 +/-0.030 (4) 0.178 +/-0.053 (4) 0.119 +/-0.026 (4) C40B183 0.103 +/-0.053 (4) 0.140 +/-0.018 (4) 0.110 +/-0.029 (4) sCD4OL: soluble CD4OL
mCD4OL: membrane-bound CD4OL
The number in parenthesis indicates the number of times the assay was repeated Table 11.
DC IL-12p40 productionIC50nM +/- SD
mAb sCD4OL-driven mCD4OL-driven C40B124 0.387 +/-0.09 (3) 0.507 +/-0.07 (5) C40B135 0.329 +/-0.02 (3) 0.430 +/-0.10 (5) C40B125 0.244 +/-0.04 (5) 0.393 +/-0.09 (5) C40B136 0.246 +/-0.05 (5) 0.379 +/-0.08 (5) C40B127 0.270 +/-0.07 (3) 0.383 +/-0.08 (5) C40B138 0.262 +/-0.06 (3) 0.341 +/-0.10 (5) C40B131 0.330 +/-0.18 (3) 0.323 +/-0.12 (5) C40B176 0.220 +/-0.11 (3) 0.245 +/-0.06 (2) C40B180 0.225 +/-0.06 (3) 0.222 +/-0.07 (2) C40B179 0.184 +/-0.07 (3) 0.297 +/-0.06 (2) C40B183 0.208 +/-0.09 (3) 0.291 +/-0.07 (2) sCD4OL: soluble CD4OL
mCD4OL: membrane-bound CD4OL
The number in parenthesis indicates the number of times the assay was repeated Affinity of the antibodies to human CD40 was assessed using Surface Plasmon Resonance (SPR) using a ProteOn XPR36 system (BioRad). A biosensor surface was prepared by coupling anti-Human IgG Fc (Jackson cat#109-005-098) to the modified alginate polymer layer surface of a GLC chip (BioRad, Cat#176-5011) using the manufacturer instructions for amine-coupling chemistry. Approximately 5000 RU
(response units) of mAbs were immobilized. The kinetic experiments were performed at 25 C in running buffer (DPBS+0.01%P20+100 g/m1 BSA). To perform kinetic experiments, 200 RU of mAbs were captured followed by injections of analytes (human or cyno CD40) at 5 concentrations (in a 4-fold serial dilution). The association phase was monitored for 3 minutes at 50 pL/min, then followed by 15 minutes of buffer flow (dissociation phase). The chip surface was regenerated with two 18 second pulses of 100 mM H3PO4 (Sigma, Cat#7961) at 100 pL/min.
The collected data were processed using ProteOn Manager software. First, the data was corrected for background using inter-spots. Then, double reference subtraction of the data was performed by using the buffer injection for analyte injections. The kinetic analysis of the data was performed using a Langmuir 1:1 binding model. The results were reported in the format of Ka (On-rate), Kd (Off-rate) and KD (equilibrium dissociation constant).
Summary of kinetics affinity for the mAbs for binding to human CD40 is shown in Table 12. The parameters reported in this table were obtained from a 1:1 Langmuir binding model for all samples. Affinity, KD = kd/ka.
Table 12.
mAb ka (1/Ms) kd (1/s) KD (M) C40B16 4.27E+06 1.57E-04 3.68E-11 C40B124 2.30E+06 9.56E-05 4.16E-11 C40B135 2.93E+06 1.45E-04 4.96E-11 C40B125 3.89E+06 1.36E-04 3.49E-11 C40B136 3.30E+06 1.13E-04 3.43E-11 C40B127 3.79E+06 1.15E-04 3.03E-11 C40B138 3.58E+06 2.15E-04 5.99E-11 C40B131 3.52E+06 2.86E-04 8.12E-11 C40B176 2.86E+06 3.07E-04 1.07E-10 C40B180 2.67E+06 3.66E-04 1.37E-10 C40B179 2.86E+06 2.67E-04 9.33E-11 C40B183 2.91E+06 3.50E-04 1.21E-10 Example 4. Antagonistic antibodies specifically binding human CD40 are potent inhibitors of CD40/CD4OL pathway and display minimal agonistic activity Four antagonistic antibodies (C40B176, C40B179, C40B180 and C40B183) were benchmarked against anti-CD40 antibodies currently in clinical developments.
The antibodies used in comparisons were: Astellas/Kirin ASKP-1240 (HC SEQ ID NO:
53, LC
SEQ ID NO: 54, Fc silent IgG4 with 5228P and L235E mutations), Antibody D (HC
SEQ
ID NO: 55, LC SEQ ID NO: 56, Fc silent IgG1 with L234A and L235A mutations;
described in U58,591,900 as antibody B IgG1K0b), Novartis CFZ533 (HC SEQ ID
NO:
57, LC SEQ ID NO: 58, Fc silent IgG1 with N297A mutation), and BMS-986090 (HC
SEQ ID NO: 59, IgG4 with 5228P mutation).
SEQ ID NO: 53 (ASKP-1240 HC) QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGS
TYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQ
GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP
CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
SEQ ID NO: 54 (ASKP-1240 LC) AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKWYDASNLESG
VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 55 (Antibody D HC) EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSG
NRITYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQDGYRYAMDY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTQTYICNVNHKP SNTKVDKKVEPKS
CDKTHTCPPCPAPEAAGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPP SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVF SC SVMHEALHNHYTQKSL
SLSPGK
SEQ ID NO: 56 (Antibody D LC) DIVMTQ SPD SLAVSLGEKVTINCKS S Q SLLNSGNQKNYLTWHQQKPGQPPKLLWW
TSTRESGVPDRFSGSGSGTDFTLTIS SLQAEDVAVYYCQNDYTYPLTFGGGTKVEIK
RTVAAP SVFIFPP S DEQLKSGTA SVVCLLNNFYPREAKVQWKVDNAL Q SGNS QESV
TEQD SKD STY SLS STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
SEQ ID NO: 57 (CFZ533 HC) QVQLVESGGGVVQPGRSLRLS CAA SGFTF S SYGMHWVRQAPGKGLEWVAVISYE
ESNRYHAD SVKGRFTISRDN SKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDY
WGQGTLVTVS SA STKGP SVFPLAP S SKS TSGGTAALGCLVKDYFPEPVTV SWN SGA
LTSGVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTQTYICNVNHKP SNTKVDKKVEPKS
CDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPP SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVF SC SVMHEALHNHYTQKSL
SLSPGK
SEQ ID NO: 58 (CFZ533 LC) DIVMTQ SPL S LTVTPGEPA SI S CRS SQ SLLYSNGYNYLDWYLQKPGQ SP QVLI S LG S
NRASGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIRR
TVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNS QESVT
EQD SKD STY SL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
SEQ ID NO: 59 (BMS-986090 HC) EVQLLESGGGLVQPGGSLRLSCAASGFTFRDYEMWWVRQAPGKGLERVSAINPQG
TRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLPFRFSDRGQGT
LVTVSSASTESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL
HNHYTQKSLSLSLGK
Table 13 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven human or cyno B cell proliferation for the tested antibodies.
Table 14 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven IL-12p40 production by human dendritic cells (DC) and the affinity kinetics for each mAb.
mAbs C40B176, C40B179, C40B180 and C40B183 exhibited comparable potency when compared to the best performing benchmark mAb ASKP-1240.
Table 13.
B cell proliferation; IC50 nM +/- SD
mAb Soluble CD4OL Membrane CD4OL Soluble CD4OL
human B-cells human B-cells cyno B-cells C40B176 0.132 +/-0.105 (4) 0.181 +/-0.054 (4) 0.108 +/-0.029 (4) C40B180 0.092 +/-0.047 (4) 0.136 +/-0.071 (4) 0.109 +/-0.047 (4) C40B179 0.132 +/-0.030 (4) 0.178 +/-0.053 (4) 0.119 +/-0.026 (4) C40B183 0.103 +/-0.053 (4) 0.140 +/-0.018 (4) 0.110 +/-0.029 (4) ASKP-1240 0.079 +/-0.017 (12) 0.132 +/-0.042 (10) 0.146+/-0.063 (8) Antibody D 0.680 +/-0.323 (4) 1.926 +/-0.368 (2) CFZ533 0.223 +/-0.117 (4) 0.279 +/-0.062 (2) BMS-986090 0.288 +/-0.136 (4) 0.393 +/-0.002 (2) Table 14.
Human DC IL-12p40 production; IC50 nM +/- SD
mAb Affinity KD (M) Soluble CD4OL Membrane CD4OL
C40B176 4.96E-11 0.220 +/-0.11 (3) 0.245 +/-0.06 (2) C40B180 5.99E-11 0.225 +/-0.06 (3) 0.222 +/-0.07 (2) C40B179 3.43E-11 0.184 +/-0.07 (3) 0.297 +/-0.06 (2) C40B183 1.07E-10 0.208 +/-0.09 (3) 0.291 +/-0.07 (2) ASKP-1240 1.81E-10 0.119+1-0.05 (6) 0.280+/-0.11 (7) Antibody D 5.8E-10 0.781 +/-0.30(3) 3.630 +/-1.19 (5) CFZ533 9.36E-12 0.320 +/-0.12 (3) 0.948 +/-0.29 (5) BMS-986090 8.7E-10 0.285 +/-0.17 (2) 0.822 +/-0.39 (5) Possible undesired agonistic activity of the mAbs was assessed using HEKB1ueTM
CD4OL NF-KB activation assay and IL12p40 production by dendritic cells as readouts without cross-linking using experimental protocols as described in Example 1.
In addition to effector silent ASKP-1240, CFZ533, BMS-986090 and Antibody D, the parental antibody C40B16 on wild-type IgG1 was evaluated.
C40B16 as wild-type IgG1 and Antibody D on silent Fc exhibited comparable non-existing or minimal agonism in the assay. ASKP-1240, CFZ533 and BMS-986090 exhibited some agonism as anti-CD40 antibody concentration increased. Figure 1 shows the dose response curves of the NF-KB reporter assay. Figure 2 shows the antibody-mediated IL12p40 production by DCs using antibody concentrations between 350 nM and 1.1 nM.
The results suggest that ASKP-1240, CFZ533 and BMS-986090 may exhibit V-region driven agonism as the agonism was demonstrated in effector silent Fc.
Agonism was also assessed at 500 ng/ml concentration of antibodies in DC or B-cell agonistic assays, comparing ASKP-1240 and C40B176, C40B179, C40B180 and C40B183. At higher antibody concentrations, ASKP-1240 induced IL-12p40 production by DCs (Figure 3A) and proliferation of B cells (Figure 3B), whereas C40B176, C40B179, C40B180 and C40B183 did not.
Overall, the results suggest that C40B16 and its variants C40B176, C40B179, C40B180 and C40B183, as well as Antibody D have reduced agonist potential compared to ASKP-1240, CFZ533 and BMS-986090. Notably, the results also suggest that the potency of C40B176, C40B179, C40B180 and C40B183 in cell based assays is as much as 10-fold better than the Antibody D molecule, and comparable to the most potent benchmark molecule (ASKP-1240).
An exemplary pharmaceutical composition of the invention for intramuscular injection may be prepared to contain 1 ml sterile buffered water, and between about 1 ng to about 100 mg/kg, e.g. about 50 ng to about 30 mg/kg or about 5 mg to about 25 mg/kg, of the antibody of the invention.
An exemplary pharmaceutical composition of the invention for intravenous infusion may be made up to contain about 200 ml of sterile Ringer's solution, and about 8 mg to about 2400 mg, about 400 mg to about 1600 mg, or about 400 mg to about 800 mg of the antibodies of the invention for administration to a 80 kg patient. Methods for preparing parenterally administrable compositions are well known and are described in more detail in, for example, "Remington's Pharmaceutical Science", 15th ed., Mack Publishing Company, Easton, PA.
"Therapeutically effective amount" of the antibodies of the invention effective in the treatment of a disease may be determined by standard research techniques.
For example, in vitro assays may be employed to help identify optimal dosage ranges.
Optionally, the dosage of the antibodies of the invention that may be effective in the treatment of a disease such as the inflammatory disease may be determined by administering the antibodies to relevant animal models well known in the art.
Selection of a particular effective dose may be determined (e.g., via clinical trials) by those skilled in the art based upon the consideration of several factors. Such factors include the disease to be treated or prevented, the symptoms involved, the patient's body mass, the patient's immune status and other factors known by the skilled artisan. The precise dose will also depend on the route of administration, and the severity of disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. The antibodies of the invention may be tested for their efficacy and effective dosage using any of the models described herein.
The antibodies of the invention may be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional protein preparations and well known lyophilization and reconstitution techniques can be employed.
Anti-idiotypic antibodies The present invention provides for an anti-idiotypic antibody binding to the antibody of the invention.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 11 and the VL or SEQ ID NO: 12.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 21 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 22 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 23 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 24 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 25 and the VL or SEQ ID NO: 27.
The invention also provides for an anti-idiotypic antibody specifically binding the antibody comprising the VH of SEQ ID NO: 26 and the VL or SEQ ID NO: 27.
An anti-idiotypic (Id) antibody is an antibody which recognizes the antigenic determinants (e.g. the paratope or CDRs) of the antibody. The Id antibody may be antigen-blocking or non-blocking. The antigen-blocking Id may be used to detect the free antibody in a sample (e.g. CD40 antibody of the invention described herein). The non-blocking Id may be used to detect the total antibody (free, partially bond to antigen, or fully bound to antigen) in a sample. An Id antibody may be prepared by immunizing an animal with the antibody to which an anti-Id is being prepared.
An anti-Id antibody may also be used as an immunogen to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody.
An anti-anti-Id may be epitopically identical to the original mAb, which induced the anti-Id.
Thus, by using antibodies to the idiotypic determinants of a mAb, it is possible to identify other clones expressing antibodies of identical specificity. Anti-Id antibodies may be varied (thereby producing anti-Id antibody variants) and/or derivatized by any suitable technique.
Immunoconjugates An "immunoconjugate" refers to the antibody of the invention conjugated to one or more heterologous molecule(s).
In some embodiments, the antibody of the invention is conjugated to one or more cytotoxic agents or an imaging agent.
Exemplary cytotoxic agents include chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), and radionuclides.
The cytotoxic agent may be one or more drugs, such as to a mayatansinoid (see, e.g., U.S. Patent No. 5,208,020, 5,416,06), an auristatin such as monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see, e.g., U.S. Patent Nos. 5,635,483 and 5,780,588, and 7,498,298), a dolastatin, a calicheamicin or derivative thereof (see, e.g., U.S. Patent Nos. 5,712,374, 5,714,586, 5,739, 116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., (1993) Cancer Res 53:3336-3342; and Lode et al.,(1998) Cancer Res 58:2925-2928); an anthracycline such as daunomycin or doxorubicin (see, e.g., Kratz et al., (2006) Current Med. Chem 13:477-523; Jeffrey et al., (2006) Bioorganic &Med Chem Letters 16:358-362; Torgov et al., (2005) Bioconj Chem 16:717-721; Nagy et al., (2000) Proc Natl Acad Sci USA 97:829-834; Dubowchik et al, Bioorg. &
Med. Chem. Letters 12: 1529-1532 (2002); King et al., (2002) J Med Chem 45:4336-4343;
and U.S. Patent No. 6,630,579), methotrexate, vindesine, a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel.
The cytotoxic agent may also be an enzymatically active toxin or fragment thereof, such as diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A
chain (from Pseudomonas aeruginosa), ricin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
The cytotoxic agent or an imaging agent may also be a radionuclide. Exemplary radionuclides include Ac-225, At-211, 1-131, 1-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, Pb-212 and radioactive isotopes of Lu. When the radioconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example Tc-99m or 1-123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as 1-123, 1-131, In-111, F-19, C-13, N-15 or 0-17.
Conjugates of the antibodies of the invention and the heterologous molecule may be made using a variety of bifunctional protein coupling agents such as N-succinimidy1-3-(2-pyridyldithio) propionate (SPDP), succinimidy1-4-(N-maleimidomethyl) cyclohexane-l-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HQ), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoy1)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin may be prepared as described in Vitetta et al., (1987) Science 238: 1098. Carbon- 14-labeled 1-isothiocyanatobenzy1-3-methyldiethylene triaminepentaacetic acid (MX- DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody.
See, e.g., W094/11026. The linker may be a "cleavable linker" facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., (1992) Cancer Res 52:
127-131; U.S. Patent No. 5,208,020) may be used.
Conjugates of the antibodies of the invention and the heterologous molecule may be prepared with cross-linker reagents such as BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo- SMPB, and SVSB
(succinimidy1-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).
The invention also provides for an immunoconjugate comprising the antibody specifically binding CD40 of SEQ ID NO: 1 of the invention linked to a therapeutic agent or an imaging agent.
Diagnostic uses and kits Kits The invention also provides for a kit comprising the antagonistic antibody specifically binding human CD40 of the invention.
The kit may be used for therapeutic uses and as diagnostic kits.
The kit may be used to detect the presence of CD40 in a biological sample.
In some embodiments, the kit comprises the antagonistic antibody specifically binding human CD40 of the invention and reagents for detecting the antibody.
The kit can include one or more other elements including: instructions for use; other reagents, e.g., a label, a therapeutic agent, or an agent useful for chelating, or otherwise coupling, an antibody to a label or therapeutic agent, or a radioprotective composition;
devices or other materials for preparing the antibody for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to a subject.
In some embodiments, the kit comprises the antibody of the invention in a container and instructions for use of the kit.
In some embodiments, the antibody in the kit is labeled.
In some embodiments, the kit comprises the antibody C40B16, C40B124, C40B135, C40B125, C40B136, C40B127, C40B138, C40B131, C40B176, C40B180, C40B179 or C40B183.
Methods of detecting CD40 The invention also provides for a method of detecting CD40 in a sample, comprising obtaining the sample, contacting the sample with the antibody of the invention, and detecting the antibody bound to CD40 in the sample.
In some embodiments, the sample may be derived from urine, blood, serum, plasma, saliva, ascites, circulating cells, circulating tumor cells, cells that are not tissue associated (i.e., free cells), tissues (e.g., surgically resected tumor tissue, biopsies, including fine needle aspiration), histological preparations, and the like.
The antibodies of the invention may be detected using known methods. Exemplary methods include direct labeling of the antibodies using fluorescent or chemiluminescent labels, or radiolabels, or attaching to the antibodies of the invention a moiety which is readily detectable, such as biotin, enzymes or epitope tags. Exemplary labels and moieties are ruthenium, In-DOTA, diethylenetriaminepentaacetic acid (DTPA), horseradish peroxidase, alkaline phosphatase and beta-galactosidase, poly-histidine (HIS
tag), acridine dyes, cyanine dyes, fluorone dyes, oxazin dyes, phenanthridine dyes, rhodamine dyes and Alexafluor0 dyes.
The antibodies of the invention may be used in a variety of assays to detect in the sample. Exemplary assays are western blot analysis, radioimmunoassay, surface plasmon resonance, immunoprecipitation, equilibrium dialysis, immunodiffusion, electrochemiluminescence (ECL) immunoassay, and immunohistochemistry, fluorescence-activated cell sorting (FACS) or ELISA assay.
The present invention will now be described with reference to the following specific, non-limiting examples.
General Materials and Methods Generation of antigens used in the studies Cloning, expression and purification of the antigens was done using standard methods. The amino acid sequences of the proteins used are shown below.
Full length human CD40 (huCD40); SEQ ID NO: 1 MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTE
TECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHC
TSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCE
TKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNK
APHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
Human CD40 extracellular domain (huCD40-ECD); SEQ ID NO: 2 EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHC
HQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVK
QIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGP
QDRLR
Macaca fascicularis (cynomolgous, herein referred to as cyno) CD40 (cCD40);
SEQ ID
NO: 3 MVRLPLQCVLWGCLLTAVYPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTE
TECLPCSESEFLDTWNRETRCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGLHCM
SESCESCVPHRSCLPGFGVKQIATGVSDTICEPCPVGFF SNVS SAFEKCRPWTSCETK
DLVVQQAGTNKTDVVCGPQDRQRALVVIPICLGILFVILLLVLVFIKKVAKKPNDK
APHPKQEPQEINFLDDLPGSNPAAPVQETLHGCQPVTQEDGKESRISVQERQ
Cyno CD40 extracellular domain (cCD40-ECD); SEQ ID NO: 4 EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECL
PCSESEFLDTWNRETRCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGLHCMSESC
ESCVPHRSCLPGFGVKQIATGVSDTICEPCPVGFF SNVS SAFEKCRPWTSCETKDLV
VQQAGTNKTDVVCGPQDRQR
Soluble human CD154; SEQ ID NO: 60 MQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQ
GLYYIYAQVTFCSNREAS SQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIH
LGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
Full length human CD154; SEQ ID NO: 64 MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDER
NLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEM
QKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQG
LYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHL
GGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLL
Binding assay in primary human and cyno Dendritic Cells (DCs) Human monocytes were isolated from either frozen/fresh PBMC using CD14 negative isolation kit per manufacturer's protocol (MACS Miltenyi). Cyno monocytes were isolated from fresh PBMC using CD14 positive isolation kit per manufacturer's protocol (MACS Miltenyi). To generate DCs, monocytes were cultured for 5 days in complete RPMI medium (Invitrogen) in the presence of 10Ong/m1 human GM-CSF and human IL-4 (Peprotech) and medium was replenished every 2 days. On day 5, DCs were stimulated with 10Ong/m1LPS (Sigma) for 24 hours. Cells were then stained with each of the tested CD40 antibodies at different concentration in flow cytometry buffer (PBS + 1%
FBS; BD Bioscience) in 100 IA volume for 30 minutes on ice followed with two washes with flow buffer. Cells were then stained for an additional 30 minutes on ice with APC-conjugated anti human IgG (Jackson ImmunoResearch) at the recommended dilution (1:100) and washed twice with flow buffer. Cells were analyzed for percent positive and Mean Fluorescence Intensity (MFI) to determine the antibody binding using Fortessa (BD
Bioscience).
Binding assay in Raji (B cells lymphoma cell line) and HEK-B1ueTM CD4OL NF-KB
cell lines Raji cells were obtained from ATCC and HEKB1ueTM CD4OL NF-KB cell line was obtained from Invivogen. Cells were cultured in complete RPMI medium per company's recommendation. Staining was done as described above for binding assay in primary human and cyno DCs.
Human DC IL-12p40 production assay Human DCs were generated by culturing purified human monocytes (2.5x106/well 6-well plates) for 6 days in 3m1 RPMI medium containing glutamax, 25mM HEPES, 10%
FBS, 1% Pen/Strep and 5Ong each GM-CSF and IL-4. On day 3, lml of the medium was removed and replaced with 2m1 fresh medium containing 5Ong/m1 each of GM-CSF
and IL-4. For agonist assays, day 6 DCs were plated into 96-well plates (100,000 cells/well) followed by titrations of each of the CD40 antibodies. For antagonist assays, day 6 DCs were plated into 96-well plates (100,000 cells/well) followed by titrations of each of the CD40 antibodies and addition of 1ug/m1 of soluble human CD154 (R&D Systems) to the cultures. For both assays, cells were cultured for 48 hours before collecting and analyzing supernatants for IL-12p40 by MSD (according to manufacturer's directions). For Jurkat D1.1 (ATCC) antagonist assays, day 6 DCs were plated into 96-well plates (10,000 cells/well) followed by titrations of each of the CD40 antibodies, after which irradiated Jurkat D1.1 cells (1,000 rads; 100,000/well) were added to the cultures. Cells were cultured for 24 hours before collecting and analyzing supernatants for IL-12p40 by MSD.
Human B cell proliferation assay Human tonsillar B cells were plated into 96-well plates (100,000 cells/well) in RPMI medium containing glutamax, 10% FBS and 1% Pen/Strep. For agonist assays, titrations of each of the CD40 antibodies were added to the cells and cultured for 48 hours.
For antagonist assays, titrations of each of the CD40 antibodies were added to the cells, followed by addition of 0.5 [tg/m1 soluble human CD154 (R&D Systems). Cells were cultured for 48 hours at 37C. For Jurkat D1.1 antagonist assays, titrations of each of the CD40 antibodies were added to the cells along with IL-21 (10Ong/m1 final, Thermo Fisher Scientific)), after which irradiated Jurkat D1.1. cells (5,000 rads;
100,000/well) were added to the cultures and incubated at 37C for 48 hours. For all assays, after 48 hours cells were pulsed with 3H-thymidine (luCi/well) in 50 1 medium and cultured for 16-18 hours before harvest and counting.
Cyno B cell proliferation assay Cyno spleen cells were plated into 96-well plates (100,000 cells/well) in RPMI
medium containing glutamax, 10% FBS and 1% Pen/Strep. Titrations of each of the CD40 antibodies were added to the cells, followed by addition of 0.5 [tg/ml soluble human CD154 (R&D Systems). Cells were cultured for 48 hours at 37C. After 48 hours, cells were pulsed with 3H-thymidine (luCi/well) in 50 1 medium and cultured for 16-18 hours before harvest and counting.
HEK-B1ueTM CD4OL NF-KB activation assay HEKB1ueTM CD4OL cell lines stably express human CD40 and NF-KB-inducible secreted embryonic alkaline phosphatase (SEAP). Activation of CD40 on HEKB1ueTM
CD4OL cells induce downstream signaling events leading to activation of NF-KB
and secretion of SEAP, which can be measured by QUANTI-BlueTm substrate conversion.
These cells were used to assess the ability of the antibodies to either block (antagonize) CD4O-CD154 interaction or activate (agonize) CD40.
Inhibition of CD40 Dependent NF-kB Activation in HEK-Blue CD4OL Cell Line HEKB1ueTM CD4OL cells (Invivogen), which were maintained according to the vendor's protocol, were seeded into 96 well tissue culture plates in 100 [11 volume (2.5 x 104 cells/well). The assay plates were covered and incubated overnight (37 C, 5% CO2) to allow the cells to recover. On the following day, a 4X solution of rhCD154-ECD-His (80 ng/ml final concentration) and 4X solution of CD40 antibodies, or Fabs, (1 ¨
25 ps/m1 final concentration) were pre-mixed and the resulting 2X solution added to the 96 well assay plates containing the cells (200 [11/we11 final volumes). After 16-24 h incubation (37 C, 5% CO2), 40 IA aliquots of the supernatants were mixed with 160 [11 of pre-warmed QUANTI-Blue TM (Invivogen) solution and incubated for 30-60 minutes prior to obtaining absorbance readings at 650 nm.
CD40 Dependent NF-kB Activation in HEK-Blue CD4OL NFkB-SEAP Cell Line HEKB1ueTM CD4OL cells were seeded as described above and recovered overnight. On the following day, 2X CD40 antibody solutions (1 ¨ 25 pg/m1 final concentration) were added to the plate at 100 [d/well and incubated overnight (37 C, 5%
CO2). After 16-24 h incubation (37 C, 5% CO2), 40 [11 aliquots of the supernatants were analyzed as described above.
Example 1. Isolation of antibodies specifically binding human CD40 using rats expressing human immunoglobulin loci Antibodies were generated using transgenic rats expressing human immunoglobulin loci, the OmniRat0; OMT, Inc. The OmniRatO endogenous immunoglobulin loci are replaced by human Igk and IgX loci and a chimeric human/rat IgH locus with V, D and J segments of human origin linked to the rat CH locus.
The IgH
locus contains 22 human VHS, all human D and .JH segments in natural configuration linked to the rat CH locus. Generation and characterization of the OmniRatO is described in Osborn, et al. J Immunol 190: 1481-1490, 2013; and Int. Pat. Publ. No. WO
14/093908.
Separate cohorts of five rats were immunized with recombinant human and cyno CD40 ECD-His or human and cyno CD40 ECD-Fc proteins. Following a 31-34 day immunization regimen, lymph nodes were harvested from two rats and used to generate hybridomas. The generated hybridomas were screened for binding to both human and cyno CD40-ECD. Hybridomas exhibiting statistically significant binding to both human and cyno CD40-ECD following one-way ANOVA with a Dunnett's mean comparison post-test were cloned and their V regions sequenced using standard procedures Example 2. Engineering of C40B16 C40B16 was generated by using the OmniRatO and identified having antagonist activity in the HEK-Blue TM CD4OL NF-KB activation assay based on the criteria that an antagonist had a signal that is lower than the 3 x standard deviation of the mean signal of HEKB1ueTM CD4OL cells treated with rhCD154-ECD-his alone.
C40B16 VH and VL were sequenced using standard methods and the framework sequences compared to the closest germline gene sequences in order to identify potential immunogenicity risks. C40B16 VH amino acid sequence was most homologous to IGHV3-23 (SEQ ID NO: 49) with 2 amino acid changes in the framework. C40B16 VL
framework was identical to that of IGLV3-1 (SEQ ID NO: 50).
The variable regions of C40B16 were engineered to reduce possible immunogenicity and/or developability risk(s) by generating mutations at positions R43, H82, N52, S54 and/or M108 in the VH (residue numbering according to SEQ ID NO:
11) and at position C33 in the VL (residue numbering according to SEQ ID NO: 12) to eliminate potential heterogeneity caused by unpaired cysteines. The generated VH/VL
domains were cloned as effector silent Fc isoforms IgGlsigma or IgG4PAA.
IgGlsigma contains mutations L234A, L235A, G237A, P238S, H268A, A3305, and P331S when compared to the wild-type IgGl. IgG4PAA contains mutations 5228P, F234A and when compared to the wild-type IgG4. Residue numbering is according to the EU
Index.
Table 3 shows the generated antibodies and introduced mutations when compared to the parental C40B16 mAb. A C33A mutation was engineered in the VL of all generated antibodies when compared to the parental C40B16 VL.
Table 4 shows the HCDR1 and the HCDR2 amino acid sequences of the antibodies.
Table 5 shows the HCDR3 and the LCDR1 amino acid sequences of the antibodies.
Table 6 shows the LCDR2 and the LCDR3 amino acid sequences of the antibodies.
Table 7 shows the SEQ ID NOs: of the amino acid and cDNA sequences of the VH and the VL regions of the antibodies.
Table 8 shows the SEQ ID NOs: of the amino acid sequences of the heavy chains and the light chains of the antibodies.
Table 9 shows the amino acid or polynucleotide sequences corresponding to SEQ
ID NOs: 11-14, 21-52 and 65-78.
Table 3.
VH Mutation compared to mAb C40B16 Isotype C40B16 parental IgG1 C40B124 R43K,H82Q,N52D,554A IgGl Sigma C40B135 R43K,H82Q,N52D,554A IgG4PAA
C40B125 R43K,H82Q,N52Q,554A IgGl Sigma C40B136 R43K,H82Q,N52Q,554A IgG4PAA
C40B127 R43K,H82Q,N53Q,554A IgGl Sigma C40B138 R43K,H82Q,N53Q,554A IgG4PAA
C4OB 131 R43K,H82Q,N53A,554A IgG4PAA
C40B176 R43K,H82Q,N53A,554A, M108L IgGl Sigma C40B180 R43K,H82Q,N53A,554A, M108L IgG4PAA
C40B179 R43K,H82Q,N53Q,554A, M108L IgGl Sigma C40B183 R43K,H82Q,N53Q,554A, M108L IgG4PAA
Table 4.
mAb Sequence SEQ Sequence SEQ ID
ID NO: NO:
Table 5.
mAb Sequence SEQ Sequence SEQ ID
ID NO: NO:
Table 6.
mAb Sequence SEQ Sequence SEQ ID
ID NO: NO:
Table 7.
VH
amino VH DNA VLVL DNA
mAb VH name acid SEQ ID VL aminoSEQ ID
acid SEQ
SEQ ID NO: name NO:
ID NO:
NO:
Table 8.
HC HC DNA LC protein LC DNA
protein SEQ ID SEQ ID SEQ ID
mAb SEQ NO: NO: NO:
ID NO:
Table 9.
Protein Sequence SEQ ID
NO:
C40B16 VH protein EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 11 AMSWVRQAPGRGLEWVSTINNSGGGTYYAD
SVKGRFTISRDNSKNTLYLHMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40B16 VL protein SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 12 CWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWASSTV
VFGGGTKLTVL
CTGGTGCAGCCTGGCGGCAGCCTGAGACTG
TCTTGTGCCGCCAGCGGCTTCACCTTCAGCA
GCTACGCTATGAGCTGGGTCCGACAGGCCC
CTGGCAGAGGACTCGAGTGGGTGTCCACCA
TCAACAACAGCGGCGGAGGCACCTACTACG
CCGACAGCGTGAAGGGCAGATTCACCATCA
GCCGGGACAACAGCAAGAACACCCTGTACC
TGCACATGAACAGCCTGCGGGCCGAGGACA
CCGCCGTGTACTATTGTGCCAAAGAGGGCG
GCAAGTACTACTACTATGCCATGGACGTGT
GGGGCCAGGGCACCACCGTGACAGTGTCAT
CT
CTGTGTCTCCTGGCCAGACCGCCAGCATCAC
CTGTAGCGGCGACAAGCTGGGCGATAAGTA
CGCCTGCTGGTATCAGCAGAAGCCCGGCCA
GAGCCCCGTGCTGGTCATCTACCAGGACAG
CAGAAGGCCCAGCGGCATCCCCGAGAGATT
CAGCGGCAGCAACAGCGGCAATACCGCCAC
CCTGACCATCAGCGGCACCCAGGCCATGGA
CGAGGCCGATTACTATTGTCAGGCCTGGGC
CAGCAGCACCGTGGTGTTTGGCGGCGGAAC
AAAGCTGACCGTGCTG
C40H60 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 21 AMSWVRQAPGKGLEWVSTIDNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H61 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 22 AMSWVRQAPGKGLEWVSTIQNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H63 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 23 AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H56 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 24 AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSS
C40H83 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 25 AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVSS
C40H86 protein EVQLVESGGGLVQPGGSLRLSCAA SGFTFS SY 26 AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVSS
C40L71 protein SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 27 AWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWASSTV
VFGGGTKLTVL
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCGACAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCCAGAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGC
AGCGTGAGCCCCGGCCAGACCGCCAGCATC
ACCTGCAGCGGCGACAAGCTGGGCGACAAG
TACGCCGCCTGGTACCAGCAGAAGCCCGGC
CAGAGCCCCGTGCTGGTGATCTACCAGGAC
AGCCGGCGGCC CAGCGGCATC CC CGAGCGG
TTCAGCGGCAGCAACAGCGGCAACACCGCC
ACC CTGACCATCAGCGGCACC CAGGCCATG
GACGAGGCCGACTACTACTGCCAGGCCTGG
GCCAGCAGCACCGTGGTGTTCGGCGGCGGC
ACCAAGCTGACCGTGCTG
C4 OB 1 6 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFS SY 3 5 protein AMSWVRQAPGRGLEWVSTINNSGGGTYYAD
SVKGRFTI SRDNSKNTLYLHMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVS SAS
TKGPSVFPLAP S SKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQ S SGLYSLS
SVVTVP S S SLGTQTYICNVNHKPSNTKVDKKV
EPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDV SHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B124 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 36 protein AMSWVRQAPGKGLEWVSTIDNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVP SS SLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B135 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 37 protein AMSWVRQAPGKGLEWVSTIDNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C4OB 125 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 38 protein AMSWVRQAPGKGLEWVSTIQNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVP SS SLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B136 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 39 protein AMSWVRQAPGKGLEWVSTIQNAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGK
C40B127 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 40 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
YTQKSLSLSPGK
C40B138 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 41 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTVSSAS
TKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQK
SLSLSLGK
C40B131 heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 42 protein AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYAMDVWGQGTTVTV S SA S
TKGP SVFPLAP C S RS TSE S TAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MI SRTPEVTCVVVDV S QEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPP S QEEMTKNQV SLTCLVKGFYP SD I
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C4OB 176 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFSSY 43 protein AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLS
SVVTVP SS SLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVF SC SVMHEALHNH
YTQKSLSLSPGK
C4OB 180 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFSSY 44 protein AMSWVRQAPGKGLEWVSTINAAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGP SVFPLAP C S RS TSE S TAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MI SRTPEVTCVVVDV S QEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPP S QEEMTKNQV SLTCLVKGFYP SD I
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C4OB 179 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFS SY 45 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPEAAGASSVFLFPPKPK
DTLMISRTPEVTCVVVDVSAEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPSSIEKTISKAKG
QPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVF SC SVMHEALHNH
YTQKSLSLSPGK
C4OB 183 heavy chain EVQLVESGGGLVQPGGSLRLS CAA SGFTFS SY 46 protein AMSWVRQAPGKGLEWVSTINQAGGGTYYAD
SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
YYCAKEGGKYYYYALDVWGQGTTVTVS SAS
TKGP SVFPLAP C S RS TSE S TAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVF SC SVMHEALHNHYTQK
SLSLSLGK
C40B16 light chain SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 47 protein CWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWASSTV
VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQA
NKATLVCLISDFYPGAVTVAWKADSSPVKAG
VETTTPSKQSNNKYAASSYLSLTPEQWKSHRS
YSCQVTHEGSTVEKTVAPTECS
C40B124, C40B135, SYELTQPPSVSVSPGQTASITCSGDKLGDKYA 48 C40B125, C40B136, AWYQQKPGQSPVLVIYQDSRRPSGIPERFSGS
C40B127, C40B138, NSGNTATLTISGTQAMDEADYYCQAWASSTV
C40B131, C40B176, VFGGGTKLTVLGQPKAAPSVTLFPPSSEELQA
C40B180. C40B179, NKATLVCLISDFYPGAVTVAWKADSSPVKAG
Light chain protein YSCQVTHEGSTVEKTVAPTECS
AMSWVRQAPGKGLEWVSAISGSGGSTYYADS
VKGRFTISRDNSKNTLYLQMNSLRAEDTAVY
YCAK
CWYQQKPGQSPVLVIYQDSKRPSGIPERFSGS
NSGNTATLTISGTQAMDEADYYCQAWDS STA
IgGlsigma Fc ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY 51 FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LS SVVTVP S S SLGTQTYICNVNHKPSNTKVDK
KVEPKSCDKTHTCPPCPAPEAAGASSVFLFPP
KPKDTLMISRTPEVTCVVVDVSAEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPSSIEKTISK
AKGQPREPQVYTLPPSREEMTKNQVSLTCLV
KGFYP SDIAVEWESNGQPENNYKTTPPVLD SD
GSFFLYSKLTVDKSRWQQGNVFS CSVMHEAL
HNHYTQKSLSLSPGK
IgG4PAA ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF 52 PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
S SVVTVPS S SLGTKTYTCNVDHKPSNTKVDKR
VESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSD
IAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
RLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
KSLSLSLGK
CTGGTGCAGCCTGGCGGCAGCCTGAGACTG
TCTTGTGCCGCCAGCGGCTTCACCTTCAGCA
GCTACGCTATGAGCTGGGTCCGACAGGCCC
CTGGCAGAGGACTCGAGTGGGTGTCCACCA
TCAACAACAGCGGCGGAGGCACCTACTACG
CCGACAGCGTGAAGGGCAGATTCACCATCA
GCCGGGACAACAGCAAGAACACCCTGTACC
TGCACATGAACAGCCTGCGGGCCGAGGACA
CCGCCGTGTACTATTGTGCCAAAGAGGGCG
GCAAGTACTACTACTATGCCATGGACGTGT
GGGGCCAGGGCACCACCGTGACAGTGTCAT
CTGCCTCCACCAAGGGCCCATCGGTCTTCCC
C40B16 heavy chain CCTGGCACCCTCCTCCAAGAGCACCTCTGGG
DNA GGCACAGCGGCCCTGGGCTGCCTGGTCAAG
GACTACTTCCCCGAACCGGTGACGGTGTCGT
GGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGG
ACTCTACTCCCTCAGCAGCGTGGTGACCGTG
CCCTCCAGCAGCTTGGGCACCCAGACCTAC
ATCTGCAACGTGAATCACAAGCCCAGCAAC
ACCAAGGTGGACAAGAAAGTTGAGCCCAAA
TCTTGTGACAAAACTCACACATGCCCACCGT
GCCCAGCACCTGAACTCCTGGGGGGACCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGA
CACCCTCATGATCTCCCGGACCCCTGAGGTC
ACATGCGTGGTGGTGGACGTGAGCCACGAA
GACCCTGAGGTCAAGTTCAACTGGTACGTG
GACGGCGTGGAGGTGCATAATGCCAAGACA
AAGCCGCGGGAGGAGCAGTACAACAGCAC
GTACCGTGTGGTCAGCGTCCTCACCGTCCTG
CACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCA
GCCCCCATCGAGAAAACCATCTCCAAAGCC
AAAGGGCAGCCCCGAGAACCACAGGTGTAC
ACC CTGCC CC CATCC CGGGAGGAGATGACC
AAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTATCCCAGCGACATCGCCGTG
GAGTGGGAGAGCAATGGGCAGCCGGAGAA
CAACTACAAGACCACGCCTCCCGTGCTGGA
CTCCGACGGCTCCTTCTTCCTCTACAGCAAG
CTCACCGTGGACAAGAGCAGGTGGCAGCAG
GGGAACGTCTTCTCATGCTCCGTGATGCATG
AGGCTCTGCACAACCACTACACGCAGAAGA
GCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCGACAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
C40B124 heaw chain GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
' 1 GGACTACTTC CC CGAA CCGGTGACGGTGTC
DNA
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTCCCATCCTCCATCGAGAAAACCATCTCCA
AAGCCAAAGGGCAGCCCCGAGAACCACAG
GTGTACACCCTGCCCCCATCCCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCGACAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CCCTGGCGCCCTGCTCCAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
C4OB 135 heavy chain CGTGGAACTCAGGCGCCCTGACCAGCGGCG
DNA TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCATGCCCA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCCCCCCAAAACCCAAGGACACTC
TCATGATCTCCCGGACCCCTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGCTGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCCAGAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
C40B125 heaw chain GCACACCTTCCCGGCTGTCCTACAGTCCTCA
' 1 GGACTCTACTCCCTCAGCAGCGTGGTGACC
DNA
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCCAGAACGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CC CTGGCGC CCTGCTC CAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
C40B136 heavy chain CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
DNA CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCC CC CATGCC CAC CATGCC CA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCC CC C CAAAAC C CAAGGACACTC
TCATGATCTC CCGGAC CC CTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGCTGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
C40B127 heaw chain TACATCTGCAACGTGAATCACAAGCCCAGC
DNA
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CC CTGGCGC CCTGCTC CAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTC CC CGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
A. C ACACCAAGGTGGACAAGAGAGTTGAGTC
C4OB 138 heavy chain CAAATATGGTCC CC CATGCC CAC CATGCC CA
DNA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCC CC C CAAAAC C CAAGGACACTC
TCATGATCTC CCGGAC CC CTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGCTGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CC CTGTCTCTGGGTAAA
C4OB 131 heavy chain GAGGTGCAGCTGGTGGAGAGCGGCGGCGGC 72 DNA CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCATGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CCCTGGCGCCCTGCTCCAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCATGCCCA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCCCCCCAAAACCCAAGGACACTC
TCATGATCTCCCGGACCCCTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CCCCCATCCCAGGAGGAGATGACCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
C4OB 176 heavy chain CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
DNA AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
C40B180 heaw chain AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
DNA
CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
ATCAACGCCGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CCCTGGCGCCCTGCTCCAGGAGCACCTCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCATGCCCA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCCTGTTCCCCCCAAAACCCAAGGACACTC
TCATGATCTCCCGGACCCCTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CCCCCATCCCAGGAGGAGATGACCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTACCCCAGCGACATCGCCGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
C4OB 179 heavy chain CCCGGCAAGGGCCTGGAGTGGGTGAGCACC
DNA ATCAACCAGGCCGGCGGCGGCACCTACTAC
GCCGACAGCGTGAAGGGCCGGTTCACCATC
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCGGTCTTCC
CC CTGGCAC CCTCCTC CAAGAGCAC CTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAA
GGACTACTTC CC CGAA CCGGTGACGGTGTC
GTGGAACTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCCTACAGTCCTCA
GGACTCTACTCCCTCAGCAGCGTGGTGACC
GTGCCCTCCAGCAGCTTGGGCACCCAGACC
TACATCTGCAACGTGAATCACAAGCCCAGC
AACACCAAGGTGGACAAGAAAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCA
CCGTGCCCAGCACCTGAAGCAGCAGGGGCA
TCTTCAGTCTTC CTCTTC CC CC CAAAACC CA
AGGACACCCTCATGATCTCCCGGACCCCTG
AGGTCACATGCGTGGTGGTGGACGTGAGCG
CCGAAGACCCTGAGGTCAAGTTCAACTGGT
ACGTGGACGGCGTGGAGGTGCATAATGCCA
AGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAATGGCAAG
GAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTC CCATC CTC CATCGAGAAAACCATCTC CA
AAGC CAAAGGGCAGCC CCGAGAAC CA CAG
GTGTACAC C CTGC CC C CATC CCGGGAGGAG
ATGACCAAGAACCAGGTCAGCCTGACCTGC
CTGGTCAAAGGCTTCTATCCCAGCGACATCG
CCGTGGAGTGGGAGAGCAATGGGCAGCCGG
AGAACAACTACAAGACCACGCCTCCCGTGC
TGGACTCCGACGGCTCCTTCTTCCTCTACAG
CAAGCTCACCGTGGACAAGAGCAGGTGGCA
GCAGGGGAACGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACGCAG
AAGAGCCTCTCCCTGTCTCCGGGTAAA
CTGGTGCAGCCCGGCGGCAGCCTGCGGCTG
AGCTGCGCCGCCAGCGGCTTCACCTTCAGC
AGCTACGCCATGAGCTGGGTGCGGCAGGCC
CC CGGCAAGGGCCTGGAGTGGGTGAGCAC C
C4OB 1 83 heaw chain ATCAACCAGGCCGGCGGCGGCACCTACTAC
' 1 GCCGACAGCGTGAAGGGCCGGTTCACCATC
DNA
AGCCGGGACAACAGCAAGAACACCCTGTAC
CTGCAGATGAACAGCCTGCGGGCCGAGGAC
ACCGCCGTGTACTACTGCGCCAAGGAGGGC
GGCAAGTACTACTACTACGCCCTGGACGTG
TGGGGCCAGGGCACCACCGTGACCGTGAGC
AGCGCCTCCACCAAGGGCCCATCCGTCTTCC
CC CTGGCGC CC TGCTC CAGGAGCACC TCCG
AGAGCACAGCCGCCCTGGGCTGCCTGGTCA
AGGACTACTTCCCCGAACCGGTGACGGTGT
CGTGGAAC TCAGGCGC C CTGAC CA GCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTC
AGGACTCTACTCCCTCAGCAGCGTGGTGAC
CGTGCCCTCCAGCAGCTTGGGCACGAAAAC
CTACACCTGCAACGTAGATCACAAGCCCAG
CAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCC CC CA TGCC CAC CATGCC CA
GCACCTGAGGCCGCCGGGGGACCATCAGTC
TTCC TGTTCC CC C CAAAAC C CAAGGACAC TC
TCATGAT CTC CCGGAC CC CTGAGGTCACGTG
CGTGGTGGTGGACGTGAGCCAGGAAGACCC
CGAGGTCCAGTTCAACTGGTACGTGGATGG
CGTGGAGGTGCATAATGCCAAGACAAAGCC
GCGGGAGGAGCAGTTCAACAGCACGTACCG
TGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGG
CAGCCCCGAGAGCCACAGGTGTACACCCTG
CC CC CATC CCAGGAGGAGATGA CCAAGAAC
CAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTAC CC CAGCGACATCGC CGTGGAGTGG
GAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGAC CA CGC CTC CCGTGC TGGACTC CGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCG
TGGACAAGAGCAGGTGGCAGGAGGGGAAT
GTCTTCTCATGCTCCGTGATGCATGAGGCTC
TGCACAACCACTACACACAGAAGAGCCTCT
CCCTGTCTCTGGGTAAA
C4OB 16 light chain TCCTACGAGCTGACCCAGCCTCCCTCCGTGT 77 DNA CTGTGTCTCCTGGCCAGACCGCCAGCATCAC
CTGTAGCGGCGACAAGCTGGGCGATAAGTA
CGC CTGCTGGTATCAGCAGAAGC CCGGC CA
GAGC CC CGTGCTGGTCATCTAC CAGGACAG
CAGAAGGCCCAGCGGCATCCCCGAGAGATT
CAGCGGCAGCAACAGCGGCAATACCGCCAC
CCTGACCATCAGCGGCACCCAGGCCATGGA
CGAGGCCGATTACTATTGTCAGGCCTGGGC
CAGCAGCACCGTGGTGTTTGGCGGCGGAAC
AAAGCTGACCGTGCTGGGTCAGCCCAAGGC
TGCACCCAGTGTCACTCTGTTCCCGCCCTCC
TCTGAGGAGCTTCAAGCCAACAAGGCCACA
CTGGTGTGTCTCATAAGTGACTTCTACCCGG
GAGCCGTGACAGTGGCCTGGAAGGCCGATA
GCAGC CC CGTCAA GGCGGGAGTGGAGAC CA
CCACACCCTCCAAACAAAGCAACAACAAGT
ACGCGGCCAGCAGCTATCTGAGCCTGACGC
CTGAGCAGTGGAAGTCCCACAGAAGCTACA
GCTGCCAGGTCACGCATGAAGGGAGCACCG
TGGAGAAGACAGTGGCCCCTACAGAATGTT
CA
C40B124, C40B135, AGCTACGAGCTGACCCAGCCCCCCAGCGTG 78 AGCGTGAGCCCCGGCCAGACCGCCAGCATC
C40B125, C40B136, ACCTGCAGCGGCGACAAGCTGGGCGACAAG
C4 OB127, C4 OB 138, TACGCCGCCTGGTACCAGCAGAAGCCCGGC
, , AGCCGGCGGCCCAGCGGCATCCCCGAGCGG
C40B180. C40B179, TTCAGCGGCAGCAACAGCGGCAACACCGCC
ACCCTGACCATCAGCGGCACCCAGGCCATG
GACGAGGCCGACTACTACTGCCAGGCCTGG
Light chain DNA GCCAGCAGCACCGTGGTGTTCGGCGGCGGC
ACCAAGCTGACCGTGCTGGGTCAGCCCAAG
GCTGCACCCAGTGTCACTCTGTTCCCGCCCT
CCTCTGAGGAGCTTCAAGCCAACAAGGCCA
CACTGGTGTGTCTCATAAGTGACTTCTACCC
GGGAGCCGTGACAGTGGCCTGGAAGGCCGA
TAGCAGCCCCGTCAAGGCGGGAGTGGAGAC
CACCACACCCTCCAAACAAAGCAACAACAA
GTACGCGGCCAGCAGCTATCTGAGCCTGAC
GCCTGAGCAGTGGAAGTCCCACAGAAGCTA
CAGCTGCCAGGTCACGCATGAAGGGAGCAC
CGTGGAGAAGACAGTGGCCCCTACAGAATG
TTCA
Example 3. Characterization of antagonistic anti-CD40 antibodies The parental C40B16 and the engineered variants were tested for their antagonistic activity in a spectrum of assays including ability of the antibodies to inhibit human soluble CD4OL (sCD4OL) or membrane-bound CD4OL (mCD4OL)-mediated proliferation of human or cyno B cells, and inhibition of IL-12p40 production by human DCs. The experiments were conducted according to protocols described in Example 1.
Membrane-bound CD4OL was provided on Jurkat cells in the assays.
All antibodies demonstrated antagonism in the assays performed.
Table 10 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven B cell proliferation. Table 11 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven IL-12p40 production by human dendritic cells.
Table 10.
B-cell proliferation 1050 nM +/- SD
sCD4OL-driven mCD4OL-driven sCD4OL-driven mAb human B-cell human B-cell cyno B-cell proliferation proliferation proliferation C40B124 0.118 +1-0.003 (4) C40B135 0.056 +/-0.040 (3) 0.131 +/-0.012 (4) 0.077 +/-0.024 (2) C40B125 0.088 +/-0.025 (6) 0.128 +/-0.019 (6) 0.083 +/-0.029 (2) C40B136 0.087 +/-0.056 (6) 0.122 +/-0.013 (4) 0.065 +/-0.038 (2) C40B127 0.073 +/-0.010 (2) 0.111 +/-0.009 (4) 0.066 +/-0.002 (2) C40B138 0.048 +/-0.035 (2) 0.106 +/-0.000 (2) 0.075 +/-0.050 (2) C40B131 0.099 +/-0.003 (4) C40B176 0.132 +/-0.105 (4) 0.181 +/-0.054 (4) 0.108 +/-0.029 (4) C40B180 0.092 +/-0.047 (4) 0.136 +/-0.071 (4) 0.109 +/-0.047 (4) C40B179 0.132 +/-0.030 (4) 0.178 +/-0.053 (4) 0.119 +/-0.026 (4) C40B183 0.103 +/-0.053 (4) 0.140 +/-0.018 (4) 0.110 +/-0.029 (4) sCD4OL: soluble CD4OL
mCD4OL: membrane-bound CD4OL
The number in parenthesis indicates the number of times the assay was repeated Table 11.
DC IL-12p40 productionIC50nM +/- SD
mAb sCD4OL-driven mCD4OL-driven C40B124 0.387 +/-0.09 (3) 0.507 +/-0.07 (5) C40B135 0.329 +/-0.02 (3) 0.430 +/-0.10 (5) C40B125 0.244 +/-0.04 (5) 0.393 +/-0.09 (5) C40B136 0.246 +/-0.05 (5) 0.379 +/-0.08 (5) C40B127 0.270 +/-0.07 (3) 0.383 +/-0.08 (5) C40B138 0.262 +/-0.06 (3) 0.341 +/-0.10 (5) C40B131 0.330 +/-0.18 (3) 0.323 +/-0.12 (5) C40B176 0.220 +/-0.11 (3) 0.245 +/-0.06 (2) C40B180 0.225 +/-0.06 (3) 0.222 +/-0.07 (2) C40B179 0.184 +/-0.07 (3) 0.297 +/-0.06 (2) C40B183 0.208 +/-0.09 (3) 0.291 +/-0.07 (2) sCD4OL: soluble CD4OL
mCD4OL: membrane-bound CD4OL
The number in parenthesis indicates the number of times the assay was repeated Affinity of the antibodies to human CD40 was assessed using Surface Plasmon Resonance (SPR) using a ProteOn XPR36 system (BioRad). A biosensor surface was prepared by coupling anti-Human IgG Fc (Jackson cat#109-005-098) to the modified alginate polymer layer surface of a GLC chip (BioRad, Cat#176-5011) using the manufacturer instructions for amine-coupling chemistry. Approximately 5000 RU
(response units) of mAbs were immobilized. The kinetic experiments were performed at 25 C in running buffer (DPBS+0.01%P20+100 g/m1 BSA). To perform kinetic experiments, 200 RU of mAbs were captured followed by injections of analytes (human or cyno CD40) at 5 concentrations (in a 4-fold serial dilution). The association phase was monitored for 3 minutes at 50 pL/min, then followed by 15 minutes of buffer flow (dissociation phase). The chip surface was regenerated with two 18 second pulses of 100 mM H3PO4 (Sigma, Cat#7961) at 100 pL/min.
The collected data were processed using ProteOn Manager software. First, the data was corrected for background using inter-spots. Then, double reference subtraction of the data was performed by using the buffer injection for analyte injections. The kinetic analysis of the data was performed using a Langmuir 1:1 binding model. The results were reported in the format of Ka (On-rate), Kd (Off-rate) and KD (equilibrium dissociation constant).
Summary of kinetics affinity for the mAbs for binding to human CD40 is shown in Table 12. The parameters reported in this table were obtained from a 1:1 Langmuir binding model for all samples. Affinity, KD = kd/ka.
Table 12.
mAb ka (1/Ms) kd (1/s) KD (M) C40B16 4.27E+06 1.57E-04 3.68E-11 C40B124 2.30E+06 9.56E-05 4.16E-11 C40B135 2.93E+06 1.45E-04 4.96E-11 C40B125 3.89E+06 1.36E-04 3.49E-11 C40B136 3.30E+06 1.13E-04 3.43E-11 C40B127 3.79E+06 1.15E-04 3.03E-11 C40B138 3.58E+06 2.15E-04 5.99E-11 C40B131 3.52E+06 2.86E-04 8.12E-11 C40B176 2.86E+06 3.07E-04 1.07E-10 C40B180 2.67E+06 3.66E-04 1.37E-10 C40B179 2.86E+06 2.67E-04 9.33E-11 C40B183 2.91E+06 3.50E-04 1.21E-10 Example 4. Antagonistic antibodies specifically binding human CD40 are potent inhibitors of CD40/CD4OL pathway and display minimal agonistic activity Four antagonistic antibodies (C40B176, C40B179, C40B180 and C40B183) were benchmarked against anti-CD40 antibodies currently in clinical developments.
The antibodies used in comparisons were: Astellas/Kirin ASKP-1240 (HC SEQ ID NO:
53, LC
SEQ ID NO: 54, Fc silent IgG4 with 5228P and L235E mutations), Antibody D (HC
SEQ
ID NO: 55, LC SEQ ID NO: 56, Fc silent IgG1 with L234A and L235A mutations;
described in U58,591,900 as antibody B IgG1K0b), Novartis CFZ533 (HC SEQ ID
NO:
57, LC SEQ ID NO: 58, Fc silent IgG1 with N297A mutation), and BMS-986090 (HC
SEQ ID NO: 59, IgG4 with 5228P mutation).
SEQ ID NO: 53 (ASKP-1240 HC) QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGS
TYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQ
GTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP
CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
SEQ ID NO: 54 (ASKP-1240 LC) AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKWYDASNLESG
VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO: 55 (Antibody D HC) EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSG
NRITYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQDGYRYAMDY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTQTYICNVNHKP SNTKVDKKVEPKS
CDKTHTCPPCPAPEAAGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPP SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVF SC SVMHEALHNHYTQKSL
SLSPGK
SEQ ID NO: 56 (Antibody D LC) DIVMTQ SPD SLAVSLGEKVTINCKS S Q SLLNSGNQKNYLTWHQQKPGQPPKLLWW
TSTRESGVPDRFSGSGSGTDFTLTIS SLQAEDVAVYYCQNDYTYPLTFGGGTKVEIK
RTVAAP SVFIFPP S DEQLKSGTA SVVCLLNNFYPREAKVQWKVDNAL Q SGNS QESV
TEQD SKD STY SLS STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
SEQ ID NO: 57 (CFZ533 HC) QVQLVESGGGVVQPGRSLRLS CAA SGFTF S SYGMHWVRQAPGKGLEWVAVISYE
ESNRYHAD SVKGRFTISRDN SKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDY
WGQGTLVTVS SA STKGP SVFPLAP S SKS TSGGTAALGCLVKDYFPEPVTV SWN SGA
LTSGVHTFPAVLQ S SGLYSLS SVVTVPS S SLGTQTYICNVNHKP SNTKVDKKVEPKS
CDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN
WYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPP SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVF SC SVMHEALHNHYTQKSL
SLSPGK
SEQ ID NO: 58 (CFZ533 LC) DIVMTQ SPL S LTVTPGEPA SI S CRS SQ SLLYSNGYNYLDWYLQKPGQ SP QVLI S LG S
NRASGVPDRF SGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIRR
TVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNS QESVT
EQD SKD STY SL S STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC
SEQ ID NO: 59 (BMS-986090 HC) EVQLLESGGGLVQPGGSLRLSCAASGFTFRDYEMWWVRQAPGKGLERVSAINPQG
TRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLPFRFSDRGQGT
LVTVSSASTESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL
HNHYTQKSLSLSLGK
Table 13 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven human or cyno B cell proliferation for the tested antibodies.
Table 14 shows the ICso values for inhibition of soluble or membrane-bound CD4OL-driven IL-12p40 production by human dendritic cells (DC) and the affinity kinetics for each mAb.
mAbs C40B176, C40B179, C40B180 and C40B183 exhibited comparable potency when compared to the best performing benchmark mAb ASKP-1240.
Table 13.
B cell proliferation; IC50 nM +/- SD
mAb Soluble CD4OL Membrane CD4OL Soluble CD4OL
human B-cells human B-cells cyno B-cells C40B176 0.132 +/-0.105 (4) 0.181 +/-0.054 (4) 0.108 +/-0.029 (4) C40B180 0.092 +/-0.047 (4) 0.136 +/-0.071 (4) 0.109 +/-0.047 (4) C40B179 0.132 +/-0.030 (4) 0.178 +/-0.053 (4) 0.119 +/-0.026 (4) C40B183 0.103 +/-0.053 (4) 0.140 +/-0.018 (4) 0.110 +/-0.029 (4) ASKP-1240 0.079 +/-0.017 (12) 0.132 +/-0.042 (10) 0.146+/-0.063 (8) Antibody D 0.680 +/-0.323 (4) 1.926 +/-0.368 (2) CFZ533 0.223 +/-0.117 (4) 0.279 +/-0.062 (2) BMS-986090 0.288 +/-0.136 (4) 0.393 +/-0.002 (2) Table 14.
Human DC IL-12p40 production; IC50 nM +/- SD
mAb Affinity KD (M) Soluble CD4OL Membrane CD4OL
C40B176 4.96E-11 0.220 +/-0.11 (3) 0.245 +/-0.06 (2) C40B180 5.99E-11 0.225 +/-0.06 (3) 0.222 +/-0.07 (2) C40B179 3.43E-11 0.184 +/-0.07 (3) 0.297 +/-0.06 (2) C40B183 1.07E-10 0.208 +/-0.09 (3) 0.291 +/-0.07 (2) ASKP-1240 1.81E-10 0.119+1-0.05 (6) 0.280+/-0.11 (7) Antibody D 5.8E-10 0.781 +/-0.30(3) 3.630 +/-1.19 (5) CFZ533 9.36E-12 0.320 +/-0.12 (3) 0.948 +/-0.29 (5) BMS-986090 8.7E-10 0.285 +/-0.17 (2) 0.822 +/-0.39 (5) Possible undesired agonistic activity of the mAbs was assessed using HEKB1ueTM
CD4OL NF-KB activation assay and IL12p40 production by dendritic cells as readouts without cross-linking using experimental protocols as described in Example 1.
In addition to effector silent ASKP-1240, CFZ533, BMS-986090 and Antibody D, the parental antibody C40B16 on wild-type IgG1 was evaluated.
C40B16 as wild-type IgG1 and Antibody D on silent Fc exhibited comparable non-existing or minimal agonism in the assay. ASKP-1240, CFZ533 and BMS-986090 exhibited some agonism as anti-CD40 antibody concentration increased. Figure 1 shows the dose response curves of the NF-KB reporter assay. Figure 2 shows the antibody-mediated IL12p40 production by DCs using antibody concentrations between 350 nM and 1.1 nM.
The results suggest that ASKP-1240, CFZ533 and BMS-986090 may exhibit V-region driven agonism as the agonism was demonstrated in effector silent Fc.
Agonism was also assessed at 500 ng/ml concentration of antibodies in DC or B-cell agonistic assays, comparing ASKP-1240 and C40B176, C40B179, C40B180 and C40B183. At higher antibody concentrations, ASKP-1240 induced IL-12p40 production by DCs (Figure 3A) and proliferation of B cells (Figure 3B), whereas C40B176, C40B179, C40B180 and C40B183 did not.
Overall, the results suggest that C40B16 and its variants C40B176, C40B179, C40B180 and C40B183, as well as Antibody D have reduced agonist potential compared to ASKP-1240, CFZ533 and BMS-986090. Notably, the results also suggest that the potency of C40B176, C40B179, C40B180 and C40B183 in cell based assays is as much as 10-fold better than the Antibody D molecule, and comparable to the most potent benchmark molecule (ASKP-1240).
Claims (7)
1) An isolated antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 61, a HCDR3 of SEQ ID NO: 62, a light chain complementarity determining region (LCDR)
1 of SEQ ID NO: 63, a LCDR2 of SEQ ID NO: 9 and a LCDR3 of SEQ ID NO: 10.
2) The isolated antibody or the antigen-binding fragment thereof of claim 1, wherein the antibody competes for binding to human CD40 of SEQ ID NO: 1 with an antibody comprising a) a heavy chain variable region (VH) of SEQ ID NO: 11 and a light chain variable region (VL) of SEQ ID NO: 12;
b) the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27; or c) the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
b) the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 27; or c) the VH of SEQ ID NO: 26 and the VL of SEQ ID NO: 27.
3) The isolated antibody or the antigen-binding fragment thereof of claim 1 or 2, wherein the antibody comprises the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 of a) SEQ ID NOs: 5, 6, 7, 8, 9 and 10, respectively.
b) SEQ ID NOs: 5, 15, 7, 20, 9 and 10, respectively;
c) SEQ ID NOs: 5, 16, 7, 20, 9 and 10, respectively;
d) SEQ ID NOs: 5, 17, 7, 20, 9 and 10, respectively;
e) SEQ ID NOs: 5, 18, 7, 20, 9 and 10, respectively;
f) SEQ ID NOs: 5, 18, 19, 20, 9 and 10, respectively; or g) SEQ ID NOs: 5, 17, 19, 20, 9 and 10, respectively.
b) SEQ ID NOs: 5, 15, 7, 20, 9 and 10, respectively;
c) SEQ ID NOs: 5, 16, 7, 20, 9 and 10, respectively;
d) SEQ ID NOs: 5, 17, 7, 20, 9 and 10, respectively;
e) SEQ ID NOs: 5, 18, 7, 20, 9 and 10, respectively;
f) SEQ ID NOs: 5, 18, 19, 20, 9 and 10, respectively; or g) SEQ ID NOs: 5, 17, 19, 20, 9 and 10, respectively.
4) The antibody or the antigen-binding fragment thereof of any of the claims 1-3, wherein the antibody binds human CD40 with a dissociation constant (K D) of about 1.5x10 -10 M
or less, when the K D is measured using ProteOn XPR36 system at 25°C in Dulbecco's phosphate buffered saline containing 0.01% polysorbate 20 (PS-20) and 100 µg/ml bovine serum albumin.
or less, when the K D is measured using ProteOn XPR36 system at 25°C in Dulbecco's phosphate buffered saline containing 0.01% polysorbate 20 (PS-20) and 100 µg/ml bovine serum albumin.
5) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-4, wherein the antibody inhibits soluble human CD40L-driven human tonsillar B
cell proliferation with an IC50 value of less than about 1x10 -9 M .
cell proliferation with an IC50 value of less than about 1x10 -9 M .
6) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-5, wherein the antibody inhibits soluble human CD40L-driven production of IL-12p40 by human dendritic cells with an IC50 value of less than about 1x10 -9 M.
7) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-6, comprising the VH and the VL of a) SEQ ID NOs: 11 and 12, respectively;
b) SEQ ID NOs: 21 and 27, respectively;
c) SEQ ID NOs: 22 and 27, respectively;
d) SEQ ID NOs: 23 and 27, respectively;
e) SEQ ID NOs: 24 and 27, respectively;
f) SEQ ID NOs: 25 and 27, respectively; or g) SEQ ID NOs: 26 and 27, respectively.
8) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-7, which is an IgG1, IgG2, IgG3 or IgG4 isotype.
9) The isolated antibody or the antigen-binding fragment thereof of claim 8, wherein the antibody comprises at least one mutation in an Fc region that reduceds binding of the antibody to a Fc.gamma. receptor when compared to a wild-type Fc.
10) The isolated antibody or the antigen-binding fragment thereof of claim 9, wherein the at least one mutation in the Fc region is a 5228P mutation, a F234A mutation, a L234A
mutation, a L235A mutation, a G237A mutation, a P238S mutation, a H268A
mutation, a A3305 mutation or a P331S mutation, wherein residue numbering is according to the EU Index.
11) The isolated antibody or the antigen-binding fragment thereof of claim 9, wherein the antibody is an IgG1 isotype and comprises a L234A/L235A/G237A/P238S/H268A/A330S5/P331S mutation.
12) The isolated antibody or the antigen-binding fragment thereof of claim 9, wherein the antibody is an IgG4 isotype and comprises a S228P/F234A/L235A mutation.
13) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-7, comprising a heavy chain and a light chain of a) SEQ ID NOs: 35 and 47, respectively;
b) SEQ ID NOs: 36 and 48, respectively;
c) SEQ ID NOs: 37 and 48, respectively;
d) SEQ ID NOs: 38 and 48, respectively;
e) SEQ ID NOs: 39 and 48, respectively;
f) SEQ ID NOs: 40 and 48, respectively;
g) SEQ ID NOs: 41 and 48, respectively;
h) SEQ ID NOs: 42 and 48, respectively;
i) SEQ ID NOs: 43 and 48, respectively;
j) SEQ ID NOs: 44 and 48, respectively;
k) SEQ ID NOs: 45 and 48, respectively; or l) SEQ ID NOs: 46 and 48, respectively.
14) The antibody of any or the antigen-binding fragment thereof of the claims 1-13, wherein the antibody is a bispecific or a multispecific antibody.
15) A pharmaceutical composition comprising the isolated antibody or the antigen-binding fragment thereof of any of the claims 1-14 and a pharmaceutically acceptable carrier.
16) An immunoconjugate comprising the isolated antibody or the antigen-binding fragment thereof of any of the claims 1-14 linked to a cytotoxic agent or an imaging agent.
17) An isolated polynucleotide encoding a) the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26;
b) the VL of SEQ ID NOs: 12 or 27; or c) the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL of SEQ ID
NOs:
12 or 27.
18) An isolated polynucleotide comprising the polynucleotide sequence of SEQ
ID NOs:
13, 14, 28, 29, 30, 31, 32, 33, or 34.
19) A vector comprising the polynucleotide of claim 17.
20) A vector comprising the polynucleotide of claim 18.
21) A host cell comprising the vector of claim 19.
22) A host cell comprising the vector of claim 20.
23) A method of producing an antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising culturing the host cell of claim 21 or 22 in conditions wherein the antibody is expressed, and isolating the antibody.
24) A method of treating a subject having an inflammatory disease, comprising administering to the subject in need thereof the isolated antibody or the antigen-binding fragment thereof of any of the claims 1-14 for a time sufficient to treat the inflammatory disease.
25) The method of claim 24, wherein the inflammatory disease is an autoimmune disease.
26) The method of claim 24, wherein the inflammatory disease is Addison's disease, an ankylosing spondylitis, an atherosclerosis, an autoimmune hepatitis, an autoimmune diabetes, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, an idiopathic thrombocytopenia, an inflammatory bowel disease (IBD), a systemic lupus erythematosus, lupus nephritis, cutaneous lupus erythematosus, a multiple sclerosis, a myasthenia gravis, a psoriasis, an arthritis, a scleroderma, Sjogren's syndrome, a systemic sclerosis, a transplantation, a kidney transplantation, a skin transplantation, a bone marrow transplantation, a graft versus host disease (GVHD) or a type I
diabetes.
27) The method of claim 26, wherein the arthritis is a rheumatoid arthritis, a juvenile arthritis, a psoriatic arthritis, Reiter's syndrome, an ankylosing spondylitis, or a gouty arthritis.
28) The method of claim 26, wherein the IBD is Crohn's disease or an ulcerative colitis.
29) The method of claim 24 further administering a second therapeutic agent.
30) The method of claim 29, wherein the second therapeutic agent is nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, hydroxychloroquine, sulfasalazine, corticosteroids, cytotoxic drugs, immunosuppressive drugs and/or antibodies.
31) The antibody or the antigen-binding fragment thereof of any of the claims 1-14 of the pharmaceutical composition of claim 15 for use in therapy.
32) An anti-idiotypic antibody binding to the antibody or the antigen-binding fragment thereof of claim 7.
33) A kit comprising the antibody or the antigen-binding fragment thereof of
7) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-6, comprising the VH and the VL of a) SEQ ID NOs: 11 and 12, respectively;
b) SEQ ID NOs: 21 and 27, respectively;
c) SEQ ID NOs: 22 and 27, respectively;
d) SEQ ID NOs: 23 and 27, respectively;
e) SEQ ID NOs: 24 and 27, respectively;
f) SEQ ID NOs: 25 and 27, respectively; or g) SEQ ID NOs: 26 and 27, respectively.
8) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-7, which is an IgG1, IgG2, IgG3 or IgG4 isotype.
9) The isolated antibody or the antigen-binding fragment thereof of claim 8, wherein the antibody comprises at least one mutation in an Fc region that reduceds binding of the antibody to a Fc.gamma. receptor when compared to a wild-type Fc.
10) The isolated antibody or the antigen-binding fragment thereof of claim 9, wherein the at least one mutation in the Fc region is a 5228P mutation, a F234A mutation, a L234A
mutation, a L235A mutation, a G237A mutation, a P238S mutation, a H268A
mutation, a A3305 mutation or a P331S mutation, wherein residue numbering is according to the EU Index.
11) The isolated antibody or the antigen-binding fragment thereof of claim 9, wherein the antibody is an IgG1 isotype and comprises a L234A/L235A/G237A/P238S/H268A/A330S5/P331S mutation.
12) The isolated antibody or the antigen-binding fragment thereof of claim 9, wherein the antibody is an IgG4 isotype and comprises a S228P/F234A/L235A mutation.
13) The isolated antibody or the antigen-binding fragment thereof of any of the claims 1-7, comprising a heavy chain and a light chain of a) SEQ ID NOs: 35 and 47, respectively;
b) SEQ ID NOs: 36 and 48, respectively;
c) SEQ ID NOs: 37 and 48, respectively;
d) SEQ ID NOs: 38 and 48, respectively;
e) SEQ ID NOs: 39 and 48, respectively;
f) SEQ ID NOs: 40 and 48, respectively;
g) SEQ ID NOs: 41 and 48, respectively;
h) SEQ ID NOs: 42 and 48, respectively;
i) SEQ ID NOs: 43 and 48, respectively;
j) SEQ ID NOs: 44 and 48, respectively;
k) SEQ ID NOs: 45 and 48, respectively; or l) SEQ ID NOs: 46 and 48, respectively.
14) The antibody of any or the antigen-binding fragment thereof of the claims 1-13, wherein the antibody is a bispecific or a multispecific antibody.
15) A pharmaceutical composition comprising the isolated antibody or the antigen-binding fragment thereof of any of the claims 1-14 and a pharmaceutically acceptable carrier.
16) An immunoconjugate comprising the isolated antibody or the antigen-binding fragment thereof of any of the claims 1-14 linked to a cytotoxic agent or an imaging agent.
17) An isolated polynucleotide encoding a) the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26;
b) the VL of SEQ ID NOs: 12 or 27; or c) the VH of SEQ ID NOs: 11, 21, 22, 23, 24, 25 or 26 and the VL of SEQ ID
NOs:
12 or 27.
18) An isolated polynucleotide comprising the polynucleotide sequence of SEQ
ID NOs:
13, 14, 28, 29, 30, 31, 32, 33, or 34.
19) A vector comprising the polynucleotide of claim 17.
20) A vector comprising the polynucleotide of claim 18.
21) A host cell comprising the vector of claim 19.
22) A host cell comprising the vector of claim 20.
23) A method of producing an antagonistic antibody or an antigen-binding fragment thereof specifically binding human CD40 of SEQ ID NO: 1, comprising culturing the host cell of claim 21 or 22 in conditions wherein the antibody is expressed, and isolating the antibody.
24) A method of treating a subject having an inflammatory disease, comprising administering to the subject in need thereof the isolated antibody or the antigen-binding fragment thereof of any of the claims 1-14 for a time sufficient to treat the inflammatory disease.
25) The method of claim 24, wherein the inflammatory disease is an autoimmune disease.
26) The method of claim 24, wherein the inflammatory disease is Addison's disease, an ankylosing spondylitis, an atherosclerosis, an autoimmune hepatitis, an autoimmune diabetes, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, an idiopathic thrombocytopenia, an inflammatory bowel disease (IBD), a systemic lupus erythematosus, lupus nephritis, cutaneous lupus erythematosus, a multiple sclerosis, a myasthenia gravis, a psoriasis, an arthritis, a scleroderma, Sjogren's syndrome, a systemic sclerosis, a transplantation, a kidney transplantation, a skin transplantation, a bone marrow transplantation, a graft versus host disease (GVHD) or a type I
diabetes.
27) The method of claim 26, wherein the arthritis is a rheumatoid arthritis, a juvenile arthritis, a psoriatic arthritis, Reiter's syndrome, an ankylosing spondylitis, or a gouty arthritis.
28) The method of claim 26, wherein the IBD is Crohn's disease or an ulcerative colitis.
29) The method of claim 24 further administering a second therapeutic agent.
30) The method of claim 29, wherein the second therapeutic agent is nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, hydroxychloroquine, sulfasalazine, corticosteroids, cytotoxic drugs, immunosuppressive drugs and/or antibodies.
31) The antibody or the antigen-binding fragment thereof of any of the claims 1-14 of the pharmaceutical composition of claim 15 for use in therapy.
32) An anti-idiotypic antibody binding to the antibody or the antigen-binding fragment thereof of claim 7.
33) A kit comprising the antibody or the antigen-binding fragment thereof of
claim 7.
34) The kit of claim 33, further comprising reagents for detecting the antibody and instructions of use.
34) The kit of claim 33, further comprising reagents for detecting the antibody and instructions of use.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562234812P | 2015-09-30 | 2015-09-30 | |
US62/234,812 | 2015-09-30 | ||
PCT/US2016/054671 WO2017059196A2 (en) | 2015-09-30 | 2016-09-30 | Antagonistic antibodies specifically binding human cd40 and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3000396A1 true CA3000396A1 (en) | 2017-04-06 |
Family
ID=58409279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3000396A Abandoned CA3000396A1 (en) | 2015-09-30 | 2016-09-30 | Antagonistic antibodies specifically binding human cd40 and methods of use |
CA3000400A Pending CA3000400A1 (en) | 2015-09-30 | 2016-09-30 | Agonistic antibodies specifically binding human cd40 and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3000400A Pending CA3000400A1 (en) | 2015-09-30 | 2016-09-30 | Agonistic antibodies specifically binding human cd40 and methods of use |
Country Status (23)
Country | Link |
---|---|
US (2) | US10544229B2 (en) |
EP (2) | EP3355921A4 (en) |
JP (2) | JP2018529351A (en) |
KR (2) | KR20180053738A (en) |
CN (2) | CN108368510B (en) |
AU (2) | AU2016331819B2 (en) |
BR (2) | BR112018006251A2 (en) |
CA (2) | CA3000396A1 (en) |
CL (1) | CL2018000833A1 (en) |
CO (1) | CO2018003436A2 (en) |
CR (1) | CR20180177A (en) |
EA (1) | EA037882B1 (en) |
EC (1) | ECSP18033227A (en) |
ES (1) | ES2906823T3 (en) |
IL (1) | IL258268B (en) |
MA (2) | MA43053A (en) |
MX (1) | MX2018003905A (en) |
MY (1) | MY196646A (en) |
NI (1) | NI201800044A (en) |
PE (1) | PE20181367A1 (en) |
PH (1) | PH12018500684A1 (en) |
SV (1) | SV2018005659A (en) |
WO (2) | WO2017059243A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018006251A2 (en) * | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | antagonist antibodies that specifically bind to human cd40 and methods of use |
ES2963807T3 (en) | 2016-06-08 | 2024-04-02 | Xencor Inc | Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linking to CD32B |
RU2769282C2 (en) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Anti-pd-l1 and il-2 cytokines |
CN110636861B (en) * | 2017-03-03 | 2022-07-08 | 詹森生物科技公司 | Synergistic therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer |
EP3630832A1 (en) * | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
EP3630831B1 (en) | 2017-05-25 | 2022-06-15 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
EP3630837A1 (en) * | 2017-06-02 | 2020-04-08 | Pfizer Inc | Chimeric antigen receptors targeting flt3 |
EA202090791A1 (en) * | 2017-09-19 | 2020-06-17 | Мэб Дискавери Гмбх | AGONISM ANTIBODIES AGAINST CD40 |
WO2019087094A1 (en) * | 2017-11-03 | 2019-05-09 | Novartis Ag | Anti-cd40 antibodies for use in treatment of sjögren's syndrome |
AR117091A1 (en) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES |
CN113728008B (en) * | 2019-04-10 | 2024-04-09 | 南开大学 | anti-CD 40 antibodies and uses thereof |
MX2022007688A (en) | 2019-12-20 | 2022-07-19 | Amgen Inc | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors. |
WO2021195326A1 (en) * | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
WO2022002065A1 (en) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | Anti-cd40 antibody or antigen-binding fragment and use thereof |
WO2022133123A1 (en) * | 2020-12-16 | 2022-06-23 | Memorial Sloan Kettering Cancer Center | Cd40 binding molecules and uses thereof |
KR20240026185A (en) * | 2021-06-28 | 2024-02-27 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Anti-CD40 antibodies, antigen-binding fragments and medical uses thereof |
WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
WO2023020475A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
TW202330600A (en) * | 2021-08-24 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fap/cd40 binding molecules and medicinal uses thereof |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US226A (en) | 1837-06-03 | Samuel goss | ||
US7709A (en) | 1850-10-08 | Chas S Gaylord | Improved spring-grapple | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
ATE87659T1 (en) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN. |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE275198T1 (en) | 1991-12-02 | 2004-09-15 | Medical Res Council | PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES. |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
DK0945465T3 (en) * | 1992-07-09 | 2007-01-15 | Novartis Vaccines & Diagnostic | Antagonistic monoclonal antibodies to human CD40 |
ES2091684T3 (en) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA. |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
JP3720353B2 (en) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | Multivalent and multispecific binding proteins, their production and use |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
KR960704576A (en) | 1993-10-01 | 1996-10-09 | 크리스토퍼 엘. 와이트 | Antibodies to CD40 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
ATE344801T1 (en) | 1999-12-29 | 2006-11-15 | Immunogen Inc | CYTOTOXIC AGENTS CONTAINING DOXORUBICIN AND DAUNORUBICIN AND THEIR THERAPEUTIC USE |
EP1253942A4 (en) | 2000-02-01 | 2004-06-16 | Tanox Inc | Cd40-binding apc-activating molecules |
WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
EP1326896B1 (en) | 2000-10-02 | 2010-11-24 | Novartis Vaccines and Diagnostics, Inc. | Human anti-cd40 antibodies |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
WO2003029296A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
ES2285118T5 (en) | 2002-05-17 | 2012-09-21 | Alligator Bioscience Ab | A METHOD FOR IN VITRO MOLECULAR DEVELOPMENT OF A PROTEIC FUNCTION. |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
CA2532781A1 (en) * | 2003-07-18 | 2005-01-27 | Mochida Pharmaceutical Co., Ltd | The anti-platelet membrane glycoprotein vi monoclonal antibody |
HN2004000285A (en) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
US20050202531A1 (en) | 2003-11-03 | 2005-09-15 | Compugen Ltd. | CD40 splice variants, compositions for making and methods of using the same |
US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
KR101128777B1 (en) * | 2003-11-04 | 2012-04-13 | 조마 테크놀로지 리미티드 | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
PL1682178T3 (en) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Methods of therapy for cancers expressing the cd40 antigen |
BR122018071808B8 (en) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
NZ548325A (en) * | 2003-12-25 | 2009-07-31 | Kirin Pharma Kk | Mutants of anti-CD40 antibody |
EP1761311A2 (en) | 2004-04-27 | 2007-03-14 | Novartis Vaccines and Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
AU2005272993B2 (en) | 2004-07-15 | 2010-02-11 | Xencor, Inc | Optimized Fc variants |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
WO2006081139A2 (en) * | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
CN109485727A (en) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody |
CA2609269C (en) | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
DE102005028778A1 (en) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food |
AU2006308860B2 (en) * | 2005-11-01 | 2012-01-12 | Novartis Ag | Uses of anti-CD40 antibodies |
AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
BRPI0710826A2 (en) * | 2006-04-21 | 2011-08-23 | Novartis Ag | antagonist anti-cd40 antibody pharmaceutical compositions |
EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
DK2395018T3 (en) * | 2006-06-06 | 2016-04-25 | Crucell Holland Bv | HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
US20090074711A1 (en) | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
EP2104501B1 (en) * | 2006-12-13 | 2014-03-12 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with igf1r inhibitors |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
AU2008231242B2 (en) * | 2007-02-23 | 2013-01-31 | Baylor Research Institute | Therapeutic applications of activation of human antigen-presenting cells through Dectin-1 |
DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
ES2437327T3 (en) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed PD-1 receptor of programmed death |
JP2010535032A (en) | 2007-07-31 | 2010-11-18 | メディミューン,エルエルシー | Multispecific epitope binding proteins and uses thereof |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
JP2011507519A (en) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
AU2009206506B2 (en) | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
CA2717576A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 binding proteins |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
DK2406288T3 (en) | 2009-03-10 | 2017-03-27 | Baylor Res Inst | ANTIGEN PRESENTING CELL-TARGETED VACCINES |
PT2423228E (en) | 2009-04-20 | 2016-02-26 | Kyowa Hakko Kirin Co Ltd | Antibody containing igg2 having amino acid mutation introduced therein |
JP2012525149A (en) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Method for making heteromultimeric molecules |
WO2011021146A1 (en) * | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
SG183847A1 (en) | 2010-03-04 | 2012-10-30 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
MY187990A (en) * | 2010-03-31 | 2021-11-07 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
AR083847A1 (en) * | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
CA3167037A1 (en) * | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulating agonistic tnfr antibodies |
PL2654780T3 (en) | 2010-12-23 | 2017-07-31 | Janssen Biotech, Inc | Active protease-resistant antibody fc mutants |
JP6170840B2 (en) | 2011-03-11 | 2017-07-26 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | Anti-CD40 antibody and use thereof |
KR101970025B1 (en) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Antibodies and other molecules that bind b7-h1 and pd-1 |
KR20190122889A (en) | 2011-04-29 | 2019-10-30 | 아펙시젠, 인코포레이티드 | Anti-cd40 antibodies and methods of use |
GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
SG10201610288TA (en) | 2011-10-13 | 2017-02-27 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40l |
CN109897103A (en) | 2011-11-04 | 2019-06-18 | 酵活有限公司 | There is the antibody design of the stabilization heterodimeric of mutation in Fc structural domain |
WO2013084147A2 (en) * | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
JP2015509492A (en) * | 2012-02-22 | 2015-03-30 | ユー3・ファーマ・ゲーエムベーハー | Combination of HB-EGF binding protein and EGFR inhibitor |
JO3787B1 (en) * | 2012-03-15 | 2021-01-31 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods, and uses |
US8781132B2 (en) * | 2012-03-19 | 2014-07-15 | Motorola Solutions, Inc. | Method and device for managing encrypted group rekeying in a radio network link layer encryption system |
US9179480B2 (en) | 2012-07-24 | 2015-11-03 | Telefonaktiebolaget L M Ericsson (Publ) | Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network |
JP6501521B2 (en) | 2012-08-24 | 2019-04-17 | 中外製薬株式会社 | FcγRIIb-specific Fc region variant |
EP2914627B1 (en) * | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
WO2014078866A2 (en) * | 2012-11-19 | 2014-05-22 | Xencor, Inc. | Engineered immunoglobulins with extended in vivo half-life |
WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
US10329350B2 (en) | 2012-12-26 | 2019-06-25 | Industrial Technology Research Institute | Method for producing a multivalent fab fragment with collagen-like peptide |
KR20200134340A (en) | 2013-01-10 | 2020-12-01 | 젠맵 비. 브이 | Human igg1 fc region variants and uses thereof |
WO2014126254A1 (en) | 2013-02-18 | 2014-08-21 | 協和発酵キリン株式会社 | Membrane-binding protein expression vector |
CN111423511B (en) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-1 |
GB201322583D0 (en) | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
EP3113796A1 (en) * | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
WO2015133882A1 (en) * | 2014-03-07 | 2015-09-11 | 사회복지법인 삼성생명공익재단 | Scfv antibody library, method for preparing same, and scfv antibody screening method using same |
WO2016028810A1 (en) | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
BR112018006251A2 (en) * | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | antagonist antibodies that specifically bind to human cd40 and methods of use |
-
2016
- 2016-09-30 BR BR112018006251A patent/BR112018006251A2/en not_active Application Discontinuation
- 2016-09-30 JP JP2018516413A patent/JP2018529351A/en active Pending
- 2016-09-30 CN CN201680070053.8A patent/CN108368510B/en active Active
- 2016-09-30 MY MYPI2018701233A patent/MY196646A/en unknown
- 2016-09-30 WO PCT/US2016/054764 patent/WO2017059243A2/en active Application Filing
- 2016-09-30 EP EP16852679.6A patent/EP3355921A4/en not_active Withdrawn
- 2016-09-30 KR KR1020187010811A patent/KR20180053738A/en unknown
- 2016-09-30 PE PE2018000484A patent/PE20181367A1/en unknown
- 2016-09-30 US US15/281,670 patent/US10544229B2/en active Active
- 2016-09-30 CA CA3000396A patent/CA3000396A1/en not_active Abandoned
- 2016-09-30 US US15/763,673 patent/US20190048089A1/en not_active Abandoned
- 2016-09-30 CR CR20180177A patent/CR20180177A/en unknown
- 2016-09-30 JP JP2018516550A patent/JP7057276B2/en active Active
- 2016-09-30 AU AU2016331819A patent/AU2016331819B2/en active Active
- 2016-09-30 CN CN201680070103.2A patent/CN109069622A/en active Pending
- 2016-09-30 MX MX2018003905A patent/MX2018003905A/en unknown
- 2016-09-30 MA MA043053A patent/MA43053A/en unknown
- 2016-09-30 AU AU2016329057A patent/AU2016329057A1/en not_active Abandoned
- 2016-09-30 KR KR1020187011659A patent/KR20180054837A/en not_active Application Discontinuation
- 2016-09-30 CA CA3000400A patent/CA3000400A1/en active Pending
- 2016-09-30 IL IL258268A patent/IL258268B/en unknown
- 2016-09-30 BR BR112018006360A patent/BR112018006360A2/en not_active Application Discontinuation
- 2016-09-30 EA EA201890834A patent/EA037882B1/en unknown
- 2016-09-30 EP EP16852707.5A patent/EP3356532B1/en active Active
- 2016-09-30 ES ES16852707T patent/ES2906823T3/en active Active
- 2016-09-30 MA MA043055A patent/MA43055A/en unknown
- 2016-09-30 WO PCT/US2016/054671 patent/WO2017059196A2/en active Application Filing
-
2018
- 2018-03-23 SV SV2018005659A patent/SV2018005659A/en unknown
- 2018-03-23 NI NI201800044A patent/NI201800044A/en unknown
- 2018-03-27 CO CONC2018/0003436A patent/CO2018003436A2/en unknown
- 2018-03-27 PH PH12018500684A patent/PH12018500684A1/en unknown
- 2018-03-29 CL CL2018000833A patent/CL2018000833A1/en unknown
- 2018-04-27 EC ECIEPI201833227A patent/ECSP18033227A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190048089A1 (en) | Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use | |
US11746161B2 (en) | Antibodies that specifically bind PD-1 and methods of use | |
US11421037B2 (en) | Nucleic acids encoding anti-CD154 antibodies | |
US20180355043A1 (en) | Antibodies Specifically Binding HLA-DR and Their Uses | |
JP2018126150A (en) | Antibodies that bind to tl1a and their uses | |
NZ739597B2 (en) | Anti-cd154 antibodies and methods of using them | |
EA040943B1 (en) | ANTIBODIES TO CD154 AND METHODS FOR THEIR APPLICATION | |
WO2020089769A1 (en) | Antibodies specifically binding hla-dr/colii_259 complex and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20220330 |
|
FZDE | Discontinued |
Effective date: 20220330 |